

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 October 2008 (02.10.2008)

PCT

(10) International Publication Number  
**WO 2008/118809 A1**

(51) International Patent Classification:  
*C12Q 1/68* (2006.01)

(21) International Application Number:  
PCT/US2008/057904

(22) International Filing Date: 21 March 2008 (21.03.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/896,801 23 March 2007 (23.03.2007) US

(71) Applicant (for all designated States except US): **IBIS BIOSCIENCES, INC.**; 1896 Rutherford Road, Carlsbad, CA 92008 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ECKER, David, J.** [US/US]; 1041 Saxony Road, Encinitas, CA 92024 (US). **SAMPATH, Rangarajan** [US/US]; 12223 Mannix Road, San Diego, CA 92129 (US). **MASSIRE, Christian** [TR/US]; 7498 Altiva Place, Carlsbad, CA 92009 (US).

(74) Agents: **CASIMIR, David, A.** et al.; CASIMIR JONES, S.C., 440 Science Drive, Suite 203, Madison, WI 53711 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(54) Title: COMPOSITIONS FOR USE IN IDENTIFICATION OF MIXED POPULATIONS OF BIOAGENTS

(57) Abstract: The present invention provides oligonucleotide primers, compositions, and kits containing the same for rapid identification of bacterial bioagents and populations of bioagents which are members of the *Staphylococcus* bacterial genus by amplification of a segment of bioagent nucleic acid followed by molecular mass analysis.



WO 2008/118809 A1

## **COMPOSITIONS FOR USE IN IDENTIFICATION OF MIXED POPULATIONS OF BIOAGENTS**

### **CROSS-REFERENCE TO RELATED APPLICATIONS**

[0001] This application claims the benefit of priority to U.S. Provisional Application Serial No. 60/896,801, filed March 23, 2007, the disclosure of which is incorporated by reference in its entirety for any purpose.

### **SEQUENCE LISTING**

[0002] Computer-readable forms of the sequence listing, on CD-ROM, containing the file named DIBIS0093WOSEQ.txt, which is 69,632 bytes (measured in MS-DOS), and were created on March 22, 2007, are herein incorporated by reference.

### **STATEMENT OF GOVERNMENT SUPPORT**

[0003] This invention was made with support from NIH/NIAID, contract: 1 UC1-AI067232-01, project: 842. The U.S. government has certain rights in the invention.

### **FIELD OF THE INVENTION**

[0004] The present invention relates generally to the field of genetic identification and quantification of bioagents, including mixed populations of bioagents and provides methods, compositions and kits useful for this purpose, as well as others, when combined with molecular mass analysis.

### **BACKGROUND OF THE INVENTION**

[0005] Drug resistance is a growing problem in disease treatment and control. Development of antibiotic resistance by bacteria, especially to broad-range antibiotics, is particularly problematic.

Resistance emerges as use and/or misuse of drugs provides a selection advantage to resistant populations of infectious bioagents. Effective surveillance of emerging drug resistance is important for identifying, monitoring and controlling resistant populations and for developing appropriate treatment strategies.

**[0006]** Use of drugs to treat infection with bioagents having a propensity towards resistance can lead to treatment failure and/or development of new drug resistance. Furthermore, the methods available for detection of drug resistance can be prohibitively time consuming and often do not provide sufficient sensitivity or precision to detect low percentages of emerging resistant populations of bioagents. Thus, treatment of patients with certain drugs is often avoided, sometimes resulting in over-use of alternative drugs, and/or development of new drug-resistant strains.

**[0007]** Quinolones, specifically fluoroquinolones, are highly potent broad-spectrum antibiotics that are used to treat several types of bacterial infections. Because of their widespread use, resistance to quinolones has become prevalent among several classes of bacterial bioagents. A SNP (single-nucleotide polymorphism) within the quinolone resistance determining region (QRDR) of the *gyrA* gene confers quinolone resistance to *Staphylococcus aureus* bacteria. Ciprofloxacin, levofloxacin, moxifloxacin and gatifloxacin, among the fluoroquinolones used in treating certain types of *Staphylococcus aureus* infections, are being used less frequently in certain types of infections due to the risk of drug-resistance development. Methicillin-resistant *Staphylococcus aureus* (MRSA) strains are particularly adept at developing quinolone resistance, and are thus not typically treated with quinolones. However, the number of antibiotics available for treating bacteria that are resistant to both methicillin and quinolones is limited. Development of sensitive, rapid methods that would enable early detection of quinolone resistant bacteria might allow for the use of quinolones before resistance emerges.

**[0008]** Standard methods for determining bacterial drug resistance rely on phenotypic characterization. These methods typically require culturing bacteria from a clinical sample for a period of at least 24-48 hours and subsequent susceptibility testing of the cultured bacteria using assays such as agar/broth dilution and/or disk diffusion, which can require an additional 18-24

hours. These tests are relatively insensitive as they rely on visible phenotypic readouts such as culture growth and can only detect a resistant population if it represents a sufficiently high proportion of total bacteria in the sample. Thus, these standard methods are labor intensive, time-consuming, and insensitive, often resulting in misdiagnosis or delay of diagnosis, and by extension, use of inappropriate drug regimens. Thus, there is a long-felt and unmet need for methods that can rapidly detect emerging populations of bioagents and provide sufficient sensitivity and resolution to identify a bioagent that represents only a small percentage of a sample. Specifically, there is a need for methods that can identify small drug-resistant populations in early stages as they emerges in a mixed-population of bioagents, for example, in a sample from a patient being treated with the drug. Such methods would enable monitoring of emerging drug resistance and subsequent design of specific therapeutic approaches tailored to specific bioagent genotypes, and would also reduce the potential for treatment failure and new drug resistance.

#### **SUMMARY OF THE INVENTION**

[0009] Provided herein are, *inter alia*, pairs of primers and compositions comprising pairs of primers; kits comprising the same; and methods for their use in identification of bioagents, populations of bioagents, population genotypes, and mixed populations of bioagents. The forward and reverse primer members of the pairs of primers are configured to amplify nucleic acids from bioagents, thereby generating amplicons for the nucleic acids. In one aspect, the bioagents are comprised within a population of bioagents. In a preferred embodiment, the primer pairs are configured to amplify one or more nucleic acids from each of the bioagents in the population of bioagents. In one embodiment the primers generate bioagent identifying nucleic acid amplicons. The amplicons are preferably generated from portions of nucleic acid sequences that encode genes essential to antibiotic sensitivity and resistance.

[0010] The primer pairs each comprise a forward and a reverse primer member. In one embodiment, the primer pair is configured to generate an amplicon from within a region defined by SEQ ID NO.: 10, a region of GenBank gi number 49484912, the QRDR (quinolone resistance determining region) of the *gyrA* gene within this GenBank gi number. In one aspect, either or both of the primer pair members comprise 20 to 35 nucleobases in length. In one aspect the forward

primer pair member comprises at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, or 100% identity to a first portion of SEQ ID NO.: 10. In another aspect, the reverse primer pair member comprises at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, or 100% reverse complementarity to a second portion of SEQ ID NO.: 10. In another embodiment, the forward primer pair member comprises at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, or 100% identity with a portion of SEQ ID NO.: 11, which is a forward primer hybridization region within SEQ ID NO.: 10. In another embodiment, the reverse primer pair member comprises at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, or 100% reverse complementarity with a portion of SEQ ID NO.: 12, a reverse primer hybridization region within SEQ ID NO.: 10. In another aspect, the primer pair members are configured to hybridize with at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, or 100% complementarity within a sequence region of a bioagent nucleic acid sequence. In one aspect the bioagent nucleic acid sequence is GenBank gi number 49484912. In another aspect, the bioagent nucleic acid sequence is GenBank gi number 57650036. In another aspect, the bioagent nucleic acid sequence is GenBank gi number 47118324. In another aspect, the bioagent nucleic acid sequence is GenBank gi number 27314460.

**[0011]** In one embodiment, the forward primer pair member comprises SEQ ID NO.:2 with 0-8 nucleobase deletions, additions and/or substitutions. In another embodiment, the forward primer pair member comprises SEQ ID NO.:3 with 0-8 nucleobase deletions, additions and/or substitutions. In another embodiment, the forward primer pair member comprises SEQ ID NO.:4 with 0-8 nucleobase deletions, additions and/or substitutions. In another embodiment, the reverse primer pair member comprises SEQ ID NO.:5 with 0-6 nucleobase deletions, additions and/or substitutions. In another embodiment, the reverse primer pair member comprises SEQ ID NO.: 6 with 0-8 nucleobase deletions, additions and/or substitutions. In another embodiment, the reverse primer pair member comprises SEQ ID NO.: 7 with 0-9 nucleobase deletions, additions and/or substitutions.

**[0012]** In one embodiment, either or both of the primer pair members comprises at least one modified nucleobase. In one aspect the modified nucleobase is a mass modified nucleobase. In one aspect, the mass modified nucleobase is 5-Iodo-C. In another aspect the modified nucleobase is a

universal nucleobase. In one aspect, the universal nucleobase is inosine. In another embodiment, either or both of the primer pair members comprise a non-templated 5' T-residue.

[0013] Compositions comprising one or more of the primer pairs and the kits comprising the same, also provided herein, are configured to provide genotyping information, including identification of population genotypes of samples, populations of bioagents, including mixed populations of bioagents.

[0014] Also provided herein are methods of identifying one or more bioagents using the primer pairs and/or kits or compositions comprising the same provided herein.

[0015] In one embodiment, the methods are performed for identifying a population genotype for a population of bioagents comprised in the sample. In a preferred embodiment, the population of bioagents is a population of bacterial bioagents. In one embodiment, the population of bioagents comprises two or more bioagents from the same genus, the same species, or even the same strain. In one aspect, the two or more bioagents have the same genotype for one or more locus, gene or nucleotide position. In one embodiment, the population of bioagents is a mixed population of bioagents. In this embodiment, two or more of the bioagents in the population are distinguishable based on one or more characteristics. In one example, the two or more bioagents are distinguishable based on two or more distinct genotypes for a gene, locus, or nucleotide position. In one aspect, the distinct genotype confers resistance to one or more drugs or therapeutic agents. In another aspect, the distinct genotype confers sensitivity to one or more drugs or therapeutic agents. In one embodiment, the mixed population of bioagents comprises a plurality of members of the *Staphylococcus* genus. In a further embodiment, the population of bioagents comprises a plurality of members of the species *Staphylococcus aureus*. In one embodiment, the population of bioagents comprises a population of bioagents with two or more distinguishable genotypes for a gene that can confer drug resistance or sensitivity. More preferably, the two or more distinguishable genotypes comprise one genotype that confers resistance to quinolones and another genotype that confers sensitivity to quinolones. In a preferred embodiment, the gene that can confer drug resistance is Gyr A. In a preferred aspect, a distinguishable genotype comprises a C → T transition at nucleotide

within the Gyr A gene, thereby conferring a leucine in place of a serine for the encoded gyrase protein. In a preferred embodiment, the C → T transition is at nucleotide 251 of a sequence extraction with coordinates 7005-9668 (SEQ ID NO.: 8) of GenBank gi number: 49484912, which comprises a nucleotide sequence encoding Gyr A. In one aspect, one or more genotypes is an emerging genotype. In one aspect, the genotype confers drug resistance. In a preferred aspect, the genotype confers quinolone resistance. In a preferred aspect, the genotype comprises a genotype of the gyrA gene sequence. In one aspect, the genotype comprises a single nucleotide polymorphism.

**[0016]** In one embodiment, the primer pair is preferably configured to generate an amplicon between about 45 and about 200, more preferably, between about 45 and about 192 linked nucleotides in length within at least a portion of the QRDR region (SEQ ID NO.:10) of the *Staphylococcus aureus* gyrA gene, which confers quinolone resistance or sensitivity. This region comprises the position of the C → T drug resistance-conferring SNP at within the gyrA gene sequence. The SNP, comprising a change of a single “C” nucleobase to a “T” nucleobase, results in a leucine instead of a serine at amino acid position 84 of the protein. In one aspect, the forward primer is configured to comprise sequence identity within SEQ ID NO.: 11, a region of GenBank gi number 49484912, and the reverse primer is configured to comprise reverse complementarity within SEQ ID NO.: 12, another region of GenBank gi number 49484912. The gyrA primer pairs provided herein, when used in the methods provided herein, can detect a single nucleotide change at this SNP position, and are thus able to determine the drug resistant/sensitive genotype for the gyrA gene for a given *Staphylococcus aureus* bioagent.

**[0017]** In one embodiment, the method is performed on a sample that comprises or is suspected of comprising a bioagent or a population of bioagents. In this embodiment, the method comprises obtaining a sample and amplifying a nucleic acid from each of two or more bioagents in the sample using a primer pair provided herein, thereby generating amplicons from the nucleic acids and determining a molecular mass for each of the amplicons using a mass spectrometer. In a preferred embodiment, the determining using a mass spectrometer is accomplished by electrospray ionization mass spectrometry (ESI-MS). In one aspect, the ESI-MS is Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS). In another aspect, it is time of flight (TOF) mass

spectrometry. In another preferred embodiment, the method further comprises calculating a base composition from each molecular mass measurement. In a preferred embodiment, the method further comprises identifying a population genotype for the population of bioagents by comparing each of the molecular mass measurements and/or each of the base compositions calculated from the molecular mass measurements to a database of base compositions and/or molecular masses indexed to the primer pair used in the method and a known bioagent genotype. The database comprises indexed information comprising the molecular mass and/or base composition data that would be derived from a known bioagent having a certain genotype were an amplicon to be generated using the same primer pairs used to amplify nucleic acids in the sample. A match between the experimentally obtained molecular mass and/or base composition obtained by the methods provided herein, for example, on a sample, and a molecular mass and/or base composition comprised in the database correlates a bioagent in the sample with the known bioagent in the database to which the molecular mass and/or base composition is indexed, thus identifying a genotype of that bioagent in the sample. Thus, a sample comprising a population of bioagents that comprises two or more genotypes for the gene or nucleic acid sequence that the primer pair is configured to amplify will correlate with two or more known bioagents in the database. Identification of one or more genotypes by the methods provided herein identifies a population genotype for a population of bioagents.

**[0018]** In one embodiment, the population of bioagents comprises at least two bacteria. In a preferred embodiment, the population of bioagents comprises at least two bacteria belonging to the *Staphylococcus* genus. More preferably, the population comprises at least two bacteria belonging to the *Staphylococcus aureus* species. In one preferred aspect, at least one of the at least two bacteria is resistant to quinolone antimicrobial therapy. In another preferred aspect, at least one of the at least two bacteria is sensitive to quinolone antimicrobial therapy. In another preferred aspect, at least one of the at least two bacteria is resistant to quinolone antimicrobial therapy and at least one of the at least two bacteria is sensitive to quinolone antimicrobial therapy.

**[0019]** In one embodiment, an antibiotic regimen is developed that is tailored to treat the identified population genotype for the population of bioagents. In a preferred aspect, the antibiotic

regimen tailored to treat the identified genotypes for the population of bioagents is delivered to the sample source. In a preferred embodiment, the sample source is a human subject from whom the sample was taken.

**[0020]** In one embodiment, the steps of the method are periodically repeated. In one aspect, the tailored antibiotic regimen is delivered continuously during the periodic repeating of the steps. In one aspect, the antibiotic regimen is modified after one or more of the periodic repeats of the steps.

**[0021]** Also provided, in one embodiment, are methods for reducing a population of bacteria in a person needing such a treatment. In this embodiment, the sample is obtained from a person suspected of comprising a population of bioagents. In the identifying step of this embodiment, a population genotype is identified in the person. In one aspect, the population of bioagents in the person comprises a single genotype. In another aspect, it comprises a mixed population of bioagents, comprising at least two distinct genotypes. In this embodiment, the method further comprises administering to the person an antibiotic regimen tailored to treat the identified genotypes for the population of bioagents. In this embodiment, preferably, the population of bioagents comprises a population of bacterial bioagents. In one aspect, the steps of obtaining a sample, amplifying, determining, calculating, and identifying are repeated. In one aspect, the tailored antibiotic regimen is delivered continuously during the periodic repeating of the steps. In one aspect, during one or more of the periodic repeats of the method, an emerging genotype is identified in said sample. In this aspect, preferably, the method further comprises modifying the antibiotic regimen to treat the emerging genotype. In one embodiment, the antibiotic regimen comprises an antibiotic for treating quinolone resistant bacteria. In another embodiment, the antibiotic regimen comprises an antibiotic for treating quinolone sensitive bacteria. In another embodiment, the antibiotic regimen comprises an antibiotic for treating quinolone resistant bacteria and an antibiotic for treating quinolone sensitive bacteria. In one aspect, the antibiotic for treating quinolone sensitive bacteria is a quinolone. In one aspect, it is a fluoroquinolone.

**[0022]** Identification of a mixed population of bioagents allows for proper subsequent steps being performed on the sample. In one embodiment, the mixed population of bioagents comprises at least

two populations of bioagents; one population that is sensitive to a first antibiotic and another population that is resistant to said first antibiotic. Subsequent steps with such a population can include treatment with a combination of said first antibiotic to reduce the population of the bioagent sensitive thereto, and treatment with a second antibiotic to reduce the population of bioagent that is resistant to said first antibiotic.

**[0023]** In a further embodiment, comparison of experimental data from the sample with the database identifies only a single genotype for the population of bioagents in the sample. In one aspect of this embodiment, subsequent steps can include treatment of the population with a first antibiotic to which the population of bioagents with the one genotype is sensitive. Periodic processing of the sample is then performed as described above, thereby monitoring for the emergence of a population in the sample with a genotype that confers resistance to the administered first antibiotic. In a preferred embodiment, identification of such an emerging drug resistant bioagent or population of drug resistant bioagents is followed by alteration or modification of the treatment regimen to comprise either a second antibiotic or a combination of the first and the second antibiotics. Rapid identification of a population of bioagents in a sample allows for antibiotic regimens to be closely tailored for treatment of the specific bioagents in said sample. Further, the methods provided herein are able to identify bioagents or populations of bioagents that represent small percentages of the total population of bioagents in a sample. Genotypes in mixed populations can be identified with high sensitivity by PCR-ESI/MS because amplified bioagent nucleic acids having different base compositions appear in different positions in the mass spectrum. The dynamic range for mixed PCR-ESI/MS detections has previously been determined to be approximately 100:1 (Hofstadler, S. A. *et al.*, *Inter. J. Mass Spectrom.* (2005) **242**, 23), which allows for detection of genotype variants with as low as 1% abundance in a mixed population. This ability allows early detection of emerging genotypes and emerging populations, including genotypes that confer drug resistance and drug resistant populations.

**[0024]** In one embodiment, one or more of the bioagents comprised in the population of bioagents represents less than 50% of the population of bioagents. In another embodiment, the one or more of the bioagents comprised in the population of bioagents represents less than 25% of the population of

bioagents. In another embodiment, one or more of the bioagents represents less than 10% of the population of bioagents. In another embodiment, one or more of the bioagents represents less than 5% of the population of bioagents. In another embodiment, one or more of the bioagents represents less than 4% of the population of bioagents. In another embodiment, one or more of the bioagents represents less than 3% of the population of bioagents. In another embodiment, one or more of the bioagents represents less than 2% of the population of bioagents. In another embodiment, one or more of the bioagents represents between about 1% and about 2% of the population of bioagents. In another embodiment, one or more of the bioagents represents about 1% of the population of bioagents.

**[0025]** In one embodiment, one or more of the genotypes identified by the method represents less than 50% of the population of bioagents. In another embodiment, one or more of the genotypes identified by the methods represents less than 25% of the population of bioagents. In another embodiment, one or more of the genotypes identified by the methods represents less than 15% of the population of bioagents. In another embodiment, one or more of the genotypes identified by the methods represents less than 10% of the population of bioagents. In another embodiment, one or more of the genotypes identified by the methods represents less than 5% of the population of bioagents. In another embodiment, one or more of the genotypes identified by the methods represents less than 4% of the population of bioagents. In another embodiment, one or more of the genotypes identified by the methods represents less than 3% of the population of bioagents. In another embodiment, one or more of the genotypes identified by the methods represents less than 2% of the population of bioagents. In another embodiment, one or more of the genotypes identified by the methods represents between 1 and 2% of the population of bioagents. In another embodiment, one or more of the genotypes identified by the methods represents about 1% of the population of bioagents.

## **BRIEF DESCRIPTION OF THE DRAWINGS**

**[0026]** The foregoing summary and detailed description is better understood when read in conjunction with the accompanying drawings which are included by way of example and not by way of limitation.

[0027] **Figure 1** is a process diagram illustrating a representative primer selection process.

[0028] **Figure 2** is a chart showing distribution of *Staphylococcus aureus* strain identification for 362 clinical isolates obtained using the genotyping primer pair panel and methods described in Example 9.

[0029] **Figure 3** shows three spectra obtained using the *gyrA* primer pair described in Example 13. The top spectrum was generated from a patient (wound) sample, and the bottom two spectra were generated from two different colonies grown from the patient sample. In all spectra, the left peak (or double peak) represents the forward strand of the amplicon, while the right peak (or double peak) represents the reverse strand. The double peaks in the top spectrum are indicative of two different *gyrA* genotypes present in the patient sample. Thus, the patient sample comprised a mixed population of bioagents. As indicated by dotted lines, one peak in each of the double-peaks corresponds with the middle spectrum, representing a quinolone resistant genotype (*Quinolone resistant colony gyrA* mutant Ser84>Leu TCA (S) --> TTA (L)), while the other corresponds with the bottom spectrum, representing a quinolone sensitive genotype (*Quinolone sensitive colony gyrA* wild-type Ser84 TCA). The identification of both quinolone resistant (middle spectrum) and sensitive (bottom spectrum) genotype colonies grown from the sample is further evidence that the double peaks in the top spectrum represent a mixed population in the patient sample. Base compositions determined in this example for each amplicon are shown above each spectrum.

[0030] **Figure 4** is a process diagram illustrating an embodiment of the calibration method.

#### DETAILED DESCRIPTION OF EMBODIMENTS

[0031] As is used herein, a “bioagent” refers to any microorganism or infectious substance, or any naturally occurring, bioengineered or synthesized component of any such microorganism or infectious substance or any nucleic acid derived from any such microorganism or infectious substance. Those of ordinary skill in the art will understand fully what is meant by the term bioagent given the instant disclosure. Preferably, the bioagent is a bacterial bioagent, a bacterium or a nucleic acid derived therefrom. More preferably, the bioagent is a member of the *Staphylococcus*

genus. More preferably still the bioagent is a strain of *Staphylococcus aureus*. A “population of bioagents” refers to a plurality of bioagents, or at least two bioagents. In some aspects, the population of bioagents is a “mixed population of bioagents,” which comprises two or more distinguishable genotypes for a particular gene, locus or nucleotide position. In other aspects, each bioagent in the plurality of bioagents comprises a single genotype for the gene, locus, or nucleotide position.

**[0032]** As used herein, “primer pairs,” or “oligonucleotide primer pairs” are synonymous terms referring to pairs of oligonucleotides (herein called “primers” or “oligonucleotide primers”) that are configured to bind to conserved sequence regions of a bioagent nucleic acid (that is conserved among two or more bioagents) and to generate bioagent identifying amplicons. The bound primers flank an intervening variable region of the bioagent between the conserved sequence sequences. Upon amplification, the primer pairs yield amplicons that provide base composition variability between two or more bioagents. The variability of the base compositions allows for the identification of one or more individual bioagents from two or more bioagents based on the base composition distinctions. The primer pairs are also configured to generate amplicons that are amenable to molecular mass analysis. Each primer pair comprises two primer pair members. The primer pair members are a “forward primer” (“forward primer pair member,” or “reverse member”), which comprises at least a percentage of sequence identity with the top strand of the reference sequence used in configuring the primer pair, and a “reverse primer” (“reverse primer pair member” or “reverse member”), which comprises at least a percentage of reverse complementarity with the top strand of the reference sequence used in configuring the primer pair. Primer pair configuration is well-known and is described in detail herein.

**[0033]** Primer pair nomenclature, as used herein, includes the identification of a reference sequence. For example, the forward primer for primer pair number 2740 is named GYRA\_NC002953\_7005-9668\_221-249\_F. This forward primer name indicates that the forward primer (“\_F”) hybridizes to residues 234-261 (“234\_261”) of a reference sequence, which in this case is represented by a sequence extraction of coordinates 7005-9668 (SEQ ID NO.: 8) from GenBank gi number 49484912 (corresponding to the version of genbank number NC\_002953, as is

indicated by the prefix “GYRA\_NC002953” and cross-reference in Table 2). In the case of this primer, the reference sequence is the gene within a *Staphylococcus aureus* genome encoding for GyrA. Primer pair name codes for the primers provided herein are defined in Table 2, which lists gene abbreviations and GenBank gi numbers that correspond with each primer name code. Sequences of the primers are also provided. One of skill in the art will understand how to determine exact hybridization coordinates of primers with respect to GenBank sequences, given the information provided herein. The primer pairs are selected and configured; however, to hybridize with two or more bioagents. So, the reference sequence in the primer name is used merely to provide a reference, and not to indicate that the primers are selected and configured to hybridize with and generate a bioagent identifying amplicon only from the reference sequence. Rather, the primers hybridize with and generate amplicons from a number of sequences. Further, the sequences of the primer members of the primer pairs are not necessarily fully complementary to the conserved region of the reference bioagent. Rather, the sequences are configured to be “best fit” amongst a plurality of bioagents at these conserved binding sequences. Therefore, the primer members of the primer pairs have substantial complementarity with the conserved regions of the bioagents, including the reference bioagent.

**[0034]** Methods for PCR primer design are well known. One of skill in the art will understand that primer pairs configured to prime amplification of a double stranded sequence are configured and named using one strand of the double stranded sequence as a reference. The forward primer is the primer of the pair that comprises full or partial sequence identity to the one strand of the sequence being used as a reference. The reverse primer is the primer of the pair that comprises reverse complementarity to the one strand of the sequence being used as a reference.

**[0035]** In one embodiment, the “plus” or “top” strand (the primary sequence as submitted to GenBank) of the nucleic acid to which the primers hybridize is used as a reference when designing primer pairs. In this case, the forward primer will comprise identity and the reverse primer will comprise reverse complementarity, to the sequence listed in GenBank for the reference sequence. The ordinarily skilled artisan will understand how to configure primer pairs based upon this disclosure. In some embodiments, the primer pair is configured using the “minus” or “bottom”

strand (reverse complement of the primary sequence as submitted to and listed in GenBank). In this case, the forward primer comprises sequence identity to the minus strand, and thus comprises reverse complementarity to the top strand, the sequence listed in GenBank. Similarly, in this case, the reverse primer comprises reverse complementarity to the minus strand, and thus comprises identity to the top strand.

**[0036]** In a preferred embodiment, the primer pairs are configured to generate an amplicon from “within a region of SEQ ID NO.: 10,” which is a specific region of Genbank gi No.: 49484912, a *Staphylococcus aureus* nucleic acid sequence. Configuring a primer pair to generate an amplicon from “within a region” of a particular nucleic acid reference sequence means that each primer of the pair hybridizes to a portion of the reference sequence that is within that region. One of ordinary skill in the art understands that shifting the coordinates of this region within which the primers hybridize slightly, in one direction or the other, will often result in an equally effective primer pair. Armed with the instant disclosure, one of skill in the art will be able to configure such primer pairs. Thus, in the above mentioned example, a primer pair that hybridizes to a portion of Genbank gi No.: 49484912 that is within a region slightly shifted with respect to SEQ ID NO.: 10 is encompassed by this description.

**[0037]** As is used herein, the term “substantial complementarity” means that a primer member of a primer pair comprises between about 70%-100%, or between about 80-100%, or between about 90-100%, or between about 95-100% identity, or between about 99-100% sequence identity with the conserved binding sequence of any given bioagent. These ranges of identity are inclusive of all whole or partial numbers embraced within the recited range numbers. For example, and not limitation, 75.667%, 82%, 91.2435% and 97% sequence identity are all numbers that fall within the above recited range of 70% to 100%, therefore forming a part of this description.

**[0038]** As used herein, “broad range survey primers” are intelligent primers configured to identify an unknown bioagent as a member of a particular division (e.g., an order, family, class, clade, or genus). However, in some cases the broad range survey primers are also able to identify unknown bioagents at the species or sub-species level. As used herein, “division-wide primers” are intelligent

primers configured to identify a bioagent at the species level and “drill-down” primers are intelligent primers configured to identify a bioagent at the sub-species level. As used herein, the “sub-species” level of identification includes, but is not limited to, strains, subtypes, variants, and isolates. Drill-down primers are not always required for identification at the sub-species level because broad range survey intelligent primers may, in some cases provide sufficient identification resolution to accomplishing this identification objective.

[0039] As used herein, the term “conserved region” refers to the region of the bioagent nucleic acid to which the primer pair members are designed to hybridize. Preferably, the conserved region is conserved among two or more bioagents. By the term “highly conserved,” it is meant that the sequence regions exhibit between about 80-100%, or between about 90-100%, or between about 95-100% identity among all, or at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% of species or strains. As used herein, the term “variable region” is used to describe a region that is between the two conserved sequence regions to which the primers of a primer pair hybridize. In other words, the variable region is a region that is flanked by the bound primers of any one primer pair described herein. The region possesses distinct base compositions among at least two bioagents, such that at least one bioagent can be identified at the family, genus, species or sub-species level using the primer pairs and the methods provided herein. The degree of variability between the at least two bioagents need only be sufficient to allow for identification using mass spectrometry or base composition analysis, as described herein. Such a difference can be as slight as a single nucleotide difference occurring between two bioagents. In a preferred embodiment, the variable region is within a reference sequence that comprises an extraction sequence with coordinates 7005-9668 (SEQ ID NO.: 8) of GenBank gi number: 49484912, which comprises a nucleotide sequence encoding gyrase A (GyrA). In another preferred embodiment, the variable region is within the QRDR segment of a gene encoding gyrase A in *Staphylococcus aureus*. In a preferred embodiment, this QRDR segment is SEQ ID NO.: 10. In another embodiment, the variable region is within a reference sequence that comprises an extraction sequence with coordinates 7032-9695 (SEQ ID NO.: 9) of GenBank gi number: 57650036, which comprises a nucleotide sequence encoding gyrase A (GyrA). In another embodiment, the variable region is within a reference sequence that comprises an extraction sequence with coordinates 7005-9674

(SEQ ID NO.: 315) of GenBank gi number: 47118324, which comprises a nucleotide sequence encoding gyrase A (GyrA). In another embodiment, the variable region is within a reference sequence that comprises an extraction sequence with coordinates 6916-9597 (SEQ ID NO.: 316) of GenBank gi number: 27314460, which comprises a nucleotide sequence encoding gyrase A (GyrA). In another preferred embodiment the variable region comprises nucleotide position 251 of a gyrA gene in *Staphylococcus aureus*. In one aspect, the variable region comprises nucleotide position 251 of the reference sequence that comprises a sequence extraction with coordinates 7005-9668 (SEQ ID NO.: 8) of GenBank gi number: 49484912, which comprises a nucleotide sequence encoding *Staphylococcus aureus* GyrA.

**[0040]** As used herein, the terms “amplicon” and “bioagent identifying amplicon” refer to a nucleic acid generated using the primer pairs described herein. The amplicon is preferably double stranded DNA; however, it may be RNA and/or DNA:RNA. The amplicon comprises the sequences of the conserved regions/primer pairs and the intervening variable region. Mass spectrometry analysis of the amplicon determines a molecular mass that can be converted into a base composition, or base composition signature for the amplicon. Since the primer pairs provided herein are configured such that two or more different bioagents, when amplified with a given primer pair, will yield amplicons with unique base composition signatures, the base composition signatures can be used to identify bioagents based on association with amplicons. As discussed herein, primer pairs are configured to generate amplicons from two or more bioagents. As such, the base composition of any given amplicon will include the primer pair, the complement of the primer pair, the conserved regions and the variable region from the bioagent that was amplified to generate the amplicon. One skilled in the art understands that the incorporation of the configured primer pair sequences into any amplicon will replace the native bioagent sequences at the primer binding site, and complement thereof. After amplification of the target region using the primers the resultant amplicons having the primer sequences generate the molecular mass data. Amplicons having any native bioagent sequences at the primer binding sites, or complement thereof, are undetectable because of their low abundance. Such is accounted for when identifying one or more bioagents using any particular primer pair. The amplicon further comprises a length that is compatible with mass spectrometry

analysis. In one embodiment, bioagent identifying amplicons generate base composition signatures that are unique to the identity or genotype of a bioagent.

**[0041]** Calculation of base composition from a mass spectrometer generated molecular mass becomes increasingly more complex as the length of the amplicon increases. For amplicons comprising unmodified nucleic acid, the upper length as a practical length limit is about 200 consecutive nucleobases. Incorporating modified nucleotides into the amplicon can allow for an increase in this upper limit. In one embodiment, the amplicons generated using any single primer pair will provide sufficient base composition information to allow for identification of at least one bioagent at the family, genus, species or subspecies level. Alternatively, amplicons greater than 200 nucleobases can be generated and then digested to form two or more fragments that are less than 200 nucleobases. Analysis of one or more of the fragments will provide sufficient base composition information to allow for identification of at least one bioagent.

**[0042]** Preferably, amplicons comprise from about 45 to about 200 consecutive nucleobases (i.e., from about 45 to about 200 linked nucleosides). One of ordinary skill in the art will appreciate that this range expressly embodies compounds of 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, and 200 nucleobases in length. One ordinarily skilled in the art will further appreciate that the above range is not an absolute limit to the length of an amplicon, but instead represents a preferred length range. Amplicons lengths falling outside of this range are also included herein so long as the amplicon is amenable to calculation of a base composition signature as herein described.

[0043] As is used herein, the term “unknown bioagent” can mean either: (i) a bioagent whose existence is not known (for example, the SARS coronavirus was unknown prior to April 2003), which is also called a “true unknown bioagent,” and/or (ii) a bioagent whose existence is known (such as the well known bacterial species *Staphylococcus aureus* for example) but which is not known to be in a sample to be analyzed and/or (iii) a bioagent that is known or suspected of being present in a sample but whose sub-species characteristics are not known (such as a bacterial resistance genotype like the QRDR region of *Staphylococcus aureus* species). For example, if the method for identification of coronaviruses disclosed in commonly owned U.S. Pre-Grant Publication No. US2005-0266397 (incorporated herein by reference in its entirety) was to be employed prior to April 2003 to identify the SARS coronavirus in a clinical sample, both meanings of “unknown” bioagent are applicable since the SARS coronavirus was unknown to science prior to April, 2003 and since it was not known what bioagent (in this case a coronavirus) was present in the sample. On the other hand, if the method of U.S. Pre-Grant Publication No. US2005-0266397 was to be employed subsequent to April 2003 to identify the SARS coronavirus in a clinical sample, only the second meaning (ii) of “unknown” bioagent would apply because the SARS coronavirus became known to science subsequent to April 2003 but because it was not known what bioagent was present in the sample.

[0044] As used herein, the term “molecular mass” refers to the mass of a compound as determined using mass spectrometry. Herein, the compound is preferably a nucleic acid, more preferably a double stranded nucleic acid, still more preferably a double stranded DNA nucleic acid and is most preferably an amplicon. When the nucleic acid is double stranded the molecular mass is determined for both strands. Here, the strands are separated either before introduction into the mass spectrometer, or the strands are separated by the mass spectrometer (for example, electro-spray ionization will separate the hybridized strands). The molecular mass of each strand is measured by the mass spectrometer.

[0045] As used herein, the term “base composition” refers to the number of each residue comprising an amplicon, without consideration for the linear arrangement of these residues in the strand(s) of the amplicon. The amplicon residues comprise, adenosine (A), guanosine (G), cytidine,

(C), (deoxy)thymidine (T), uracil (U), inosine (I), nitroindoles such as 5-nitroindole or 3-nitropyrrole, dP or dK (Hill *et al.*), an acyclic nucleoside analog containing 5-nitroindazole (Van Aerschot *et al.*, Nucleosides and Nucleotides, 1995, 14, 1053-1056), the purine analog 1-(2-deoxy-beta.-D-ribofuranosyl)-imidazole-4-carboxamide, 2,6-diaminopurine, 5-propynyluracil, 5-propynylcytosine, phenoxazines, including G-clamp, 5-propynyl deoxy-cytidine, deoxy-thymidine nucleotides, 5-propynylcytidine, 5-propynyluridine and mass tag modified versions thereof, including 7-deaza-2'-deoxyadenosine-5'-triphosphate, 5-iodo-2'-deoxyuridine-5'-triphosphate, 5-bromo-2'-deoxyuridine-5'-triphosphate, 5-bromo-2'-deoxycytidine-5'-triphosphate, 5-iodo-2'-deoxycytidine-5'-triphosphate, 5-hydroxy-2'-deoxyuridine-5'-triphosphate, 4-thiothymidine-5'-triphosphate, 5-aza-2'-deoxyuridine-5'-triphosphate, 5-fluoro-2'-deoxyuridine-5'-triphosphate, O6-methyl-2'-deoxyguanosine-5'-triphosphate, N2-methyl-2'-deoxyguanosine-5'-triphosphate, 8-oxo-2'-deoxyguanosine-5'-triphosphate or thiothymidine-5'-triphosphate. In some embodiments, the mass-modified nucleobase comprises 15.<sup>sup</sup>N or 13.<sup>sup</sup>C or both 15.<sup>sup</sup>N and 13.<sup>sup</sup>C. Preferably, the non-natural nucleosides used herein include 5-propynyluracil, 5-propynylcytosine and inosine. Herein the base composition for an unmodified DNA amplicon is notated as A.sub.wG.sub.xC.sub.yT.sub.z, wherein w, x, y and z are each independently a whole number representing the number of said nucleoside residues in an amplicon. Base compositions for amplicons comprising modified nucleosides are similarly notated to indicate the number of said natural and modified nucleosides in an amplicon. Base compositions are calculated from a molecular mass measurement of an amplicon, as described below. The calculated base composition for any given amplicon is then compared to a database of base compositions. A match between the calculated base composition and a single database entry reveals the identity of the bioagent.

**[0046]** As is used herein, the term “base composition signature” refers to the base composition generated by any one particular amplicon. The base composition signature for each of one or more amplicons provides a fingerprint for identifying the bioagent(s) present in a sample. Base composition signatures are unique for each genotype of the bioagent.

**[0047]** As used herein, the term “database” is used to refer to a collection of base composition and/or molecular mass data. The base composition and/or molecular mass data in the database is

indexed to bioagents and to primer pairs. The base composition data reported in the database comprises the number of each nucleoside in an amplicon that would be generated for each bioagent using each primer pair. The database can be populated by empirical data. In this aspect of populating the database, a bioagent is selected and a primer pair is used to generate an amplicon. The amplicon's molecular mass is determined using a mass spectrometer and the base composition calculated therefrom. An entry in the database is made to associate the base composition and/or molecular mass with the bioagent and the primer pair used. The database may also be populated using other databases comprising bioagent information. For example, using the GenBank database it is possible to perform electronic PCR using an electronic representation of a primer pair. This *in silico* method will provide the base composition for any or all selected bioagent(s) stored in the GenBank database. The information is then used to populate the base composition database as described above. A base composition database can be *in silico*, a written table, a reference book, a spreadsheet or any form generally amenable to databases. Preferably, it is *in silico*. The database can similarly be populated with molecular masses that is gathered either empirically or is calculated from other sources such as GenBank.

**[0048]** As used herein, the term “nucleobase” is synonymous with other terms in use in the art including “nucleotide,” “deoxynucleotide,” “nucleotide residue,” “deoxynucleotide residue,” “nucleotide triphosphate (NTP),” “residue,” or deoxynucleotide triphosphate (dNTP). As is used herein, a nucleobase includes natural and modified residues, as described herein.

**[0049]** As used herein, a “wobble base” is a variation in a codon found at the third nucleotide position of a DNA triplet. Variations in conserved regions of sequence are often found at the third nucleotide position due to redundancy in the amino acid code.

**[0050]** As used herein, “housekeeping gene” refers to a gene encoding a protein or RNA involved in basic functions required for survival and reproduction of a bioagent. Housekeeping genes include, but are not limited to, genes encoding RNA or proteins involved in translation, replication, recombination and repair, transcription, nucleotide metabolism, amino acid metabolism, lipid

metabolism, energy generation, uptake, secretion and the like. In some embodiments, the primers are configured to produce amplicons from within a housekeeping gene.

**[0051]** As used herein, a “bioagent division” is defined as group of bioagents above the species level and includes but is not limited to, orders, families, genus, classes, clades, genera or other such groupings of bioagents above the species level.

**[0052]** As used herein, a “sub-species characteristic” is a genetic characteristic that provides the means to distinguish two members of the same bioagent species. For example, one bacterial strain could be distinguished from another bacterial strain of the same species by possessing a genetic change (e.g., for example, a nucleotide deletion, addition or substitution) in one of the bacterial genes, such as the GyrA gene.

**[0053]** As used herein, “triangulation identification” means the employment of more than one primer pair to generate a corresponding amplicon for identification of a bioagent. The more than one primer pair can be used in individual wells or in a multiplex PCR assay. Alternatively, PCR reaction may be carried out in single wells comprising a different primer pair in each well. Following amplification, the amplicons are pooled into a single well or container which is then subjected to molecular mass analysis. The combination of pooled amplicons can be chosen such that the expected ranges of molecular masses of individual amplicons are not overlapping and thus will not complicate identification of signals. Triangulation works as a process of elimination, wherein a first primer pair identifies that an unknown bioagent may be one of a group of bioagents. Subsequent primer pairs are used in triangulation identification to further refine the identity of the bioagent amongst the subset of possibilities generated with the earlier primer pair. Triangulation identification is complete when the identity of the bioagent is determined. The triangulation identification process is also used to reduce false negative and false positive signals, and enable reconstruction of the origin of hybrid or otherwise engineered bioagents. For example, identification of the three part toxin genes typical of *B. anthracis* (Bowen et al., J. Appl. Microbiol., 1999, 87, 270-278) in the absence of the expected signatures from the *B. anthracis* genome would suggest a genetic engineering event.

[0054] As is used herein, the term “single primer pair identification” means that one or more bioagents can be identified using a single primer pair. A base composition signature for an amplicon may singly identify one or more bioagents.

[0055] As used herein, the term “etiology” refers to the causes or origins, of diseases or abnormal physiological conditions.

[0056] As used herein, “population genotype” refers to the one or more genotypes for a particular gene, locus, or nucleotide position that are present in a population of bioagents. In some embodiments, the population comprises a plurality of bioagents, all with a single genotype for a particular gene, locus or nucleotide position. In these embodiments, the population genotype comprises one genotype for that gene locus or position. In other embodiments, the population of bioagents is a “mixed population,” in which the plurality of bioagents has at least two distinct genotypes for a particular gene, locus or nucleotide position. In this embodiment, the population genotype comprises at least two distinct genotypes for that gene, locus or position.

[0057] The term "sample" in the present specification and claims is used in its broadest sense. On the one hand it is meant to include a specimen or culture (e.g., microbiological cultures). Preferably, the sample is from a human patient suspected of having a bacterial infection, for example, a blood, tissue, or wound sample. More preferably it is a blood, tissue, or wound swab. On the other hand, it is meant to include both biological and environmental samples. A sample may include a specimen of synthetic origin. Biological samples may be from an animal, including human, and may be fluid, solid (e.g., stool) or tissue, as well as liquid or solid food and feed products or ingredients such as dairy items, vegetables, meat and meat by-products, or waste. Biological samples may be obtained from all of the various families of domestic animals, as well as feral or wild animals, including, but not limited to, such animals as ungulates, bear, fish, lagamorphs, rodents, etc. Environmental samples include environmental material such as surface matter, soil, water, air and industrial samples, as well as samples obtained from food and dairy processing instruments, apparatus, equipment, utensils, disposable and non-disposable items. These examples are not to be construed as limiting the sample types applicable to the present invention. The term "source of target nucleic

acid" refers to any sample that contains nucleic acids (RNA or DNA). Particularly preferred sources of target nucleic acids are biological samples including, but not limited to blood, saliva, cerebral spinal fluid, pleural fluid, milk, lymph, sputum and semen. In some embodiments, the sample is purified. The term "sample source" refers to the source of the sample, for example, the animal, human, fluid, tissue, culture, or other source from which the sample was isolated and/or purified.

**[0058]** Provided herein are methods for detection and identification of bioagents in an unbiased manner using bioagent identifying amplicons. In one aspect, the methods are for detection and identification of population genotype for a population of bioagents. Primers are selected to hybridize to conserved sequence regions of nucleic acids derived from a bioagent and which bracket (flank) variable sequence regions to yield a bioagent identifying amplicon which can be amplified and which is amenable to molecular mass determination. The molecular mass is converted to a base composition, which indicates the number of each nucleotide in the amplicon. The molecular mass or corresponding base composition signature of the amplicon is then queried against a database of molecular masses or base composition signatures indexed to bioagents and to the primer pair used to generate the amplicon. A match of the measured base composition to a database entry base composition associates the sample bioagent to an indexed bioagent in the database. Thus, the identity of the unknown bioagent or population of bioagents is determined. Prior knowledge of the unknown bioagent or population of bioagents is not necessary. In some instances, the measured base composition associates with more than one database entry base composition. Thus, a second/subsequent primer pair is used to generate an amplicon, and its measured base composition is similarly compared to the database to determine its identity in triangulation identification. For example, a first primer pair might identify that a bacterial bioagent is present in a sample that is a member of the *Staphylococcus* genus. A second primer might determine that it is a member of the *Staphylococcus aureus* species. A third primer pair might identify that the bioagent is resistant to quinolones. Furthermore, the method can be applied to rapid parallel multiplex analyses, the results of which can be employed in a triangulation identification strategy. The present method provides rapid throughput and does not require nucleic acid sequencing of the amplified target sequence for bioagent detection and identification.

**[0059]** In some embodiments, the methods are performed on nucleic acids comprised in a sample suspected of comprising a population of bioagents. In one aspect, the methods further comprise administering or delivering to the sample source an antibiotic regimen tailored to treat the identified genotypes for the population of bacteria. In this aspect, the antibiotic regimen is determined based on the genotype(s) identified by the method, with the goal of being able to effectively reduce the bioagents in the population. In one embodiment, the steps of the method are repeated “periodically” or more than one additional time following the initial identification. In one aspect, the periodic repeating of the steps is done at regular intervals. In other aspects, it is done sporadically or at irregular time points. In another aspect, it is done in response to a trigger, such as the appearance of one or more symptoms. In one aspect, the antibiotic regimen is modified based on one or more genotypes identified during the periodic repeating of the steps. In one embodiment, the antibiotic regimen comprises an antibiotic for treating quinolone resistant bacteria. In another embodiment, the antibiotic regimen comprises an antibiotic for treating quinolone sensitive bacteria. In one aspect, the antibiotic for treating quinolone sensitive bacteria is a quinolone. In one aspect, it is a fluoroquinolone.

**[0060]** Despite enormous biological diversity, all forms of life on earth share sets of essential, common features in their genomes. Since genetic data provide the underlying basis for identification of bioagents by the current methods, it is necessary to select segments of nucleic acids which ideally provide enough variability to distinguish each individual bioagent and whose molecular mass is amenable to molecular mass determination.

**[0061]** In some embodiments, at least one bacterial nucleic acid segment is amplified in the process of identifying the bioagent. Thus, the nucleic acid segments that can be amplified by the primers disclosed herein and that provide enough variability to distinguish each individual bioagent and whose molecular masses are amenable to molecular mass determination are herein described as bioagent identifying amplicons.

**[0062]** In some embodiments, bioagent identifying amplicons amenable to molecular mass determination that are produced by the primers described herein are either of a length, size and/or

mass compatible with the particular mode of molecular mass determination or compatible with a means of providing a predictable fragmentation pattern in order to obtain predictable fragments of a length compatible with the particular mode of molecular mass determination. Such means of providing a predictable fragmentation pattern of an amplicon include, but are not limited to, cleavage with restriction enzymes or cleavage primers, for example. Thus, in some embodiments, bioagent identifying amplicons are larger than 200 nucleobases and are amenable to molecular mass determination following restriction digestion. Methods of using restriction enzymes and cleavage primers are well known to those with ordinary skill in the art.

**[0063]** In some embodiments, amplicons corresponding to bioagent identifying amplicons are obtained using the polymerase chain reaction (PCR) which is a routine method to those with ordinary skill in the molecular biology arts. Other amplification methods may be used such as ligase chain reaction (LCR), low-stringency single primer PCR, and multiple strand displacement amplification (MDA). These methods are also known to those with ordinary skill. (Michael, SF., *Biotechniques* (1994), 16:411-412 and Dean et al., *Proc. Natl. Acad. Sci. U.S.A.* (2002), 99, 5261-5266)

**[0064]** A representative process flow diagram used for primer selection and validation process is outlined in Figure 1. For each group of diverse organisms, candidate target sequences are identified **(200)** from which nucleotide alignments are created **(210)** and analyzed **(220)**. Primers are then configured by selecting appropriate priming regions **(230)** to facilitate the selection of candidate primer pairs **(240)**. The primer pair sequence is a “best fit” amongst the aligned sequences, meaning that the primer pair sequence may or may not be fully complementary to the hybridization region on any one of the bioagents in the alignment. Thus, best fit primer pair sequences are those with sufficient complementarity with two or more bioagents to hybridize with the two or more bioagents and generate an amplicon. The primer pairs are then subjected to *in silico* analysis by electronic PCR (ePCR) **(300)** wherein bioagent identifying amplicons are obtained from sequence databases such as GenBank or other sequence collections **(310)** and checked for specificity *in silico* **(320)**. Bioagent identifying amplicons obtained from ePCR of GenBank sequences **(310)** can also be analyzed by a probability model which predicts the capability of a given amplicon to identify

unknown bioagents. Preferably, the base compositions of amplicons with favorable probability scores are then stored in a base composition database (325). Alternatively, base compositions of the bioagent identifying amplicons obtained from the primers and GenBank sequences can be directly entered into the base composition database (330). Candidate primer pairs (240) are validated by *in vitro* amplification by a method such as PCR analysis (400) of nucleic acid from a collection of organisms (410). Amplicons thus obtained are analyzed to confirm the sensitivity, specificity and reproducibility of the primers used to obtain the amplicons (420).

[0065] Synthesis of primers is well known and routine in the art. The primers may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed.

[0066] The primers are employed as compositions for use in methods for identification of bacterial bioagents as follows: a primer pair composition is contacted with nucleic acid (such as, for example, DNA or DNA reverse transcribed from RNA) of an unknown bacterial bioagent. The nucleic acid is then amplified by a nucleic acid amplification technique, such as PCR for example, to obtain an amplicon that represents a bioagent identifying amplicon. The molecular mass of each strand of the double-stranded amplicon is determined by a molecular mass measurement technique such as mass spectrometry for example. Preferably the two strands of the double-stranded amplicon are separated during the ionization process; however, they may be separated prior to mass spectrometry measurement. In some embodiments, the mass spectrometer is electrospray Fourier transform ion cyclotron resonance mass spectrometry (ESI-FTICR-MS) or electrospray time of flight mass spectrometry (ESI-TOF-MS). A list of possible base compositions can be generated for the molecular mass value obtained for each strand and the choice of the correct base composition from the list is facilitated by matching the base composition of one strand with a complementary base composition of the other strand. The measured molecular mass or base composition calculated therefrom is then compared with or queried against a database of molecular masses or base compositions indexed to primer pairs and to known bacterial bioagents. A match between the

measured molecular mass or base composition of the amplicon and the database molecular mass or base composition for that indexed primer pair will associate the measured molecular mass or base composition with an indexed bacterial bioagent, thus indicating the identity of the unknown bioagent. In some embodiments, the primer pair used is one of the primer pairs of Table 1. In some embodiments, the method is repeated using a different primer pair to resolve possible ambiguities in the identification process or to improve the confidence level for the identification assignment (triangulation identification).

**[0067]** In some embodiments, a bioagent identifying amplicon may be produced using only a single primer (either the forward or reverse primer of any given primer pair), provided an appropriate amplification method is chosen, such as, for example, low stringency single primer PCR (LSSP-PCR). Adaptation of this amplification method in order to produce bioagent identifying amplicons can be accomplished by one with ordinary skill in the art without undue experimentation. (Pena, SDJ *et al.*, Proc. Natl. Acad. Sci. U.S.A (1994) 91, 1946–1949).

**[0068]** In some embodiments, the oligonucleotide primers are broad range survey primers which hybridize to conserved regions of a nucleic acid encoding a gene that is common to all known members of the *Staphylococcus* genus, though the sequences of the gene that are within the variable region vary. The broad range primer may identify the unknown bioagent, depending on which bioagent is in the sample. In other cases, the molecular mass or base composition of an amplicon does not provide enough resolution to unambiguously identify the unknown bioagent as any one bacterial bioagent at or below the species level. These cases benefit from further analysis of one or more amplicons generated from at least one additional broad range survey primer pair or from at least one additional division-wide primer pair or from at least one additional drill-down primer pair. Identification of sub-species characteristics is often critical for determining proper clinical treatment of viral infections, or in rapidly responding to an outbreak of a new viral strain to prevent massive epidemic or pandemic.

**[0069]** In some embodiments, the primers used for amplification hybridize to and amplify genomic DNA, DNA of bacterial plasmids, transposons and other exogenous nucleic acid, or DNA

reverse transcribed from RNA. Among other things, the identification of non-bacterial nucleic acids or combinations of bacterial and non-bacterial nucleic acids are useful for detecting bioengineered bioagents.

**[0070]** In some embodiments, the primers used for amplification hybridize directly to bacterial RNA and act as reverse transcription primers for obtaining DNA from direct amplification of bacterial RNA. Methods of amplifying RNA to produce cDNA using reverse transcriptase are well known to those with ordinary skill in the art and can be routinely established without undue experimentation.

**[0071]** One with ordinary skill in the art of design of amplification primers will recognize that a given primer need not hybridize with 100% complementarity in order to effectively prime the synthesis of a complementary nucleic acid strand in an amplification reaction. Primer pair sequences may be a “best fit” amongst the aligned bioagent sequences, thus not be fully complementary to the hybridization region on any one of the bioagents in the alignment. Moreover, a primer may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event. (e.g., for example, a loop structure or a hairpin structure). The primers may comprise at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity with any of the primers listed in Table 1 or other primer disclosed herein. Thus, in some embodiments, an extent of variation of 70% to 100%, or any range falling within, of the sequence identity is possible relative to the specific primer sequences disclosed herein. Determination of sequence identity is described in the following example: a primer 20 nucleobases in length which is identical to another 20 nucleobase primer having two non-identical residues has 18 of 20 identical residues ( $18/20 = 0.9$  or 90% sequence identity). In another example, a primer 15 nucleobases in length having all residues identical to a 15 nucleobase segment of primer 20 nucleobases in length would have  $15/20 = 0.75$  or 75% sequence identity with the 20 nucleobase primer. Percent identity need not be a whole number, for example when a 28 consecutive nucleobase primer is completely identical to a 31 consecutive nucleobase primer ( $28/31 = 0.9032$  or 90.3% identical). Similarly, either or both of the primers of the primer pairs provided herein may comprise 0-9 nucleobase deletions, additions, and/or substitutions relative to any of the primers

listed in Table 1, or elsewhere herein. In other words, either or both of the primers may comprise 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 nucleobase deletions, 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 nucleobase additions, 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9 nucleobase substitutions relative to the sequences of any of the primers disclosed herein. In one aspect, the primers comprise the sequence of any of the primers listed in Table 1 with the non-templated T residue removed from the 5' terminus. In one aspect, the primers comprise the sequence of any of the primers listed in Table 1 with the non-templated T residue removed from the 5' terminus and comprising 0-9 nucleobase deletions, additions, and/or substitutions.

**[0072]** Percent homology, sequence identity or target complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison WI), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482-489). In some embodiments, target complementarity of primers with respect to the conserved priming regions of bacterial nucleic acid, is between about 70% and about 80%. In other embodiments, homology, sequence identity or complementarity, is between about 80% and about 90%. In yet other embodiments, homology, sequence identity or complementarity, is at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or is 100%.

**[0073]** In some embodiments, the primers described herein comprise at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 98%, or at least 99%, or 100% (or any range falling within) sequence identity with the primer sequences specifically disclosed herein.

**[0074]** One with ordinary skill is able to calculate percent sequence identity or percent sequence homology and is able to determine, without undue experimentation, the effects of variation of primer sequence identity on the function of the primer in its role in priming synthesis of a complementary strand of nucleic acid for production of a corresponding bioagent identifying amplicon.

[0075] In some embodiments, the oligonucleotide primers are 13 to 35 nucleobases in length (13 to 35 linked nucleotide residues). These embodiments comprise oligonucleotide primers 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 nucleobases in length, or any range therewithin.

[0076] In some embodiments, any given primer comprises a modification comprising the addition of a non-templated T residue to the 5' end of the primer (i.e., the added T residue does not necessarily hybridize to the nucleic acid being amplified). The addition of a non-templated T residue has an effect of minimizing the addition of non-templated A residues as a result of the non-specific enzyme activity of *Taq* polymerase (Magnuson *et al.*, Biotechniques, 1996, 21, 700-709), an occurrence which may lead to ambiguous results arising from molecular mass analysis. Primer pairs comprising the sequence of any of the primer pairs described herein, but lacking the non-templated T residue at the 5' end of the primer are also encompassed by this disclosure.

[0077] Primers may contain one or more universal bases. Because any variation (due to codon wobble in the third position) in the conserved regions among species is likely to occur in the third position of a DNA (or RNA) triplet, oligonucleotide primers can be configured such that the nucleotide corresponding to this position is a base which can bind to more than one nucleotide, referred to herein as a "universal nucleobase." For example, under this "wobble" pairing, inosine (I) binds to U, C or A; guanine (G) binds to U or C, and uridine (U) binds to U or C. Other examples of universal nucleobases include nitroindoles such as 5-nitroindole or 3-nitropyrrole (Loakes et al., Nucleosides and Nucleotides, 1995, 14, 1001-1003), the degenerate nucleotides dP or dK (Hill *et al.*), an acyclic nucleoside analog containing 5-nitroindazole (Van Aerschot et al., Nucleosides and Nucleotides, 1995, 14, 1053-1056) or the purine analog 1-(2-deoxy-.beta. -D-ribofuranosyl)-imidazole-4-carboxamide (Sala et al., Nucl. Acids Res., 1996, 24, 3302-3306).

[0078] In some embodiments, to compensate for the somewhat weaker binding by the wobble base, the oligonucleotide primers are configured such that the first and second positions of each triplet are occupied by nucleotide analogs which bind with greater affinity than the unmodified nucleotide. Examples of these analogs include, but are not limited to, 2,6-diaminopurine which

binds to thymine, 5-propynyluracil which binds to adenine and 5-propynylcytosine and phenoxazines, including G-clamp, which binds to G. Propynylated pyrimidines are described in U.S. Patent Nos. 5,645,985, 5,830,653 and 5,484,908, each of which is commonly owned and incorporated herein by reference in its entirety. Propynylated primers are described in U.S. Pre-Grant Publication No. 2003-0170682; also commonly owned and incorporated herein by reference in its entirety. Phenoxazines are described in U.S. Patent Nos. 5,502,177, 5,763,588, and 6,005,096, each of which is incorporated herein by reference in its entirety. G-clamps are described in U.S. Patent Nos. 6,007,992 and 6,028,183, each of which is incorporated herein by reference in its entirety.

**[0079]** In some embodiments, to enable broad priming of rapidly evolving bioagents, primer hybridization is enhanced using primers and probes containing 5-propynyl deoxy-cytidine and deoxy-thymidine nucleotides. These modified primers offer increased affinity and base pairing selectivity.

**[0080]** In some embodiments, non-template primer tags are used to increase the melting temperature ( $T_{sub.m}$ ) of a primer-template duplex in order to improve amplification efficiency. A non-template tag is at least three consecutive A or T nucleotide residues on a primer which are not complementary to the template. In any given non-template tag, A can be replaced by C or G and T can also be replaced by C or G. Although Watson-Crick hybridization is not expected to occur for a non-template tag relative to the template, the extra hydrogen bond in a G-C pair relative to an A-T pair confers increased stability of the primer-template duplex and improves amplification efficiency for subsequent cycles of amplification when the primers hybridize to strands synthesized in previous cycles.

**[0081]** In other embodiments, propynylated tags may be used in a manner similar to that of the non-template tag, wherein two or more 5-propynylcytidine or 5-propynyluridine residues replace template matching residues on a primer. In other embodiments, a primer contains a modified internucleoside linkage such as a phosphorothioate linkage, for example.

[0082] In some embodiments, the primers contain mass-modifying tags. Reducing the total number of possible base compositions of a nucleic acid of specific molecular weight provides a means of avoiding a persistent source of ambiguity in determination of base composition of amplicons. Addition of mass-modifying tags to certain nucleobases of a given primer will result in simplification of *de novo* determination of base composition of a given bioagent identifying amplicon from its molecular mass.

[0083] In some embodiments, the mass modified nucleobase comprises one or more of the following: for example, 7-deaza-2'-deoxyadenosine-5'-triphosphate, 5-iodo-2'-deoxyuridine-5'-triphosphate, 5-bromo-2'-deoxyuridine-5'-triphosphate, 5-bromo-2'-deoxycytidine-5'-triphosphate, 5-iodo-2'-deoxycytidine-5'-triphosphate, 5-hydroxy-2'-deoxyuridine-5'-triphosphate, 4-thiothymidine-5'-triphosphate, 5-aza-2'-deoxyuridine-5'-triphosphate, 5-fluoro-2'-deoxyuridine-5'-triphosphate, O6-methyl-2'-deoxyguanosine-5'-triphosphate, N2-methyl-2'-deoxyguanosine-5'-triphosphate, 8-oxo-2'-deoxyguanosine-5'-triphosphate or thiothymidine-5'-triphosphate. In some embodiments, the mass-modified nucleobase comprises  $^{15}\text{N}$  or  $^{13}\text{C}$  or both  $^{15}\text{N}$  and  $^{13}\text{C}$ .

[0084] In some embodiments, the molecular mass of a given bioagent identifying amplicon is determined by mass spectrometry. Mass spectrometry has several advantages, not the least of which is high bandwidth characterized by the ability to separate (and isolate) many molecular peaks across a broad range of mass to charge ratio ( $m/z$ ). Thus mass spectrometry is intrinsically a parallel detection scheme without the need for radioactive or fluorescent labels since every amplicon is identified by its molecular mass. The current state of the art in mass spectrometry is such that less than femtomole quantities of material can be readily analyzed to afford information about the molecular contents of the sample. An accurate assessment of the molecular mass of the material can be quickly obtained, irrespective of whether the molecular weight of the sample is several hundred, or in excess of one hundred thousand atomic mass units (amu) or Daltons.

[0085] In some embodiments, intact molecular ions are generated from amplicons using one of a variety of ionization techniques to convert the sample to gas phase. These ionization methods

include, but are not limited to, electrospray ionization (ES), matrix-assisted laser desorption ionization (MALDI) and fast atom bombardment (FAB). Upon ionization, several peaks are observed from one sample due to the formation of ions with different charges. Averaging the multiple readings of molecular mass obtained from a single mass spectrum affords an estimate of molecular mass of the bioagent identifying amplicon. Electrospray ionization mass spectrometry (ESI-MS) is particularly useful for very high molecular weight polymers such as proteins and nucleic acids having molecular weights greater than 10 kDa, since it yields a distribution of multiply-charged molecules of the sample without causing a significant amount of fragmentation.

**[0086]** The mass detectors used include, but are not limited to, Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS), time of flight (TOF), ion trap, quadrupole, magnetic sector, Q-TOF, and triple quadrupole.

**[0087]** In some embodiments, assignment of previously unobserved base compositions (also known as “true unknown base compositions”) to a given phylogeny can be accomplished via the use of pattern classifier model algorithms. Base compositions, like sequences, vary slightly from strain to strain within species, for example. In some embodiments, the pattern classifier model is the mutational probability model. On other embodiments, the pattern classifier is the polytope model.

**[0088]** In one embodiment, it is possible to manage this diversity by building “base composition probability clouds” around the composition constraints for each species. This permits identification of organisms in a fashion similar to sequence analysis. Using three primer pairs, a “pseudo four-dimensional plot” can be used to visualize the concept of base composition probability clouds. Optimal primer design requires optimal choice of bioagent identifying amplicons and maximizes the separation between the base composition signatures of individual bioagents. Areas where clouds overlap indicate regions that may result in a misclassification, a problem which is overcome by a triangulation identification process using bioagent identifying amplicons not affected by overlap of base composition probability clouds.

[0089] In some embodiments, base composition probability clouds provide the means for screening potential primer pairs in order to avoid potential misclassifications of base compositions. In other embodiments, base composition probability clouds provide the means for predicting the identity of an unknown bioagent whose assigned base composition was not previously observed and/or indexed in a bioagent identifying amplicon base composition database due to evolutionary transitions in its nucleic acid sequence. Thus, in contrast to probe-based techniques, mass spectrometry determination of base composition does not require prior knowledge of the composition or sequence in order to make the measurement.

[0090] Provided herein are bioagent classifying information at a level sufficient to identify a given bioagent. Furthermore, the process of determining a previously unknown base composition for a given bioagent (for example, in a case where sequence information is unavailable) has downstream utility by providing additional bioagent indexing information with which to populate base composition databases. The process of future bioagent identification is thus greatly improved as more base composition signature indexes become available in base composition databases.

[0091] In some embodiments, the identity and quantity of an unknown bioagent can be determined using the process illustrated in Figure 4. Primers (500) and a known quantity of a calibration polynucleotide (505) is added to a sample containing nucleic acid of an unknown bioagent. The total nucleic acid in the sample is then subjected to an amplification reaction (510) to obtain amplicons. The molecular masses of amplicons are determined (515) from which are obtained molecular mass and abundance data. The molecular mass of the bioagent identifying amplicon (520) provides for its identification (525) and the molecular mass of the calibration amplicon obtained from the calibration polynucleotide (530) provides for its quantification (535). The abundance data of the bioagent identifying amplicon is recorded (540) and the abundance data for the calibration data is recorded (545), both of which are used in a calculation (550) which determines the quantity of unknown bioagent in the sample.

[0092] A sample comprising an unknown bioagent is contacted with a primer pair which amplifies the nucleic acid from the bioagent, and a known quantity of a polynucleotide that

comprises a calibration sequence. The rate of amplification is reasonably assumed to be similar for the nucleic acid of the bioagent and for the calibration sequence. The amplification reaction then produces two amplicons: a bioagent identifying amplicon and a calibration amplicon. The bioagent identifying amplicon and the calibration amplicon should be distinguishable by molecular mass while being amplified at essentially the same rate. Effecting differential molecular masses can be accomplished by choosing as a calibration sequence, a representative bioagent identifying amplicon (from a specific species of bioagent) and performing, for example, a 2-8 nucleobase deletion or insertion within the variable region between the two priming sites. The amplified sample containing the bioagent identifying amplicon and the calibration amplicon is then subjected to molecular mass analysis by mass spectrometry, for example. The resulting molecular mass analysis of the nucleic acid of the bioagent and of the calibration sequence provides molecular mass data and abundance data for the nucleic acid of the bioagent and of the calibration sequence. The molecular mass data obtained for the nucleic acid of the bioagent enables identification of the unknown bioagent by base composition analysis. The abundance data enables calculation of the quantity of the bioagent, based on the knowledge of the quantity of calibration polynucleotide contacted with the sample.

**[0093]** In some embodiments, construction of a standard curve where the amount of calibration polynucleotide spiked into the sample is varied provides additional resolution and improved confidence for the determination of the quantity of bioagent in the sample. The use of standard curves for analytical determination of molecular quantities is well known to one with ordinary skill and can be performed without undue experimentation. Alternatively, the calibration polynucleotide can be amplified in its own reaction well or wells under the same conditions as the bioagent. A standard curve can be prepared therefrom, and a relative abundance of the bioagent determined by methods such as linear regression. In some embodiments, multiplex amplification is performed where multiple bioagent identifying amplicons are amplified with multiple primer pairs which also amplify the corresponding standard calibration sequences. In this or other embodiments, the standard calibration sequences are optionally included within a single construct (preferably a vector) which functions as the calibration polynucleotide. Competitive PCR, quantitative PCR, quantitative competitive PCR, multiplex and calibration polynucleotides are all methods and materials well known to those ordinarily skilled in the art and can be performed without undue experimentation.

[0094] In some embodiments, the calibrant polynucleotide is used as an internal positive control to confirm that amplification conditions and subsequent analysis steps are successful in producing a measurable amplicon. Even in the absence of copies of the genome of a bioagent, the calibration polynucleotide should give rise to a calibration amplicon. Failure to produce a measurable calibration amplicon indicates a failure of amplification or subsequent analysis step such as amplicon purification or molecular mass determination. Reaching a conclusion that such failures have occurred is in itself, a useful event. In some embodiments, the calibration sequence is comprised of DNA. In some embodiments, the calibration sequence is comprised of RNA.

[0095] In the preferred embodiment, the calibration sequence is inserted into a vector which then itself functions as the calibration polynucleotide. In some embodiments, more than one calibration sequence is inserted into the vector that functions as the calibration polynucleotide. Such a calibration polynucleotide is herein termed a “combination calibration polynucleotide.” The process of inserting polynucleotides into vectors is routine to those skilled in the art and can be accomplished without undue experimentation. Thus, it should be recognized that the calibration method should not be limited to the embodiments described herein. The calibration method can be applied for determination of the quantity of any bioagent identifying amplicon when an appropriate standard calibrant polynucleotide sequence is configured and used. The process of choosing an appropriate vector for insertion of a calibrant is also a routine operation that can be accomplished by one with ordinary skill without undue experimentation.

[0096] It is preferable for some primer pairs to produce bioagent identifying amplicons within more conserved regions of *Staphylococci* bacteria while others produce bioagent identifying amplicons within regions that are likely to evolve more quickly. Primer pairs that characterize amplicons in a conserved region with low probability that the region will evolve past the point of primer recognition are useful as a broad range survey-type primer. Primer pairs that characterize an amplicon corresponding to an evolving genomic region are useful for distinguishing emerging strain variants.

[0097] The primer pairs described herein establish a platform for identifying members of the *Staphylococcus* genus. Base composition analysis eliminates the need for prior knowledge of bioagent sequence to generate hybridization probes. Thus, in another embodiment, there is provided a method for determining the etiology of a bacterial infection when the process of identification of bacteria is carried out in a clinical setting and, even when the bacteria is a new species never observed before. This is possible because the methods are not confounded by naturally occurring evolutionary variations (a major concern when using probe based or sequencing dependent methods for characterizing viruses that evolve rapidly). Measurement of molecular mass and determination of base composition is accomplished in an unbiased manner without sequence prejudice and without the need for specificity as is required with probes.

[0098] Another embodiment provides a means of tracking the spread of any species or strain of bacteria when a plurality of samples obtained from different locations are analyzed by the methods described above in an epidemiological setting. For example, a plurality of samples from a plurality of different locations is analyzed with primers which produce bioagent identifying amplicons, a subset of which contains a specific bacteria. The corresponding locations of the members of the bacteria-containing subset indicate the spread of the specific bacteria to the corresponding locations.

[0099] Also provided are kits for carrying out the methods described herein. In some embodiments, the kit may comprise a sufficient quantity of one or more primer pairs to perform an amplification reaction on a target polynucleotide from a bioagent to form a bioagent identifying amplicon. In some embodiments, the kit may comprise from one to fifty primer pairs, from one to twenty primer pairs, from one to ten primer pairs, from one to eight primer pairs or from two to five primer pairs. In some embodiments, the kit may comprise one or more primer pairs recited in Table 1. In a preferred embodiment, the kit comprises eight primer pairs from Table 1. In a preferred aspect the eight primer pairs comprised in the kit are selected from: SEQ ID NO.: 58:SEQ ID NO.:142, SEQ ID NO.: 62:SEQ ID NO.:147, SEQ ID NO.: 294:SEQ ID NO.:295, SEQ ID NO.: 35:SEQ ID NO.:121, SEQ ID NO.: 39:SEQ ID NO.:125, SEQ ID NO.: 47:SEQ ID NO.:132, SEQ ID NO.: 55:SEQ ID NO.:139, SEQ ID NO.: 21:SEQ ID NO.:104, SEQ ID NO.: 22:SEQ ID NO.:106, SEQ ID NO.: 70:SEQ ID NO.:155, SEQ ID NO.: 329:SEQ ID NO.: 330, SEQ ID NO.:

331:SEQ ID NO.:332, SEQ ID NO.: 2:SEQ ID NO.:5, SEQ ID NO.: 3:SEQ ID NO.:6, SEQ ID NO.: 3:SEQ ID NO.:7, and SEQ ID NO.: 4:SEQ ID NO.:5. In another preferred aspect, the eight primer pairs comprised in the kit are selected from: SEQ ID NO.: 72:SEQ ID NO.:156, SEQ ID NO.: 79:SEQ ID NO.:166, SEQ ID NO.: 76:SEQ ID NO.:162, SEQ ID NO.: 83:SEQ ID NO.:170, SEQ ID NO.: 87:SEQ ID NO.:172, SEQ ID NO.: 90:SEQ ID NO.:177, SEQ ID NO.: 93:SEQ ID NO.:180, SEQ ID NO.: 94:SEQ ID NO.:181, SEQ ID NO.: 72:SEQ ID NO.:158, SEQ ID NO.: 2:SEQ ID NO.:5, SEQ ID NO.: 3:SEQ ID NO.:6, SEQ ID NO.: 3:SEQ ID NO.:7, and SEQ ID NO.: 4:SEQ ID NO.:5. In another preferred embodiment, the kit comprises nine oligonucleotide primer pairs. In a preferred aspect, the nine oligonucleotide primer pairs are SEQ ID NO.: 58:SEQ ID NO.:142, SEQ ID NO.: 62:SEQ ID NO.:147, SEQ ID NO.: 294:SEQ ID NO.:295, SEQ ID NO.: 35:SEQ ID NO.:121, SEQ ID NO.: 39:SEQ ID NO.:125, SEQ ID NO.: 47:SEQ ID NO.:132, SEQ ID NO.: 55:SEQ ID NO.:139, SEQ ID NO.: 21:SEQ ID NO.:104, SEQ ID NO.: 22:SEQ ID NO.:106, SEQ ID NO.: 70:SEQ ID NO.:155, and SEQ ID NO.: 3:SEQ ID NO.:7. In another preferred aspect, the nine oligonucleotide primers comprised in the kit are SEQ ID NO.: 72:SEQ ID NO.:156, SEQ ID NO.: 79:SEQ ID NO.:166, SEQ ID NO.: 76:SEQ ID NO.:162, SEQ ID NO.: 83:SEQ ID NO.:170, SEQ ID NO.: 87:SEQ ID NO.:172, SEQ ID NO.: 90:SEQ ID NO.:177, SEQ ID NO.: 93:SEQ ID NO.:180, SEQ ID NO.: 94:SEQ ID NO.:181, SEQ ID NO.: 72:SEQ ID NO.:158, and SEQ ID NO.: 3:SEQ ID NO.:7. In another preferred embodiment, the kit comprises 17 oligonucleotide primer pairs. Preferably, the 17 oligonucleotide primer pairs comprised in the kit are SEQ ID NO.: 58:SEQ ID NO.:142, SEQ ID NO.: 62:SEQ ID NO.:147, SEQ ID NO.: 294:SEQ ID NO.:295, SEQ ID NO.: 35:SEQ ID NO.:121, SEQ ID NO.: 39:SEQ ID NO.:125, SEQ ID NO.: 47:SEQ ID NO.:132, SEQ ID NO.: 55:SEQ ID NO.:139, SEQ ID NO.: 21:SEQ ID NO.:104, SEQ ID NO.: 22:SEQ ID NO.:106, SEQ ID NO.: 70:SEQ ID NO.:155, SEQ ID NO.: 72:SEQ ID NO.:156, SEQ ID NO.: 79:SEQ ID NO.:166, SEQ ID NO.: 76:SEQ ID NO.:162, SEQ ID NO.: 83:SEQ ID NO.:170, SEQ ID NO.: 87:SEQ ID NO.:172, SEQ ID NO.: 90:SEQ ID NO.:177, SEQ ID NO.: 93:SEQ ID NO.:180, SEQ ID NO.: 94:SEQ ID NO.:181, SEQ ID NO.: 72:SEQ ID NO.:158, and SEQ ID NO.: 3:SEQ ID NO.:7.

**[00100]** In some embodiments, the kit may comprise one or more broad range survey primer(s), division wide primer(s), or drill-down primer(s), or any combination thereof. A kit may be

configured so as to comprise select primer pairs for identification of a particular bioagent. For example, a broad range survey primer kit may be used initially to identify an unknown bioagent as a member of the genus *Staphylococcus*. Another example of a division-wide kit may be used to distinguish *Staphylococcus aureus* from *Staphylococcus epidermidis*, for example. A drill-down kit may be used, for example, to distinguish resistance and sensitivity of bacteria to one or more antibiotics. In some embodiments, the kit may contain standardized calibration polynucleotides for use as internal amplification calibrants.

**[00101]** In some embodiments, the kit may also comprise a sufficient quantity of reverse transcriptase (if an RNA is to be identified for example), a DNA polymerase, suitable nucleoside triphosphates (including any of those described above), a DNA ligase, and/or reaction buffer, or any combination thereof, for the amplification processes described above. A kit may further include instructions pertinent for the particular embodiment of the kit, such instructions describing the primer pairs and amplification conditions for operation of the method. A kit may also comprise amplification reaction containers such as microcentrifuge tubes and the like. A kit may also comprise reagents or other materials for isolating bioagent nucleic acid or bioagent identifying amplicons from amplification, including, for example, detergents, solvents, or ion exchange resins which may be linked to magnetic beads. A kit may also comprise a table of measured or calculated molecular masses and/or base compositions of bioagents using the primer pairs of the kit.

**[00102]** In one embodiment, population genotypes for mixed populations of bioagents can be identified. Population genotypes for mixed populations can be identified with high sensitivity by PCR-ESI/MS because amplified bioagent nucleic acids having different base compositions appear in different positions in the mass spectrum. The dynamic range for mixed PCR-ESI/MS detections has previously been determined to be approximately 100:1 (Hofstadler, S. A. *et al.*, *Inter. J. Mass Spectrom.* (2005) **242**, 23), which allows for detection of genotype variants with as low as 1% abundance in a mixed population. This detection using PCR-ESI/MS surveillance does not require secondary testing.

**[00103]** The following examples serve only as illustration, and not limitation.

## EXAMPLES

### **Example 1: Selection of Design and Validation of Primers that Define Bioagent Identifying Amplicons for *Staphylococcus***

[00104] For design of primers that define *Staphylococcus* identifying amplicons, a series of *Staphylococcus* genome segment sequences were obtained, aligned and scanned for regions where pairs of PCR primers would amplify products of about 45 to about 200 nucleotides in length and distinguish individual species, strains, and/or genotypes by their molecular masses or base compositions. A typical process shown in Figure 1 is employed for this type of analysis.

[00105] A database of expected base compositions for each primer region was generated using an *in silico* PCR search algorithm, such as (ePCR). An existing RNA structure search algorithm (Macke et al., Nucl. Acids Res., 2001, 29, 4724-4735, which is incorporated herein by reference in its entirety) has been modified to include PCR parameters such as hybridization conditions, mismatches, and thermodynamic calculations (SantaLucia, Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 1460-1465, which is incorporated herein by reference in its entirety). This structure search algorithm can be used for other nucleic acids, such as DNA. This also provides information on primer specificity of the selected primer pairs.

[00106] Table 1 lists a collection of primers (sorted by primer pair number) configured to identify *Staphylococcus* bioagents using the methods described herein. The primer pair number is an in-house database index number. Primer sites (conserved regions which primers were configured to hybridize within) were identified on *Staphylococcus* genes including *arcC*, *aroE*, *ermA*, *ermC*, *gmk*, *gyrA*, *mecA*, *mecR1*, *mupR*, *nuc*, *pta*, *pvluk*, *tpi*, *tsst*, *tufB*, and *yqi*. The forward and reverse primer names shown in Table 1 indicate the gene region of a bacterial genome to which the forward and reverse primers hybridize relative to a reference sequence. The forward primer name GYRA\_NC002953-7005-9668\_234\_261\_F indicates that the forward primer (“\_F”) hybridizes to the *GyrA* gene (“GYRA”), specifically to residues 234-261 (“234\_261”) of a reference sequence represented by a sequence extraction of coordinates 7005-9668 (SEQ ID NO.: 8) from GenBank gi number 49484912 (as indicated by cross-references in Table 2 for the prefix “GYRA\_NC002953”). This sequence extraction reference includes sequence encoding for the *gyrA* gene (“GYRA”). The

primer pair name codes appearing in Table 1 are defined in Table 2. For example, Table 2 lists gene abbreviations and GenBank gi numbers that correspond with each primer name code. For example, for the above-mentioned primer pair has the code “GYRA\_NC002953” and is thus configured to hybridize to sequence encoding the *gyrA* gene, and the extraction sequence (SEQ ID NO.: 8) 7005-9668 corresponds to coordinates 7005-9668 of GenBank gi number 49484912, which is a *Staphylococcus aureus* sequence. One of skill in the art will understand how to determine the exact hybridization coordinates of the primers with respect to the GenBank sequences, given this information. The reference nomenclature in the primer name is selected to provide a reference, and does not necessarily mean that the primer pair has been configured with 100% complementarity to that target site on the reference sequence. One with ordinary skill knows how to obtain individual gene sequences or portions thereof from genomic sequences present in GenBank. In Table 1, Tp = 5-propynyluracil; Cp = 5-propynylcytosine; \* = phosphorothioate linkage; I = inosine. T. GenBank gi numbers for reference sequences of bacteria are shown in Table 2 (below). In some cases, the reference sequences are extractions from bacterial genomic sequences or complements thereof. A description of the primer design is provided herein.

**Table 1: Primer Pairs for Identification of *Staphylococcus***

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
258	RNASEP_SA_3 _49_F	GAGGAAAGTCCAT GCTCAC	255	RNASEP_SA_358 _379_R	ATAAGCCATGTTT TGTTCCATC	312
258	RNASEP_SA_3 _49_F	GAGGAAAGTCCAT GCTCAC	255	RNASEP_EC_345 _362_R	ATAAGCCGGGTTT TGTCG	313
258	RNASEP_SA_3 _49_F	GAGGAAAGTCCAT GCTCAC	255	RNASEP_BS_363 _384_R	GTAAGCCATGTTT TGTTCCATC	314
258	RNASEP_EC_6 _77_F	GAGGAAAGTCCGG GCTC	257	RNASEP_SA_358 _379_R	ATAAGCCATGTTT TGTTCCATC	312
258	RNASEP_EC_6 _77_F	GAGGAAAGTCCGG GCTC	257	RNASEP_EC_345 _362_R	ATAAGCCGGGTTT TGTCG	313

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
258	RNASEP_EC_6 1_77_F	GAGGAAAGTCCGG GCTC	257	RNASEP_BS_363 384_R	GTAAGCCAIGTTT TGTTCCATC	314
258	RNASEP_BS_4 3_61_F	GAGGAAAGTCCAT GCTC3C	256	RNASEP_SA_358 379_R	ATAAGCCAIGTTC TGTTCCATC	312
258	RNASEP_BS_4 3_61_F	GAGGAAAGTCCAT GCTC3C	256	RNASEP_EC_345 362_R	ATAAGCCGGGTTTC TGTCG	313
258	RNASEP_BS_4 3_61_F	GAGGAAAGTCCAT GCTC3C	256	RNASEP_BS_363 384_R	GTAAGCCAIGTTT TGTTCCATC	314
259	RNASEP_BS_4 3_61_F	GAGGAAAGTCCAT GCTC3C	256	RNASEP_BS_363 384_R	GTAAGCCAIGTTT TGTTCCATC	314
260	RNASEP_EC_6 1_77_F	GAGGAAAGTCCGG GCTC	257	RNASEP_EC_345 362_R	ATAAGCCGGGTTTC TGTCG	313
262	RNASEP_SA_3 1_49_F	GAGGAAAGTCCAT GCTCAC	255	RNASEP_SA_358 379_R	ATAAGCCAIGTTC TGTTCCATC	312
877	MECA_Y14051 _3774_3802_ F	TAAACAAACTAC GGTAACATTGATC GCA	57	MECA_Y14051_3 828_3854_R	TCCCAATCTAACT TCCACATACCATC T	141
878	MECA_Y14051 _3645_3670_ F	TGAAGTAGAAATG ACTGAACGTCCGA	56	MECA_Y14051_3 690_3719_R	TGATCCTGAATGT TTATATCTTAAC GCCT	140
879	MECA_Y14051 _4507_4530_ F	TCAGGTACTGCTA TCCACCCTCAA	58	MECA_Y14051_4 555_4581_R	TGGATAGACGTCA TATGAAGGTGTGC T	142
880	MECA_Y14051 _4510_4530_ F	TGTACTGCTATCC ACCCTCAA	59	MECA_Y14051_4 586_4610_R	TATTTCTTCTGTTAC TCATGCCATACA	143
881	MECA_Y14051 _4669_4698_ F	TCACCAGGTTCAA CTCAAAAATATT AACA	61	MECA_Y14051_4 765_4793_R	TAACCACTCCAAG ATTTATCTTTTG CCA	146
882	MECA_Y14051 _4520_4530P F	TCpCpACpCpCpT pCpAA	60	MECA_Y14051_4 590_4600P_R	TpACpTpCpATpG CpCpA	144
883	MECA_Y14051 _4520_4530P F	TCpCpACpCpCpT pCpAA	60	MECA_Y14051_4 600_4610P_R	TpATpTpCpTpTp CpGTpT	145
2C56	MECI- R_NC003923- 41798- 41609_33_60 F	TTTACACATATCG TGAGCAATGAACT GA	62	MECI- R_NC003923- 41798- 41609_86_113_ R	TTGTGATATGGAG GTGTAGAAGGTGT TA	147
2C57	AGR- III_NC00392 3-2108074- 2109507_1_2 3_F	TCACCAGTTTGCC ACGTATCTTCAA	191	AGR- III_NC003923- 2108074- 2109507_56_79 R	ACCTGCATCCCTA AACGTACTTGC	266
2C58	AGR- III_NC00392 3-2108074- 2109507_569 _596_F	TGAGCTTTTAGTT CACTTTTCAACA GC	192	AGR- III_NC003923- 2108074- 2109507_622_6 53_R	TACTTCAGCTTCG TCCAATAAAAAAT CACAAAT	267

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
2C59	AGR- III_NC003923-2108074-2109507_1024_1052_F	TTTCACACAGCGT GTTTATAGTTCTA CCA	193	AGR- III_NC003923-2108074-2109507_1070_1098_R	TGTAGGCAAGTGC ATAAGAAATTGAT ACA	268
2C60	AGR- I_AJ617706_622_651_F	TGGTGACTTCATA ATGGATGAAGTTG AAGT	217	AGR- I_AJ617706_694_726_R	TCCCCATTTAATA ATTCCACCTACTA TCACACT	292
2C61	AGR- I_AJ617706_580_611_F	TGGGATTTTAAAA AACATTGGTAACA TCGCAG	218	AGR- I_AJ617706_626_655_R	TGGTACTTCAACT TCATCCATTATGA AGTC	293
2C62	AGR- II_NC002745-2079448-2080879_620651_F	TCTTGCAGCAGTT TATTIGATGAACC TAAAGT	219	AGR- II_NC002745-2079448-2080879_700_731_R	TTGTTTATIGTTT CCATATGCTACAC ACTTTC	294
2C63	AGR- II_NC002745-2079448-2080879_649679_F	TGTACCCGCTGAA TTAACGAATTTAT ACGAC	220	AGR- II_NC002745-2079448-2080879_715_745_R	TCGCCATAGCTAA GTTGTTTATTTGTT TCCAT	1
2C64	AGR- IV_AJ617711_931_961_F	TGGTATTCTATTT TGCTGATAATGAC CTGC	221	AGR- IV_AJ617711_1004_1035_R	TGCGCTATCAACG ATTTTGACAAAT ATGTGA	296
2C65	AGR- IV_AJ617711_250_283_F	TGGCACTCTTGCC TTCAATATTAGTA AACTATCA	222	AGR- IV_AJ617711_309_335_R	TCCCATACCTATG GCGATAACTGTCA T	297
2C66	BLAZ_NC002952(1913827..1914672)_68_68_F	TCCACTTATCGCA AAAGGAAAAATTA GCA	223	BLAZ_NC002952(1913827..1914672)_68_68_R	TGGCCACTTTTAT CAGCAACCTTACA GTC	280
2C67	BLAZ_NC002952(1913827..1914672)_68_68_2_F	TGCACTTATCGCA AAAGGAAATTA GCAA	224	BLAZ_NC002952(1913827..1914672)_68_68_2_R	TAGTCTTTTGAA CACCGTCTTAAAT TAAAGT	281
2C68	BLAZ_NC002952(1913827..1914672)_68_68_3_F	TGATACTTCAACG CCGCTGCTTTC	225	BLAZ_NC002952(1913827..1914672)_68_68_3_R	TGGAACACCGTCT TTAATTAAGTAT CTCC	282
2C69	BLAZ_NC002952(1913827..1914672)_68_68_4_F	TACTACTCAACGC CTGCTGCTTTC	226	BLAZ_NC002952(1913827..1914672)_68_68_4_R	TCTTTTCTTTGCT TAATTTTCCATT CCGAT	283
2C70	BLAZ_NC002952(1913827..1914672)_133_F	TGCAATTGCTTTA GTTTAAAGTGCAT GTAAATC	227	BLAZ_NC002952(1913827..1914672)_34_67_R	TTACTTCCCTACC ACTTTTAGTATCT AAAGCATA	284
2C71	BLAZ_NC002952(1913827..1914672)_34_F	TCCTTGCTTTAGT TTTAAGTGCATGT AATCAA	228	BLAZ_NC002952(1913827..1914672)_40_68_R	TGGGGACTTCCTT ACCACTTTTAGTA TCTAA	285
2C72	BSA- A_NC003923-1304065-1303589_99_125_F	TAGCGAATGTGGC TTTACTTCACAAT T	194	BSA- A_NC003923-1304065-1303589_165_193_R	TGCAAGGGAAACC TAGAATTACAAAC CCT	269

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
2C73	BSA- A_NC003923- 1304065- 1303589_194 218 F	ATCAATTGGTGG CCAGAACCTGG	195	BSA- A_NC003923- 1304065- 1303589_253_2 78 R	TGCATAGGGAAGG TAACACCMAGTT	270
2C74	BSA- A_NC003923- 1304065- 1303589_328 349 F	TTGACTGCGGCAC AACACGGAT	196	BSA- A_NC003923- 1304065- 1303589_388_4 15 R	TAACAACGTTACC TTCGCGATCCACT AA	271
2C75	BSA- A_NC003923- 1304065- 1303589_253 278 F	TGCTATGGTGTTA CCTTCCCTATGCA	197	BSA- A_NC003923- 1304065- 1303589_317_3 44 R	TGTTGTGCGGCAG TCMAATATCTAAA TA	272
2C76	BSA- B_NC003923- 1917149- 1914156_953 982 F	TAGCAACAAATAT ATCTGAAGCAGCG TACT	198	BSA- B_NC003923- 1917149- 1914156_1011_ 1039 R	TGTGAAGAACTTT CAAATCTGIGAAT CCA	273
2C77	BSA- B_NC003923- 1917149- 1914156_105 0_1081 F	TGAAACTATGCA TTTGAACAACCTCG TGAATA	199	BSA- B_NC003923- 1917149- 1914156_1109_ 1136 R	TCTTCTTGAAAAA TTGTTGTCCCGAA AC	274
2C78	BSA- B_NC003923- 1917149- 1914156_126 0_1286 F	TGATTATCATGCG CCATATGATGCAG A	200	BSA- B_NC003923- 1917149- 1914156_1323_ 1353 R	TGGACTAA1AACA ATGAGCTCATTTGT ACTGA	275
2C79	BSA- B_NC003923- 1917149- 1914156_212 6_2153 F	TTTCATCTTATCG AGGACCCGAAATC GA	201	BSA- B_NC003923- 1917149- 1914156_2186_ 2216 R	TGAATATGTAATG CAAACCAAGTCATT GTCAT	276
2C80	ERMA_NC0029 52-55890- 56621_366_3 92 F	TGCTATCTTATC GTTGAGAAGGGAT T	28	ERMA_NC002952 -55890- 56621_487_513 R	TGAGTCTAGACTT GGCTTAGGATGAA A	114
2C81	ERMA_NC0029 52-55890- 56621_366_3 95 F	TAGCTATCTTATC GTTGAGAAGGGAT TTGC	294	ERMA_NC002952 -55890- 56621_438_465 R	TGAGCATTTTAT ATCCATCTCCACC AT	295
2C82	ERMA_NC0029 52-55890- 56621_374_4 02 F	TGATCGTTGAGAA GGGATTTGCGAAA AGA	27	ERMA_NC002952 -55890- 56621_473_504 R	TCTTGGCTTAGGA TGAAAATATAGTG GTGGTA	113
2C83	ERMA_NC0029 52-55890- 56621_404_4 27 F	TGCAAAATCTGCA ACCAGCTTTGC	29	ERMA_NC002952 -55890- 56621_491_520 R	TCAATACAGAGTC TACACTTGGCTTA GGAT	115
2C84	ERMA_NC0029 52-55890- 56621_489_5 16 F	TCATCCTTAGCCA AGTGTAGACTCTG TA	30	ERMA_NC002952 -55890- 56621_586_615 R	TGGACGATATCA CGGTTTACCCACT TATA	116

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
2C85	ERMA_NC0029 52-55890- 56621_586_6 14_F	TATAAGTGGGTAA ACCGTGAATATCG TGT	31	ERMA_NC002952 -55890- 56621_640_665 R	TTGACATTTCAT GCTTCAAAGCCTG	117
2C86	ERMC_NC0059 08-2004- 2738_95_116 F	TCTGAACATGATA ATATCTTTGAAAT CGGCTC	35	ERMC_NC005908 -2004- 2738_173_206_ R	TCCGTAGITTTGC ATAATTTATGGTC TATTTCAA	121
2C87	ERMC_NC0059 08-2004- 2738_90_120 F	TCATGATAAATATC TTTGAATTCGGCT CAGGA	33	ERMC_NC005908 -2004- 2738_160_199_ R	TTTATGGTCTATT TCATGGCAGTTA CGAA	119
2C88	ERMC_NC0059 08-2004- 2738_115_13 9_F	TCAGGAAAAGGGC ATTTTACCCTTG	34	ERMC_NC005908 -2004- 2738_161_197_ R	TATGGTCTATTTC AATGGCAGTTACG A	120
2C89	ERMC_NC0059 08-2004- 2738_374_39 7_F	TAATCGTGAATA CGGCTTTGCTA	36	ERMC_NC005908 -2004- 2738_425_452_ R	TCAACTTCTGCCA TTAAAAAGTAATGC CA	122
2C90	ERMC_NC0059 08-2004- 2738_101_12 5_F	TCTTTGAAATCGG CTCAGGAAAAGG	32	ERMC_NC005908 -2004- 2738_159_198_ R	TGATGGTCTATTT CAATGCCAGTTAC GAAA	118
2C91	ERMB_Y13600 -625- 1362_291_32 1_F	TGTTGGGAGTATT CCTTACCATTAA GCACA	229	ERMB_Y13600- 625- 1362_352_380_ R	TCAACAATCAGAT AGATGTCAGACGC ATG	286
2C92	ERMB_Y13600 -625- 1362_344_36 7_F	TGGAAAGCCATGC GTCTGACATCT	230	ERMB_Y13600- 625- 1362_415_437_ R	TGCAGAGCAACC CTAGTGTTCCG	287
2C93	ERMB_Y13600 -625- 1362_404_42 9_F	TGGATATTCACCG AACACTAGGGTTG	231	ERMB_Y13600- 625- 1362_471_493_ R	TAGGATGAAAGCA TTCCGCTGGC	288
2C94	ERMB_Y13600 -625- 1362_465_48 7_F	TAAAGCTGCCAGCG GAATGCTTTC	232	ERMB_Y13600- 625- 1362_521_545_ R	TCACTCTGTGGTAT GGCGGGTAAGTT	289
2C95	PVLUK_NC003 923- 1529595- 1531285_688 713_F	TGAGCTGCATCAA CTGTATTGGATAG	39	PVLUK_NC00392 3-1529595- 1531285_775_0 04_R	TGGAAAACTCATG AAATTAAACTGAA AGGA	125
2C96	PVLUK_NC003 923- 1529595- 1531285_103 9_1068_F	TGGAACAAAATAG TCTCTCGGATTTT GACT	37	PVLUK_NC00392 3-1529595- 1531285_1095_ 1125_R	TCATTAGGTAAAA TGTCTGGCATGA TCCAA	123
2C97	PVLUK_NC003 923- 1529595- 1531285_908 936_F	TGACTAACATCCA TATTCTGCCATA CGT	40	PVLUK_NC00392 3-1529595- 1531285_950_9 78_R	TCTCATGAAAAAG GCTCAGGAGATAC AAG	126

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
2098	PVLUK_NC003923-1529595-1531285_610_633_F	TCGGAATCTGATGTTGCAGTTGTT	38	PVLUK_NC003923-1529595-1531285_654_682_R	TCACACCTGTAAGTGAGAAAAAGGTTGA1	124
2099	SA442_NC003923-2538576-2538831_11_35_F	TGTCGGTACACGATATCTCTCACGA	205	SA442_NC003923-2538576-2538831_98_124_R	TTTCCGATGCAACGTAATGAGATTCA	13
2100	SA442_NC003923-2538576-2538831_98_124_F	TGAAATCTCATTAAGTTGCATCGGAATA	206	SA442_NC003923-2538576-2538831_163_188_R	TCGTATGACCAGCTTCGGTACTACTA	14
2101	SA442_NC003923-2538576-2538831_103_126_F	TCTCATTTACGTTGCATCGAAACA	207	SA442_NC003923-2538576-2538831_161_187_R	TTTATGACCAGCTTCGGTACTACTAA	15
2102	SA442_NC003923-2538576-2538831_166_188_F	TAGTACCGAAGCTGGTCATACGA	208	SA442_NC003923-2538576-2538831_231_257_R	TCATAATCAAGCGAACCCTTTTTCACG	96
2103	SEA_NC003923-2052219-2051456_115_135_F	TGCAGGGAACAGCTTTAGGCA	209	SEA_NC003923-2052219-2051456_173_200_R	TCGATCGTCACTCTCTTTATTTTCAGTT	97
2104	SEA_NC003923-2052219-2051456_572_598_F	TAACCTCTGATGTTTTCATGCCAAGCT	210	SEA_NC003923-2052219-2051456_621_651_R	TGTAATTAACCGAAGCTTCTGTAGAAATATG	98
2105	SEA_NC003923-2052219-2051456_382_414_F	TGTAAGGTGGTGTAAAGTTACATGATAATAATC	211	SEA_NC003923-2052219-2051456_464_492_R	TAACCGTTTCCAAAGGTACTGTATTTTGT	317
2106	SEA_NC003923-2052219-2051456_377_406_F	TTGTATGTATGGTGGTGTAACGTTACATGA	212	SEA_NC003923-2052219-2051456_459_492_R	TAACCGTTTCCAAAGGTACTGTATTTTGTATTACC	318
2107	SFB_NC002758-2135540-2135140_208_237_F	TTTCACATGTAATTTCGATATTCGCACTGA	247	SFB_NC002758-2135540-2135140_273_298_R	TCATCTGGTTTAGGATCTGGTTGACT	304
2108	SEB_NC002758-2135540-2135140_206_235_F	TATTCACATGTAATTTTGATATTCGCACT	248	SEB_NC002758-2135540-2135140_281_304_R	TGCAACTCATCTGTATTAGGATCT	305
2109	SEB_NC002758-2135540-2135140_402_402_F	TAACAACTCGCCTTACGAAACGGGATATA	249	SEB_NC002758-2135540-2135140_402_402_R	TGTGCAGGCATCATGTATACCAA	306

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
2110	SEB_NC002758-2135540-2135140_402_402_2_F	TTGTATGTATGGTGGTGTAAGTGAGCA	250	SEB_NC002758-2135540-2135140_402_402_2_R	TTACCATCTTCAAATACCCGAACAGTAA	307
2111	SEC_NC003923-851678-852768_546_575_F	TTAACATGAAGGAACCACTTTGATAATGG	213	SEC_NC003923-851678-852768_620_647_R	TGAGTTTGCACTTCAAAAGAAATTTGTGT	319
2112	SEC_NC003923-851678-852768_537_566_F	TGGAATAACAAAACATGAAGGAAACCACCT	214	SEC_NC003923-851678-852768_619_647_R	TCAGTTTGCACTTCAAAAGAAATTTGTGTT	320
2113	SEC_NC003923-851678-852768_720_749_F	TGAGTTTAACAGTTCACCATATGAAACAGG	215	SEC_NC003923-851678-852768_794_815_R	TCGCCTGGTGCAGGCATCATAT	321
2114	SEC_NC003923-851678-852768_787_810_F	TGGTATGATATGATGCCATGCACCA	216	SEC_NC003923-851678-852768_853_886_R	TCTTCACACTTTTGAATCAACCGTTTATTGTCT	322
2115	SED_M28521_657_682_F	TGGTGGTGAAATACATAGGACTGCTT	183	SED_M28521_741_770_R	TGTACACCATTTATCCACAAATTGATTGGT	258
2116	SED_M28521_690_711_F	TGGAGGTGTCACTCCACACGAA	184	SED_M28521_739_770_R	TGGGCACCATTTATCCACAAATTGATTGGTAT	259
2117	SED_M28521_833_854_F	TTTGACACAAGCAAGCGCTATTT	185	SED_M28521_888_911_R	TCGCGCTGTAATTTTTCCTCCGAGA	260
2118	SED_M28521_962_987_F	TGGATGTAAAGGGTGATTTTCCCGAA	186	SED_M28521_1022_1043_R	TGTCATATGAAGGTGCTCTGTGGATTA	261
2119	SEA-SEE_NC002952-2131289-2130703_16_45_F	TTTACACTACTTTTACTTCATTGCCCTAACG	233	SEA-SEE_NC002952-2131289-2130703_71_98_R	TCATTTATTTCTTCGCTTTTCTCGCTAC	290
2120	SEA-SEE_NC002952-2131289-2130703_249_278_F	TGATCATCCGTGGTACAACGATTTATAGT	234	SEA-SEE_NC002952-2131289-2130703_314_344_R	TAAGCACCATATAACTCTACTTTTCCCTT	291
2121	SEE_NC002952-2131289-2130703_409_437_F	TGACATGATAATAACCGATTGACCGAGA	235	SEE_NC002952-2131289-2130703_465_494_R	TCTATAGGTACTGTAGTTTGTTTCCGTCT	323
2122	SEE_NC002952-2131289-2130703_525_550_F	TGTTCAAGAGCTACATCTTCAGGCAA	236	SEE_NC002952-2131289-2130703_586_586_R	TTTGCACCTTACCOCCAAAGCT	324
2123	SEE_NC002952-2131289-2130703_525_549_F	TGTTCAAGAGCTACATCTTCAGGCAA	237	SEE_NC002952-2131289-2130703_586_586_2_R	TACCTTACCGCCAAGCTGTCT	325

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
2124	SEE_NC002952-2131289-2130703_361_384_F	TCTGGAGGCACACCAAATAAAACA	238	SEE_NC002952-2131289-2130703_444_471_R	TCCGTCTATCCACAAGTTAATIGGTACT	326
2125	SEG_NC002758-1955100-1954171_225_251_F	TGCTCAACCCGATCCTAAATTAGACGA	251	SEG_NC002758-1955100-1954171_321_346_R	TAATCCTCTTCCTTCAACAGGTGGA	308
2126	SEG_NC002758-1955100-1954171_623_651_F	TGGACAATAGACAATCACTTGGATTTACA	252	SEG_NC002758-1955100-1954171_671_702_R	TGCTTTGTAATCTAGTTCCTGAATAGTAACCA	309
2127	SEG_NC002758-1955100-1954171_540_564_F	TGGAGGTGTGTGTATGTATGGTGGT	253	SEG_NC002758-1955100-1954171_607_635_R	TGTCTATTGTCGATTGTTACCTGTACAGT	310
2128	SEG_NC002758-1955100-1954171_694_718_F	TACAAAGCAAGACACTGGCTCACTA	254	SEG_NC002758-1955100-1954171_735_762_R	TGATTCAAATGCAGAACCATCAAACCTCG	311
2129	SEH_NC002953-60024-60977_449_472_F	TTGCAACTGCTGATTAGCTCAGA	239	SEH_NC002953-60024-60977_547_576_R	TAGTGTGTGACCTCCATATAGACATTGAGAC	327
2130	SEH_NC002953-60024-60977_408_434_F	TAGAAATCAAGGTGACATGGGCAATGA	240	SEH_NC002953-60024-60977_450_473_R	TTCTGAGCTAAATCAGCAGTTGCA	328
2131	SEH_NC002953-60024-60977_547_576_F	TCTGAATGTCTATATGGAGGTACAACTA	241	SEH_NC002953-60024-60977_608_634_R	TACCATCTACCCAATCATTAGCACCAA	298
2132	SEH_NC002953-60024-60977_546_575_F	TTCTGATGTCTATATGGAGGTACAACT	242	SEH_NC002953-60024-60977_594_616_R	TAGCACCAATCACCTTTCCCTGT	299
2133	SEI_NC002758-1957830-1956949_324_349_F	TCAACTCGAATTTTCAACAGGTACCA	243	SEI_NC002758-1957830-1956949_419_446_R	TCACAAGGACCATTTATAATCAATGCCAA	300
2134	SEI_NC002758-1957830-1956949_336_363_F	TTCAACAGGTACC AATGATTTCATCTCA	244	SEI_NC002758-1957830-1956949_420_447_R	TGTACAAGGACCA TTATAATCAATGCCA	301
2135	SEI_NC002758-1957830-1956949_356_384_F	TGATCTCAGAATCTAATAATTGGGACGAA	245	SEI_NC002758-1957830-1956949_449_474_R	TCTGGCCCTCCATACATGTATTAG	302
2136	SEI_NC002758-1957830-1956949_223_253_F	TCTCAAGGTGATA TTGGTGTAGGTAACTTAA	246	SEI_NC002758-1957830-1956949_290_316_R	TGGGTAGGTTTTTATCTGTGACGCCTT	303
2137	SEJ_AF053140_1307_1332_F	TGTGGAGTAACAC TGCAIGAAAACAA	187	SEJ_AF053140_1381_1404_R	TCTAGCGGAACAA CAGTTCTGATG	262

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
2138	SEJ_AF053140_1378_1403_F	TAGCATCAGAACT GTGTTCCGCTAG	188	SEJ_AF053140_1429_1458_R	TCCTGAAGATCTA GTTCTTGAATGGT TACT	263
2139	SEJ_AF053140_1431_1459_F	TAACCATTCAGA ACTAGATCTTCAG GCA	189	SEJ_AF053140_1500_1531_R	TAGTCCTTTCCTGA ATTTTACCATCAA AGGTAC	264
2140	SEJ_AF053140_1434_1461_F	TCATTCAAGAACT AGATCTTCAGGCA AG	190	SEJ_AF053140_1521_1549_R	TCAGGTATGAAAC ACGATTAGTCCTT TCT	265
2141	TSST_NC002758-2137564-2138293_206_236_F	TGGTITAGATAAT TCCTTAGGATCTA TGCCT	66	TSST_NC002758-2137564-2138293_273_305_R	TGTAAAAGCAGGG CTATAATAAGGAC TC	151
2142	TSST_NC002758-2137564-2138293_232_258_F	TGCGTATAAAAAA CACAGATGGCAGC A	67	TSST_NC002758-2137564-2138293_289_313_R	TGCCCTTTTGTAA AAGCAGGGCIAT	152
2143	TSST_NC002758-2137564-2138293_382_410_F	TCCAAATAAGTGG CGTTACAAATACT GAA	68	TSST_NC002758-2137564-2138293_443_478_R	TACTTTAAGGGGC TATCTTTACCATG AACT	153
2144	TSST_NC002758-2137564-2138293_297_325_F	TCTTTTACAAAAG GGGAAAAAGTTGA CTT	69	TSST_NC002758-2137564-2138293_347_373_R	TAAGTTCTCTCGC TAGTATGTTGGCT T	154
2145	ARCC_NC003923-2725050-2724595_37_58_F	TCGCCGGCAATGC CATTCGATA	75	ARCC_NC003923-2725050-2724595_97_128_R	TGAGTTAAAATGC GATTGATTTCAGT TTCCAA	161
2146	ARCC_NC003923-2725050-2724595_131_161_F	TGAAIAGTGATAG AACTGTAGGCACA ATCGT	72	ARCC_NC003923-2725050-2724595_214_245_R	TCTTCTTCTTTCG TATAAAAAGGACC AATTGG	156
2147	ARCC_NC003923-2725050-2724595_218_249_F	TTGGTCTTTTTTA TACGAAAAGAAGAA GTTGAA	74	ARCC_NC003923-2725050-2724595_322_353_R	TGGTGTCTTAGTA TAGATTGAGGTAG TGGTGA	160
2148	AROE_NC003923-1674726-1674277_371_393_F	TTGCGAATAGAAC GATGCTCTCGT	80	AROE_NC003923-1674726-1674277_435_464_R	TCGAATTCAGCTA AATCTTTTCAGC ATCT	167
2149	AROE_NC003923-1674726-1674277_30_62_F	TGGCCCTTTAAAT ATTCCAATTGAAG ATTTTCA	79	AROE_NC003923-1674726-1674277_155_181_R	TACCTGCATTAAT CGCTTGTCATCA A	166
2150	AROE_NC003923-1674726-1674277_204_232_F	TGATGGCAAGTGG ATAGGGTATAATA CAC	76	AROE_NC003923-1674726-1674277_303_335_R	TAAGCAATACCTT TACTTGCACCACC TC	162
2151	G_LPF_NC003923-1296927-1297391_270_301_F	TGCACCGGCTATT AAGAATTACTTTG CCAACT	202	G_LPF_NC003923-1296927-1297391_382_414_R	TGCACCAATTAAT GCTCCGACAACTA AAGGATT	277

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
2152	GLPF_NC003923-1296927-1297391_27_51_F	TGGATGGGGATTA CGGTTACAATG	203	GLPF_NC003923-1296927-1297391_81_108_R	TAAAGACACCGCT GGGTTTAAATGTG CA	278
2153	GLPF_NC003923-1296927-1297391_239_260_F	TAGCTGGCGCGAA ATTAGGTGT	204	GLPF_NC003923-1296927-1297391_323_359_R	TCACCGATAAATA AAATACCTAAAGT TAATGCCATTG	279
2154	GMK_NC003923-1190906-1191334_91_122_F	TACTTTTAAAA CTAGGGATGCGTT TGAAGC	81	GMK_NC003923-1190906-1191334_166_197_R	TGATATTGAACFG GTGTACCATAATA GTTGCC	168
2155	GMK_NC003923-1190906-1191334_240_267_F	TGAACTACAAGGT GCAAAGCAAGTTA GA	82	GMK_NC003923-1190906-1191334_305_333_R	TCCCTCTCTCAAG TGATCTAAACTTG GAG	169
2156	GMK_NC003923-1190906-1191334_301_329_F	TCACCTCCAAGTT TAGATCACTTGAG AGA	83	GMK_NC003923-1190906-1191334_403_432_R	TGGGACGTAATCG TATAAATCATCA TTTC	170
2157	PTA_NC003923-628885-629355_237_263_F	TCTTCTTTATGCT CGTAAAGCAGATC G	87	PTA_NC003923-628885-629355_314_345_R	TGGTACACCTGGT TTCGTTTTGATGA TTTGTA	172
2158	PTA_NC003923-628885-629355_141_171_F	TGAATTAGTTCAA TCATTTGTTGAAC GACGT	84	PTA_NC003923-628885-629355_211_239_R	TGCATTGTACCGA AGTAGTTCACATT GTT	171
2159	PTA_NC003923-628885-629355_328_355_F	TCCAAACCAGGTG TATCAAGAACATC AGG	88	PTA_NC003923-628885-629355_393_422_R	TGTTCTGGATTGA TTGCACAATCACC AAAG	175
2160	TPI_NC003923-830671-831072_131_160_F	TGCAAGTTAAGAA AGCTGTTGCAGGT TTAT	89	TPI_NC003923-830671-831072_209_239_R	TGAGATGTTGATG ATTTACCAGTTCC GATTG	176
2161	TPI_NC003923-830671-831072_1_34_F	TCCACGAAACAG ATGAAGAAATTAA CAAAAAAG	90	TPI_NC003923-830671-831072_97_129_R	TGGTACAACATCG TTAGCTTTACCAC TTTCACG	177
2162	TPI_NC003923-830671-831072_199_227_F	TCAAAC TGGGCAA TCGGAAGTGGTAA ATC	91	TPI_NC003923-830671-831072_253_286_R	TGGCAGCAALAGT TTGACGTACAAAT GCACACAT	178
2163	YQI_NC003923-378916-379431_142_167_F	TGAATTGCTGCTA TGAAAGGTGGCTT	93	YQI_NC003923-378916-379431_259_284_R	TCCCCAGCTAGCA CGATGTCATTTTC	180
2164	YQI_NC003923-378916-379431_44_7_F	TACAACATATTAT TAAAGAGACGGGT TTGAATCC	95	YQI_NC003923-378916-379431_120_145_R	TTCTGTCTGGATT TTGTCTTGTCTCT	182
2165	YQI_NC003923-378916-379431_135_160_F	TCCAGCACGAATT GCTGCTATGAAAG	92	YQI_NC003923-378916-379431_193_221_R	TCCAACCCAGAAC CACATACITTTATT CAC	179

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
2166	YQI_NC003923-378916-379431_275_300_F	TAGCTGGCGGTATGGAGAATATGTCT	94	YQI_NC003923-378916-379431_364_395_R	TCCATCTGTATAAACATCATATACCA TGCTATC	181
2167	BLAZ_(1913827..1914672)_546_575_F	TCCACTTATCGCA AATGGAAAATTAA GCAA	223	BLAZ_(1913827..1914672)_655_683_R	TGGCCACTTTTAT CAGCAACCTTACA GTC	280
2168	BLAZ_(1913827..1914672)_546_575_F	TGCACTTATCGCA AATGGAAAATTAA GCAA	224	BLAZ_(1913827..1914672)_628_659_R	TAGTCTTTTGGAA CACCGTCTTTAAT TAAAGT	281
2169	BLAZ_(1913827..1914672)_507_531_F	TGATACTTCAACG CCTGCTGCTTTC	225	BLAZ_(1913827..1914672)_622_651_R	TGGAACACCGTCT TTAATTAAAGTAT CTCC	282
2170	BLAZ_(1913827..1914672)_508_531_F	TACTACTCAACGC CTGCTGCTTTC	226	BLAZ_(1913827..1914672)_553_583_R	TCTTTTCTTTTGCT TAATTTTCCACTT GCGAT	283
2171	BLAZ_(1913827..1914672)_24_56_F	TGCAATTGCTTTA CTCTTAACTGCAT GTAATTC	227	BLAZ_(1913827..1914672)_121_154_R	TTACTTCCTTACC ACTTTTAGTATCT AAAGCATA	284
2172	BLAZ_(1913827..1914672)_26_58_F	TCCTTGCTTTAGT TTCAAGTGCATGT AATTCAA	228	BLAZ_(1913827..1914672)_127_157_R	TGGGGACTTCCTT ACCACTTTTAGTA TCTAA	285
2173	BLAZ_NC002952-1913827-1914672_546_575_F	TCCACTTATCGCA AATGGAAAATTAA GCAA	223	BLAZ_NC002952-1913827-1914672_655_683_R	TGGCCACTTTTAT CAGCAACCTTACA GTC	280
2174	BLAZ_NC002952-1913827-1914672_546_575_2_F	TGCACTTATCGCA AATGGAAAATTAA GCAA	224	BLAZ_NC002952-1913827-1914672_628_659_R	TAGTCTTTTGGAA CACCGTCTTTAAT TAAAGT	281
2175	BLAZ_NC002952-1913827-1914672_507_531_F	TGATACTTCAACG CCTGCTGCTTTC	225	BLAZ_NC002952-1913827-1914672_622_651_R	TGGAACACCGTCT TTAATTAAAGTAT CTCC	282
2176	BLAZ_NC002952-1913827-1914672_508_531_F	TACTACTCAACGC CTGCTGCTTTC	226	BLAZ_NC002952-1913827-1914672_553_583_R	TCTTTTCTTTTGCT TAATTTTCCACTT GCGAT	283
2177	BLAZ_NC002952-1913827-1914672_24_56_F	TGCAATTGCTTTA GTCTTAACTGCAT GTAATTC	227	BLAZ_NC002952-1913827-1914672_121_154_R	TTACTTCCTTACC ACTTTTAGTATCT AAAGCATA	284
2178	BLAZ_NC002952-1913827-1914672_26_58_F	TCCTTGCTTTAGT TTCAAGTGCATGT AATTCAA	228	BLAZ_NC002952-1913827-1914672_127_157_R	TGGGGACTTCCTT ACCACTTTTAGTA TCTAA	285
2247	TJFB_NC002758-615038-616222_693_721_F	TGTTGAACGTGGT CAAATCAAAGTTG GTG	46	TJFB_NC002758-615038-616222_793_820_R	TGTCACCAGCTTC AGCGTAGICTAAT AA	132
2248	TJFB_NC002758-615038-616222_690_716_F	TCGTGTTGAACGT GGTCAAATCAAAG T	45	TJFB_NC002758-615038-616222_793_820_R	TGTCACCAGCTTC AGCGTAGICTAAT AA	132

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
2249	TUFB_NC0027 58-615038- 616222_696_ 725_F	TGAACGTGGTCAA ATCAAAGTTGGTG AAGA	47	TJFB_NC002758 -615038- 616222_793_82 0_R	TGTCACCAGCTTC AGCGTAGICTAAT AA	132
2250	TUFB_NC0027 58-615038- 616222_488_ 513_F	TCCAGGTGACGA TGTACCTGTAATC	42	TJFB_NC002758 -615038- 616222_601_63 0_R	TGGTTTGICAGAA TCAGTTCTGGAG TTGG	128
2251	TUFB_NC0027 58-615038- 616222_945_ 972_F	TGAAGGTGGACGT CACACTCCATTCT TC	51	TJFB_NC002758 -615038- 616222_1030_1 060_R	TAGGCATAACCAAT TTCAGTACCTTCT GGTAA	135
2252	TUFB_NC0027 58-615038- 616222_333_ 356_F	TCCAATGCCACAA ACTCGTGAACA	41	TJFB_NC002758 -615038- 616222_424_45 9_R	TTCCATTTCAACT AATTCTAATAATT CTTCATCGTC	127
2253	NUC_NC00275 8-894288- 894974_402_ 424_F	TCCTGAAGCAAGT GCATTTACGA	52	NJC_NC002758- 894288- 894974_483_50 9_R	TACGCTAAGCCAC GTCCATAATTATC A	136
2254	NUC_NC00275 8-894288- 894974_53_8 1_F	TCCTTATAGGGAT GGCTATCACTAAT GTT	53	NJC_NC002758- 894288- 894974_165_18 9_R	TGTTTGTGATGCA TTTGCTGAGCTA	137
2255	NUC_NC00275 8-894288- 894974_169_ 194_F	TCAGCAAATGCAT CACAAACAGATAA	54	NJC_NC002758- 894288- 894974_222_25 0_R	TAGTTGAAGTTGC ACTATATACCTGT GGA	138
2256	NUC_NC00275 8-894288- 894974_316_ 345_F	TACAAAGGTCAAC CAATGACATTGAG ACTA	55	NJC_NC002758- 894288- 894974_396_42 1_R	TAAATGCACCTGC TTCAGGGCCATAT	139
2309	MUPR_X75439 1658_1689 F	TCCTTTGATATAT TATGCGATGGAAG GTTGGT	18	MJPR_X75439_1 744_1773_R	TCCCTTCCTTAAT ATGAGAAGGAAAC CACT	101
2310	MUPR_X75439 _1330_1353_ F	TTCTTCCTTTTGA AAGCGACGGTT	17	MJPR_X75439_1 413_1441_R	TGAGCTGGTGCTA TATGAACAATACC AGT	100
2312	MUPR_X75439 _1314_1338_ F	TTTCTCCTTTTGG AAAGC3ACGGTT	16	MJPR_X75439_1 381_1409_R	TATATGAACAATA CCAGTTCTCTCTG AGT	99
2313	MUPR_X75439 _2486_2516_ F	TAATTGGGCTCTT TCTCGCTTAAACA CCTTA	21	MJPR_X75439_2 548_2574_R	TTAATCTGGCTGC GGAAGTGAAATCG T	104
2314	MUPR_X75439 _2547_2572_ F	TACGATTTCACTT CCGCAGCCAGATT	23	MJPR_X75439_2 605_2630_R	TCGTCTCTCGAA TCTCCGATAACCC	109
2315	MUPR_X75439 _2666_2696_ F	TGCTACAATACG CTTTATGAAATTT TAACA	24	MJPR_X75439_2 711_2740_R	TCAGATATAAATG GAACAAATGGAGC CACT	110
2316	MUPR_X75439 _2813_2843_ F	TAATCAAGCATTG GAAGATGAAATGC ATACC	25	MJPR_X75439_2 867_2890_R	TCTGCATTTTTCG GAGCCTGTCTA	111
2317	MUPR_X75439 _884_914_F	TGACATGGACTCC CCCTATATACTC TTGAG	26	MJPR_X75439_9 77_1007_R	TGTACAATAAGGA GTCACCTTATGTC CCTTA	112

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
2504	ARCC_NC003923-2725050-2724595_135_161F F'	TAGTpGATpAGAA CpTpGTAGGCpAC pAAtpCpGT'	73	ARCC_NC003923-2725050-2724595_214_239P_R	TCpTpTpTpCpGT ATAAAAAGGACpC pAAtpTpGG'	159
2505	PTA_NC003923-628885-629355_237_263P F'	TCTTGTPTpTAT GCpTpGGTAAAGC AGATGG	86	PTA_NC003923-628885-629355_314_342P_R	TACpACpCpTGGT pTpTpCpGTpTpT pTpGATGATpTpT pCTA	174
2738	GYRA_NC002953-7005-9668_166_195 F'	TAAGGTATGACAC CGGTAATTCATA TAAA	2	GYRA_NC002953-7005-9668_265_297_R	TCTTGAGCCATAC GTACCATTCC	5
2739	GYRA_NC002953-7005-9668_221_249 F'	TAATCGGTAAATA TCACCTCATGGT GAC	3	GYRA_NC002953-7005-9668_316_343_R	TATCCATTGAACC AAAGTTACCTTGG CC	6
2740	GYRA_NC002953-7005-9668_221_249 F'	TAATGGGTAAATA TCACCTCATGGT GAC	3	GYRA_NC002953-7005-9668_253_293_R	TAGCCATACGTAC CATTTGCTTCATAA ATAGA	7
2741	GYRA_NC002953-7005-9668_234_261 F'	TCACCTCATGGT GACTCATCTATTT AT	4	GYRA_NC002953-7005-9668_265_297_R	TCTTGAGCCATAC GTACCATTCC	5
3004	TUFB_NC002758-615038-616222_684_704 F'	TACAGGCCGTGTT GAACGTGG	43	TJFB_NC002758-615038-616222_778_809_R	TCAGCGTAGTCTA ATAATTTACGGAA CATTTC	129
3005	TUFB_NC002758-615038-616222_688_710 F'	TGCCGTGTTGAAC CTGGTCAAAT	44	TJFB_NC002758-615038-616222_783_813_R	TGCTTCAGCGTAG TCTAATAATTTAC GGAAC	130
3006	TUFB_NC002758-615038-616222_700_726 F'	TGTGGTCAAATCA AAGTTGGTGAAGA A	49	TJFB_NC002758-615038-616222_778_807_R	TGCGTAGTCTAAT AATTTACGGAACA TTTC	134
3007	TUFB_NC002758-615038-616222_702_726 F'	TGGTCAAATCAAA GTTGGTGAAGAA	50	TJFB_NC002758-615038-616222_778_807_R	TGCGTAGTCTAAT AATTTACGGAACA TTTC	134
3008	TUFB_NC002758-615038-616222_696_726 F'	TGAACGTGGTCAA ATCAAAGTTGGTG AAGAA	48	TJFB_NC002758-615038-616222_785_818_R	TCACCAGCTTCAG CGTAGTCTAATAA TTTACGGA	133
3009	TUFB_NC002758-615038-616222_690_716 F'	TCGTGTTGACCGT GGTCAAATCAAAG T	45	TJFB_NC002758-615038-616222_778_812_R	TCTTCAGCGTAGT CTAATAATTTACG GAACATTTC	131
3010	MECI-R_NC003923-41798-41609_36_59_F'	TCACATATCGTGA GCAATGAAGTG	63	MECI-R_NC003923-41798-41609_89_112_R	TGTGATATGGAGG TGTAGAAGGTG	148

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
3C11	MECI- R_NC003923- 41798- 41609_40_66 _F	TGGGCGTGAGCAA TGAAGTATTATA C	64	MECI- R_NC003923- 41798- 41609_81_110_ _R	TGGGATGGAGGTG TAGAAGGTGTTAT CATC	149
3C12	MECI- R_NC003923- 41798- 41609_33_60 _F	TGGACACATATCG TGAGCAATGAACT GA	62	MECI- R_NC003923- 41798- 41609_81_110_ _R	TGGGATGGAGGTG TAGAAGGTGTTAT CATC	149
3C13	MECI- R_NC003923- 41798- 41609_29_60 _F	TGGGTTTACACAT ATCGTGAGCAATG AATGA	65	MECI- R_NC003923- 41798- 41609_81_113 _R	TGGGATATGGAG GTGTAGAAGGTGT TATCATC	150
3C14	MUPR_X75439 _2490_2514 _F	TGGGCTCTTTCTC GCTTAAACACCT	20	MJPR_X75439_2 _548_2570_R	TCTGGCTCGGAA GTGAAATCGT	103
3C15	MUPR_X75439 _2490_2513_ _F	TGGGCTCTTTCTC GCTTAAACACC	19	MJPR_X75439_2 _547_2568_R	TGGCTGCGGAAGT GAAATCGTA	102
3C16	MUPR_X75439 _2482_2510_ _F	TAGATAATTGGGC TCTTCTCGCTTA AAC	22	MJPR_X75439_2 _551_2573_R	TATCTGGCTGCG GAAGTGAAT	106
3C17	MUPR_X75439 _2490_2514_ _F	TGGGCTCTTTCTC GCTTAAACACCT	20	MJPR_X75439_2 _549_2573_R	TAATCTGGCTGCG GAAGTGAATCG	105
3C18	MUPR_X75439 _2482_2510_ _F	TAGATAATTGGGC TCTTCTCGCTTA AAC	22	MJPR_X75439_2 _559_2589_R	TCGTATATTCGTT AATTAATCTGGCT GCGGA	108
3C19	MUPR_X75439 _2490_2514_ _F	TGGGCTCTTTCTC GCTTAAACACCT	20	MJPR_X75439_2 _554_2581_R	TCGTAAATTAATC TGGCTGCGGAAGT GA	107
3C20	AROE_NC0039 23-1674726- 1674277_204 _232_F	TGATGGCAAGTGG ATAGGGTATAATA CAG	76	AROE_NC003923 -1674726- 1674277_309_3 _35_R	TAAGCAATACCTT TACTTGCACCACC T	163
3C21	AROE_NC0039 23-1674726- 1674277_207 _232_F	TGGCGAGTGGATA GGGTATAATACAG	78	AROE_NC003923 -1674726- 1674277_311_3 _39_R	TTCATAAGCAATA CCTTTACTTGCAC CAC	165
3C22	AROE_NC0039 23-1674726- 1674277_207 _232_F	TGGCpAACTpGGA TpAGGGTpATpAA TpACpAG	77	AROE_NC003923 -1674726- 1674277_311_3 _35P_R	TAAGCAATACCPt pTpTpACTpTpGC pACpCpAC	164
3C23	ARCC_NC0039 23-2725050- 2724595_124 _155_F	TCTGAAATGAATA GTGATAGAAGTGT AGCCAC	71	ARCC_NC003923 -2725050- 2724595_214_2 _45_R	TCTTCTTCTTTCTG TATAAAAAGGACC AATTGG	156
3C24	ARCC_NC0039 23-2725050- 2724595_131 _161_F	TGAATAGTGATAG AACTGTAGGCACA ATCGT	72	ARCC_NC003923 -2725050- 2724595_212_2 _42_R	TCTTCTTCTGTAT AAAAGGACCAAT TGGTT	157

Primer Pair Number	Forward Primer Name	Forward Sequence	Forward SEQ ID NO.	Reverse Primer Name	Reverse Sequence	Reverse SEQ ID NO.
3C25	ARCC_NC003923-2725050-2724595_131_161_F	TGAAATAGTGATAG AACTGTAGGCACA ATCGT	72	ARCC_NC003923-2725050-2724595_232_260_R	TGCGCTAATTCCTT CAACTTCTTCTTT CGT	158
3C26	PTA_NC003923-628885-629355_231_259_F	TACAATGCTTGTT TATGCTGGTAAAG CAG	85	PTA_NC003923-628885-629355_322_351_R	TGTTCTTGATACA CCTGGTTTCGTTT TGAT	173
3C27	PTA_NC003923-628885-629355_231_259_F	TACAATGCTTGTT TATGCTGGTAAAG CAG	85	PTA_NC003923-628885-629355_314_345_R	TGGTACACCTGGT TTCGTTTIGATGA TTTGTA	172
3C28	PTA_NC003923-628885-629355_237_263_F	TCTTCTTTATGCT GGTAAAGCAGATG G	87	PTA_NC003923-628885-629355_322_351_R	TCTTCTTCATACA CCTGGTTTCGTTT TGAT	173
3105	TSST1_NC002758.2_35_57_F	TAAGCCCTTTGTT GCTTTCGACA	329	TSST1_NC002758.2_46_173_R	TCAGACCCACTAC TATACCAGTCTAG CA	330
3106	TSST1_NC002758.2-2137509-2138213_519_546_F	TCGTCAATCAGCTA ACTCAAATACATG GA	70	TSST1_NC002758.2-2137509-2138213_593-620_R	TCACTTTGATATG TGGATCCGTCATT CA	155
3107	TSST1_NC002758.2_334_357_F	TGCCAACATACTA GCGAAGGAAGT	331	TSST1_NC002758.2_415_445_R	TCCCATGAACCTT AACTTTTAAAGGT AGTTC	332

[00107] As noted above, primer pair name codes for primer pairs listed in Table 1, cross-referenced to corresponding reference sequence, bioagent, and gene information are shown in Table 2. The primer name code typically represents the gene to which the given primer pair is targeted. The primer names also include specific coordinates with respect to a reference sequence to which the primer hybridizes. As exemplified above, this reference sequence is often defined by an extraction of a section of sequence or defined by a GenBank gi number (indicated by extraction coordinates in the primer pair name), or the corresponding complementary sequence of the extraction, or, in cases when no extraction coordinates are listed, to the entire sequence of the GenBank gi number. Gene abbreviations are shown in bold type in the “Gene Name” column of Table 2.

**[00108]** Methods for PCR primer design are well known. One of skill in the art will understand that primer pairs configured to prime amplification of a double stranded sequence are configured and named using one strand of the double stranded sequence as a reference. The forward primer is the primer of the pair that comprises full or partial sequence identity to the one strand of the sequence being used as a reference. The reverse primer is the primer of the pair that comprises reverse complementarity to the one strand being of the sequence being used as a reference.

**[00109]** In one embodiment, the “plus” or “top” strand (the primary sequence as submitted to GenBank) of the nucleic acid to which the primers hybridize is used as a reference when designing primer pairs. In this case, the forward primer will comprise identity and the reverse primer will comprise reverse complementarity, to the sequence listed in GenBank for the reference sequence. In some embodiments, the primer pair is configured using the “minus” or “bottom” strand (reverse complement of the primary sequence as submitted to and listed in GenBank). In this case, the forward primer comprises sequence identity to the minus strand, and thus comprises reverse complementarity to the top strand, the sequence listed in GenBank. Similarly, in this case, the reverse primer comprises reverse complementarity to the minus strand, and thus comprises identity to the top strand.

**[00110]** Herein, when the primer is configured using the minus strand as a reference, the extraction sequence is preferably listed in a descending fashion in the primer name (as in the case of the coordinates 1674726-1674277 of the forward primer pair name AROE\_NC003923-1674726-1674277\_30\_62\_F). In this case, the forward primer comprises reverse complementarity to the sequence listed in GenBank for the reference gi number. Thus, in the case of this exemplary primer, the forward primer is configured to hybridize within nucleotides 1674697 and 1674665 of gi number 21281729, which is 30 (the first number in the hybridization coordinates 30-62) nucleotides in the reverse direction from the first coordinate (1674697) listed in the extraction sequence. The hybridization site and region of the reference sequence to which a primer in Table 1 hybridizes can be determined and verified with bioinformatics alignment tools as described below using the primer sequence and the reference gi number provided in Table 2.

[00111] To determine the exact primer hybridization coordinates of a given pair of primers on a given bioagent nucleic acid sequence and to determine the sequences, molecular masses and base compositions of an amplification product to be obtained upon amplification of nucleic acid of a known bioagent with known sequence information in the region of interest with a given pair of primers, one with ordinary skill in bioinformatics is capable of obtaining alignments of the primers of the present invention with the GenBank gi number of the relevant nucleic acid sequence of the known bioagent. For example, the reference sequence GenBank gi numbers (Table 2) provide the identities of the sequences which can be obtained from GenBank. Alignments can be done using a bioinformatics tool such as BLASTn provided to the public by NCBI (Bethesda, MD).

Alternatively, a relevant GenBank sequence may be downloaded and imported into custom programmed or commercially available bioinformatics programs wherein the alignment can be carried out to determine the primer hybridization coordinates and the sequences, molecular masses and base compositions of the amplification product. For example, to obtain the hybridization coordinates of primer pair number 2095 (SEQ ID NO.: 39: SEQ ID NO.:125), First the forward primer (SEQ ID NO: 39) is subjected to a BLASTn search on the publicly available NCBI BLAST website. "RefSeq\_Genomic" is chosen as the BLAST database since the gi numbers refer to genomic sequences. The BLAST query is then performed. Among the top results returned is a match to GenBank gi number 21281729 (Accession Number NC\_003923). The result shown below, indicates that the forward primer hybridizes to positions 1530282..1530307 of the genomic sequence of *Staphylococcus aureus* subsp. aureus MW2 (represented by gi number 21281729).

Staphylococcus aureus subsp. aureus MW2, complete genome  
Length=2820462

Features in this part of subject sequence:

Panton-Valentine leukocidin chain F precursor

Score = 52.0 bits (26), Expect = 2e-05  
Identities = 26/26 (100%), Gaps = 0/26 (0%)  
Strand=Plus/Plus

```

Query   1          TGAGCTGCATCAACTGTATTGGATAG   26 (SEQ ID: 39)
          |||||
Sbjct   1530282    TGAGCTGCATCAACTGTATTGGATAG   1530307 (SEQ ID: 39)

```

[00112] The hybridization coordinates of the reverse primer (SEQ ID NO: 125) can be determined in a similar manner and thus, the bioagent identifying amplicon can be defined in terms of genomic coordinates. The query/subject arrangement of the result would be presented in Strand = Plus/Minus format because the reverse strand hybridizes to the reverse complement of the genomic sequence. The preceding sequence analyses are well known to one with ordinary skill in bioinformatics and thus, Table 2 contains sufficient information to determine the primer hybridization coordinates of any of the primers of Table 1 to the applicable reference sequences described therein.

**Table 2: Primer Name Codes and Reference Sequences**

Primer name code	Gene Name	Organism	Reference GenBank gi number
RNASEP_BDF	<b>RNase P</b> (ribonuclease P)	<i>Bordetella pertussis</i>	33591275
RNASEP_BKM	<b>RNase P</b> (ribonuclease P)	<i>Burkholderia mallei</i>	53723370
RNASEP_BS	<b>RNase P</b> (ribonuclease P)	<i>Bacillus subtilis</i>	16077068
RNASEP_CLB	<b>RNase P</b> (ribonuclease P)	<i>Clostridium perfringens</i>	18308982
RNASEP_EC	<b>RNase P</b> (ribonuclease P)	<i>Escherichia coli</i>	16127994
RNASEP_RKF	<b>RNase P</b> (ribonuclease P)	<i>Rickettsia prowazekii</i>	15603881
RNASEP_SA	<b>RNase P</b> (ribonuclease P)	<i>Staphylococcus aureus</i>	15922990
RNASEP_VBC	<b>RNase P</b> (ribonuclease P)	<i>Vibrio cholerae</i>	15640032
ICD_CXB	<b>icd</b> (isocitrate dehydrogenase)	<i>Coxiella burnetii</i>	29732244
TS111A	multi-locus TS111A insertion element	<i>Acinetobacter baumannii</i>	29732244
OMPA_AY435227	<b>ompA</b> (outer membrane protein A)	<i>Rickettsia prowazekii</i>	40287451
OMP_B_RKP	<b>ompB</b> (outer membrane protein B)	<i>Rickettsia prowazekii</i>	15603881
GLTA_RKP	<b>glta</b> (citrate synthase)	<i>Vibrio cholerae</i>	15603881
TOXR_VDC	<b>toxR</b> (transcription regulator toxR)	<i>Francisella tularensis</i>	15640032
ASD_FRT	<b>asd</b> (Aspartate semialdehyde dehydrogenase)	<i>Francisella tularensis</i>	56707187
GALE_FRT	<b>galE</b> (UDP-glucose 4-epimerase)	<i>Shigella flexneri</i>	56707187

Primer name code	Gene Name	Organism	Reference GenBank gi number
IPAH_SGF	<b>ipaH</b> (invasion plasmid antigen)	<i>Campylobacter jejuni</i>	30061571
HUPB_CJ	<b>hupB</b> (DNA-binding protein Hu-beta)	<i>Coxiella burnetii</i>	15791399
MUPK_X75439	<b>mupR</b> (mupriocin resistance gene)	<i>Staphylococcus aureus</i>	438226
PARC_X95819	<b>parC</b> (topoisomerase IV)	<i>Acinetobacter baumannii</i>	1212748
SED_M28521	<b>sed</b> (enterotoxin D)	<i>Staphylococcus aureus</i>	1492109
SEJ_AFC53140	<b>sej</b> (enterotoxin J)	<i>Staphylococcus aureus</i>	3372540
AGR-III_NC003923	<b>agr-III</b> (accessory gene regulator-III)	<i>Staphylococcus aureus</i>	21281729
ARCC_NC003923	<b>arcC</b> (carbamate kinase)	<i>Staphylococcus aureus</i>	21281729
ARO_E_NC003923	<b>aroE</b> (shikimate 5-dehydrogenase)	<i>Staphylococcus aureus</i>	21281729
BSA-A_NC003923	<b>bsa-a</b> (glutathione peroxidase)	<i>Staphylococcus aureus</i>	21281729
BSA-B_NC003923	<b>bsa-b</b> (epidermin biosynthesis protein EpiB)	<i>Staphylococcus aureus</i>	21281729
GLPF_NC003923	<b>glpF</b> (glycerol transporter)	<i>Staphylococcus aureus</i>	21281729
GMK_NCC03923	<b>gmk</b> (guanylate kinase)	<i>Staphylococcus aureus</i>	21281729
MECT-R_NC003923	<b>mecR1</b> (truncated methicillin resistance protein)	<i>Staphylococcus aureus</i>	21281729
PTA_NCC03923	<b>pta</b> (phosphate acetyltransferase)	<i>Staphylococcus aureus</i>	21281729
PVLUK_NC003923	<b>pvluk</b> (Panton-Valentine leukocidin chain F precursor)	<i>Staphylococcus aureus</i>	21281729
SA442_NC003923	<b>sa442 gene</b>	<i>Staphylococcus aureus</i>	21281729
SEA_NCC03923	<b>sea</b> (staphylococcal enterotoxin A precursor)	<i>Staphylococcus aureus</i>	21281729
SEC_NCC03923	<b>sec4</b> (enterotoxin type C precursor)	<i>Staphylococcus aureus</i>	21281729
TEI_NCC03923	<b>tpi</b> (triosephosphate isomerase)	<i>Staphylococcus aureus</i>	21281729
YQI_NCC03923	<b>yqi</b> (acetyl-CoA C-acetyltransferase homologue)	<i>Staphylococcus aureus</i>	21281729
AGR-II_NC002745	<b>agr-II</b> (accessory gene regulator-II)	<i>Staphylococcus aureus</i>	29165615
AGR-I_AJ617706	<b>agr-I</b> (accessory gene regulator-I)	<i>Staphylococcus aureus</i>	46019543
AGR-IV_AJ617711	<b>agr-IV</b> (accessory gene regulator-III)	<i>Staphylococcus aureus</i>	46019563
BLAZ_NC002952	<b>blaZ</b> (beta lactamase III)	<i>Staphylococcus aureus</i>	49482253
ERMA_NC002952	<b>ermA</b> (rRNA methyltransferase A)	<i>Staphylococcus aureus</i>	49482253
ERME_Y13600	<b>ermB</b> (rRNA methyltransferase B)	<i>Staphylococcus aureus</i>	49482253
SEA-SEE_NC002952	<b>sea</b> (staphylococcal enterotoxin A precursor)	<i>Staphylococcus aureus</i>	49482253
SEA-SEE_NC002952	<b>sea</b> (staphylococcal enterotoxin A precursor)	<i>Staphylococcus aureus</i>	49482253
SEE_NCC02952	<b>sea</b> (staphylococcal enterotoxin A precursor)	<i>Staphylococcus aureus</i>	49482253
SEH_NCC02953	<b>seh</b> (staphylococcal enterotoxin H)	<i>Staphylococcus aureus</i>	49484912

Primer name code	Gene Name	Organism	Reference GenBank gi number
ERM_C_NC005908	<b>ermC</b> (rRNA methyltransferase C)	<i>Staphylococcus aureus</i>	49489772
NUC_NCC02758	<b>nuc</b> (staphylococcal nuclease)	<i>Staphylococcus aureus</i>	15922990
SEB_NCC02758	<b>seb</b> (enterotoxin type B precursor)	<i>Staphylococcus aureus</i>	57634611
SEG_NCC02758	<b>seg</b> (staphylococcal enterotoxin G)	<i>Staphylococcus aureus</i>	57634611
SEI_NCC02758	<b>sei</b> (staphylococcal enterotoxin I)	<i>Staphylococcus aureus</i>	57634611
TSST_NC002758	<b>tsst</b> (toxic shock syndrome toxin-1)	<i>Staphylococcus aureus</i>	15922990
TUF3_NC002758	<b>tufB</b> (Elongation factor Tu)	<i>Staphylococcus aureus</i>	15922990
TSST1_NCC02758.2	<b>tsst</b> (toxic shock syndrome toxin-1)	<i>Staphylococcus aureus</i>	57634611

## Example 2: Sample Preparation and PCR

[00113] Samples were processed to obtain bacterial genomic material using a Qiagen QIAamp Virus BioRobot MDx Kit (Valencia, CA 91355). Resulting genomic material was amplified using an MJ Thermocycler Dyad unit (BioRad laboratories, Inc., Hercules, CA 94547) and the amplicons were characterized on a Bruker Daltonics MicroTOF instrument (Billerica, MA 01821). The resulting molecular mass measurements were converted to base compositions and were queried into a database having base compositions indexed with primer pairs and bioagents.

[00114] All PCR reactions were assembled in 50 .micro.L reaction volumes in a 96-well microtiter plate format using a Packard MP11 liquid handling robotic platform (Perkin Elmer, Boston, MA 02118) and M.J. Dyad thermocyclers (BioRad, Inc., Hercules, CA 94547). The PCR reaction mixture consisted of 4 units of Amplitaq Gold, 1x buffer II (Applied Biosystems, Foster City, CA), 1.5 mM MgCl.sub.2, 0.4 M betaine, 800 .micro.M dNTP mixture and 250 nM of each primer. The following typical PCR conditions were used: 95.deg.C for 10 min followed by 8 cycles of 95.deg.C for 30 seconds, 48.deg.C for 30 seconds, and 72.deg.C 30 seconds with the 48.deg.C annealing temperature increasing 0.9.deg.C with each of the eight cycles. The PCR was then continued for 37 additional cycles of 95.deg.C for 15 seconds, 56.deg.C for 20 seconds, and 72.deg.C 20 seconds. Those ordinarily skilled in the art will understand PCR reactions.

**Example 3: Solution Capture Purification of PCR Products for Mass Spectrometry with Ion Exchange Resin-Magnetic Beads**

[00115] For solution capture of nucleic acids with ion exchange resin linked to magnetic beads, 25  $\mu$ l of a 2.5 mg/mL suspension of BioClone amine terminated supraparamagnetic beads (San Diego, CA 92126) were added to 25 to 50  $\mu$ l of a PCR (or RT-PCR) reaction containing approximately 10 pM of an amplicon. The above suspension was mixed for approximately 5 minutes by vortexing or pipetting, after which the liquid was removed after using a magnetic separator. The beads containing bound PCR amplicon were then washed three times with 50mM ammonium bicarbonate/50% MeOH or 100mM ammonium bicarbonate/50% MeOH, followed by three more washes with 50% MeOH. The bound PCR amplicon was eluted with a solution of 25mM piperidine, 25mM imidazole, 35% MeOH which included peptide calibration standards.

**Example 4: Mass Spectrometry and Base Composition Analysis**

[00116] The ESI-FTICR mass spectrometer is based on a Bruker Daltonics (Billerica, MA) Apex II 70e electrospray ionization Fourier transform ion cyclotron resonance mass spectrometer that employs an actively shielded 7 Tesla superconducting magnet. The active shielding constrains the majority of the fringing magnetic field from the superconducting magnet to a relatively small volume. Thus, components that might be adversely affected by stray magnetic fields, such as CRT monitors, robotic components, and other electronics, can operate in close proximity to the FTICR spectrometer. All aspects of pulse sequence control and data acquisition were performed on a 600 MHz Pentium II data station running Bruker's Xmass software under Windows NT 4.0 operating system. Sample aliquots, typically 15  $\mu$ l, were extracted directly from 96-well microtiter plates using a CTC HTS PAL autosampler (LEAP Technologies, Carrboro, NC) triggered by the FTICR data station. Samples were injected directly into a 10  $\mu$ l sample loop integrated with a fluidics handling system that supplies the 100  $\mu$ l/hr flow rate to the ESI source. Ions were formed via electrospray ionization in a modified Analytica (Branford, CT) source employing an off

axis, grounded electrospray probe positioned approximately 1.5 cm from the metalized terminus of a glass desolvation capillary. The atmospheric pressure end of the glass capillary was biased at 6000 V relative to the ESI needle during data acquisition. A counter-current flow of dry N<sub>2</sub> was employed to assist in the desolvation process. Ions were accumulated in an external ion reservoir comprised of an rf-only hexapole, a skimmer cone, and an auxiliary gate electrode, prior to injection into the trapped ion cell where they were mass analyzed. Ionization duty cycles > 99% were achieved by simultaneously accumulating ions in the external ion reservoir during ion detection. Each detection event consisted of 1M data points digitized over 2.3 s. To improve the signal-to-noise ratio (S/N), 32 scans were co-added for a total data acquisition time of 74 s.

**[00117]** The ESI-TOF mass spectrometer is based on a Bruker Daltonics MicroTOF<sup>sup</sup>.TM. Ions from the ESI source undergo orthogonal ion extraction and are focused in a reflectron prior to detection. The TOF and FTICR are equipped with the same automated sample handling and fluidics described above. Ions are formed in the standard MicroTOF<sup>sup</sup>.TM ESI source that is equipped with the same off-axis sprayer and glass capillary as the FTICR ESI source. Consequently, source conditions were the same as those described above. External ion accumulation was also employed to improve ionization duty cycle during data acquisition. Each detection event on the TOF was comprised of 75,000 data points digitized over 75 .micro.s.

**[00118]** The sample delivery scheme allows sample aliquots to be rapidly injected into the electrospray source at high flow rate and subsequently be electrosprayed at a much lower flow rate for improved ESI sensitivity. Prior to injecting a sample, a bolus of buffer was injected at a high flow rate to rinse the transfer line and spray needle to avoid sample contamination/carryover. Following the rinse step, the autosampler injected the next sample and the flow rate was switched to low flow. Following a brief equilibration delay, data acquisition commenced. As spectra were co-added, the autosampler continued rinsing the syringe and picking up buffer to rinse the injector and sample transfer line. In general, two syringe rinses and one injector rinse were required to minimize sample carryover. During a routine screening protocol a new sample mixture was injected every 106 seconds. More recently a fast wash station for the syringe needle has been implemented which,

when combined with shorter acquisition times, facilitates the acquisition of mass spectra at a rate of just under one spectrum/minute.

[00119] Raw mass spectra were post-calibrated with an internal mass standard and deconvoluted to monoisotopic molecular masses. Unambiguous base compositions were derived from the exact mass measurements of the complementary single-stranded oligonucleotides. Quantitative results are obtained by comparing the peak heights with an internal PCR calibration standard present in every PCR well at 500 molecules per well. Calibration methods are commonly owned and disclosed in PCT pre-grant publication number WO 2005/094421, which is incorporated herein by reference in entirety.

**Example 5: *De Novo* Determination of Base Composition of Amplicons using Molecular Mass Modified Deoxynucleotide Triphosphates.**

[00120] Because the molecular masses of the four natural nucleobases have a relatively narrow molecular mass range (A = 313.058, G = 329.052, C = 289.046, T = 304.046, values in Daltons – See Table 3), a persistent source of ambiguity in assignment of base composition can occur as follows: two nucleic acid strands having different base composition may have a difference of about 1 Da when the base composition difference between the two strands is  $G \leftrightarrow A$  (-15.994) combined with  $C \leftrightarrow T$  (+15.000). For example, one 99-mer nucleic acid strand having a base composition of A.sub.27G.sub.30C.sub.21T.sub.21 has a theoretical molecular mass of 30779.058 while another 99-mer nucleic acid strand having a base composition of A.sub.26G.sub.31C.sub.22T.sub.20 has a theoretical molecular mass of 30780.052 is a molecular mass difference of only 0.994 Da. A 1 Da difference in molecular mass may be within the experimental error of a molecular mass measurement and thus, the relatively narrow molecular mass range of the four natural nucleobases imposes an uncertainty factor in this type of situation. One method for removing this theoretical 1 Da uncertainty factor uses amplification of a nucleic acid with one mass-tagged nucleobase and three natural nucleobases.

[00121] Addition of significant mass to one of the 4 nucleobases (dNTPs) in an amplification reaction, or in the primers themselves, will result in a significant difference in mass of the resulting amplicon (greater than 1 Da) arising from ambiguities such as the  $G \leftrightarrow A$  combined with  $C \leftrightarrow T$  event (Table 3). Thus, the same the  $G \leftrightarrow A$  (-15.994) event combined with 5-Iodo- $C \leftrightarrow T$  (-110.900) event would result in a molecular mass difference of 126.894 Da. The molecular mass of the base composition  $A_{27}G_{30}5\text{-Iodo-}C_{21}T_{21}$  (33422.958) compared with  $A_{\text{sub.26}}G_{\text{sub.315}}\text{-Iodo-}C_{\text{sub.22}}T_{\text{sub.20}}$ , (33549.852) provides a theoretical molecular mass difference is +126.894. The experimental error of a molecular mass measurement is not significant with regard to this molecular mass difference. Furthermore, the only base composition consistent with a measured molecular mass of the 99-mer nucleic acid is  $A_{\text{sub.27}}G_{\text{sub.305}}\text{-Iodo-}C_{\text{sub.21}}T_{\text{sub.21}}$ . In contrast, the analogous amplification without the mass tag has 18 possible base compositions.

**Table 3: Molecular Masses of Natural Nucleobases and the Mass-Modified Nucleobase 5-Iodo-C and Molecular Mass Differences Resulting from Transitions**

Nucleobase	Molecular Mass	Transition	$\Delta$ Molecular Mass
A	313.058	A-->T	-9.012
A	313.058	A-->C	-24.012
A	313.058	A-->5-Iodo-C	101.888
A	313.058	A-->G	15.994
T	304.046	T-->A	9.012
T	304.046	T-->C	-15.000
T	304.046	T-->5-Iodo-C	110.900
T	304.046	T-->G	25.006
C	289.046	C-->A	24.012
C	289.046	C-->T	15.000
C	289.046	C-->G	40.006
5-Iodo-C	414.946	5-Iodo-C-->A	-101.888
5-Iodo-C	414.946	5-Iodo-C-->T	-110.900
5-Iodo-C	414.946	5-Iodo-C-->G	-85.894
G	329.052	G-->A	-15.994
G	329.052	G-->T	-25.006
G	329.052	G-->C	-40.006
G	329.052	G-->5-Iodo-C	85.894

[00122] Mass spectra of bioagent-identifying amplicons can be analyzed using a maximum-likelihood processor, such as is widely used in radar signal processing. This processor first makes maximum likelihood estimates of the input to the mass spectrometer for each primer by running matched filters for each base composition aggregate on the input data. This includes the response to a calibrant for each primer.

[00123] The algorithm emphasizes performance predictions culminating in probability-of-detection versus probability-of-false-alarm plots for conditions involving complex backgrounds of naturally occurring organisms and environmental contaminants. Matched filters consist of *a priori* expectations of signal values given the set of primers used for each of the bioagents. A genomic sequence database is used to define the mass base count matched filters. The database contains the sequences of known bacterial bioagents and includes threat organisms as well as benign background organisms. The latter is used to estimate and subtract the spectral signature produced by the background organisms. A maximum likelihood detection of known background organisms is implemented using matched filters and a running-sum estimate of the noise covariance. Background signal strengths are estimated and used along with the matched filters to form signatures which are then subtracted. The maximum likelihood process is applied to this “cleaned up” data in a similar manner employing matched filters for the organisms and a running-sum estimate of the noise-covariance for the cleaned up data.

[00124] The amplitudes of all base compositions of bioagent-identifying amplicons for each primer are calibrated and a final maximum likelihood amplitude estimate per organism is made based upon the multiple single primer estimates. Models of all system noise are factored into this two-stage maximum likelihood calculation. The processor reports the number of molecules of each base composition contained in the spectra. The quantity of amplicon corresponding to the appropriate primer set is reported as well as the quantities of primers remaining upon completion of the amplification reaction.

[00125] Base count blurring can be carried out as follows. Electronic PCR can be conducted on nucleotide sequences of the desired bioagents to obtain the different expected base counts that could

be obtained for each primer pair. See for example, Schuler, *Genome Res.* 7:541-50, 1997; or the e-PCR program available from National Center for Biotechnology Information (NCBI, NIH, Bethesda, MD 20894). One illustrative embodiment uses one or more spreadsheets from a workbook comprising a plurality of spreadsheets (e.g., Microsoft Excel). First in this example, there is a worksheet with a name similar to the workbook name; this worksheet contains the raw electronic PCR data. Second, there is a worksheet named “filtered bioagents base count” that contains bioagent name and base count; there is a separate record for each strain after removing sequences that are not identified with a genus and species and removing all sequences for bioagents with less than 10 strains. Third, there is a worksheet, “Sheet1” that contains the frequency of substitutions, insertions, or deletions for this primer pair. This data is generated by first creating a pivot table from the data in the “filtered bioagents base count” worksheet and then executing an Excel VBA macro. The macro creates a table of differences in base counts for bioagents of the same species, but different strains. One of ordinary skill in the art understands the additional pathways for obtaining similar table differences without undo experimentation.

**[00126]** Application of an exemplary script, involves the user defining a threshold that specifies the fraction of the strains that are represented by the reference set of base counts for each bioagent. The reference set of base counts for each bioagent may contain as many different base counts as are needed to meet or exceed the threshold. The set of reference base counts is defined by taking the most abundant strain’s base type composition and adding it to the reference set and then the next most abundant strain’s base type composition is added until the threshold is met or exceeded. The current set of data was obtained using a threshold of 55%, which was obtained empirically.

**[00127]** For each base count not included in the reference base count set for that bioagent, the script then proceeds to determine the manner in which the current base count differs from each of the base counts in the reference set. This difference may be represented as a combination of substitutions,  $S_i=X_i$ , and insertions,  $I_i=Y_i$ , or deletions,  $D_i=Z_i$ . If there is more than one reference base count, then the reported difference is chosen using rules that aim to minimize the number of changes and, in instances with the same number of changes, minimize the number of insertions or deletions. Therefore, the primary rule is to identify the difference with the minimum sum ( $X_i+Y_i$ )

or  $(X_i + Z_i)$ , *e.g.*, one insertion rather than two substitutions. If there are two or more differences with the minimum sum, then the one that will be reported is the one that contains the most substitutions.

[00128] Differences between a base count and a reference composition are categorized as one, two, or more substitutions, one, two, or more insertions, one, two, or more deletions, and combinations of substitutions and insertions or deletions. The different classes of nucleobase changes and their probabilities of occurrence have been delineated in U.S. Patent Application Publication No. 2004209260, which is incorporated herein by reference in entirety.

**Example 6: *Staphylococcus* Bacterial Surveillance Panel.**

[00129] The compositions and methods described herein are useful for screening a sample suspected of comprising one or more unknown bioagents to determine the identity of at least one of the bioagents. The compositions and methods provided are also useful for determining population genotype for a sample suspected of comprising a population of bioagents. In one embodiment, the population is a mixed population. The identification of the at least one bioagent or one or more genotypes is accomplished by generating base composition signatures using the methods provided herein for portions of genes shared by two or more members of the *Staphylococcus* genus. The base composition signatures generated using the methods provided are then compared to a database comprising a plurality of base composition signatures that are indexed to primer pairs used in generating the base composition signatures and bioagents. The plurality of base composition signatures in the database is at least two, is more preferably at least 5, is more preferably still at least 14, is more preferably still at least 19, is more preferably still at least 25 and is more preferably still at least 35. The base composition signatures comprising this plurality identify at least one bioagent when that bioagent's measured and calculated base composition signature is queried against the plurality of base composition signatures comprised in the database.

**Example 7 Identification of Drug Resistance Genes and Virulence Factors in *Staphylococcus aureus***

[00130] Three primer pair panels, each comprising eight primer pairs, were configured for identification of the *Staphylococcus aureus* species and for identification of drug resistance genes and virulence factors of *Staphylococcus aureus* bioagents. These panels are shown in Tables 4-6. The primer sequences in these panels can also be found in Table 1, and are cross-referenced in Tables 4-6 by primer pair numbers, primer pair names, and SEQ ID NOs.

**Table 4: Panel of Primer Pairs for Identification of Drug Resistance Genes and Virulence Factors in *Staphylococcus aureus***

Primer Pair No.	Forward Primer Name	Forward Primer (SEQ ID NO:)	Reverse Primer Name	Reverse Primer (SEQ ID NO:)	Target Gene
879	MECA_Y14051_4507_4530_F	58	MECA_Y14051_4555_4581_R	142	mecA
2056	MecI-R_NC003923-41798-41609_33_60_F	62	MecI-R_NC003923-41798-41609_86_113_R	147	MecI-R
2081	ERMA_NC002952-55890-56621_366_395_F	294	ERMA_NCC02952-55890-56621_438_465_R	295	ermA
2086	ERM_C_NC005908-2004-2738_85_116_F	35	ERM_C_NCC05908-2004-2738_173_206_R	121	ermC
2095	PVLUK_NC003923-1529595-1531285_688_713_F	39	PVLUK_NC003923-1529595-1531285_775_804_R	125	Pv-luk
2249	TUFB_NC002758-615038-616222_696_725_F	47	TUFB_NCC02758-615038-616222_793_820_R	132	tufB
2256	NUC_NC002758-894288-894974_316_345_F	55	NUC_NCC02758-894288-894974_396_421_R	139	Nuc
2313	MUPR_X75439_2486_2516_F	21	MUPR_X75439_2548_2574_R	104	mupR

**Table 5: Panel of Primer Pairs for Identification of Drug Resistance Genes and Virulence Factors in *Staphylococcus aureus***

Primer Pair No.	Forward Primer Name	Forward Primer (SEQ ID NO:)	Reverse Primer Name	Reverse Primer (SEQ ID NO:)	Target Gene
879	MECA_Y14051_4507_4530_F	58	MECA_Y14051_4555_4581_R	142	mecA
2056	MecI-R_NC003923-41798-41609_33_60_F	62	MecI-R_NC003923-41798-41609_86_113_R	147	MecI-R
2081	ERMA_NC002952-55890-56621_366_395_F	294	ERMA_NCC02952-55890-56621_438_465_R	295	ermA
2086	ERM_C_NC005908-2004-2738_85_116_F	35	ERM_C_NCC05908-2004-2738_173_206_R	121	ermC
2095	PVLUK_NC003923-1529595-1531285_688_713_F	39	PVLUK_NC003923-1529595-1531285_775_804_R	125	Pv-luk
2249	TUFB_NC002758-615038-616222_696_725_F	47	TUFB_NCC02758-615038-616222_793_820_R	132	tufB
2256	NUC_NC002758-894288-894974_316_345_F	55	NUC_NCC02758-894288-894974_396_421_R	139	Nuc
3016	MUPR_X75439_2482_2510_F	22	MUPR_X75439_2551_2573_R	106	mupR

**Table 6: Panel of Primer Pairs for Identification of Drug Resistance Genes and Virulence Factors in *Staphylococcus aureus***

Primer Pair No.	Forward Primer Name	Forward Primer (SEQ ID NO:)	Reverse Primer Name	Reverse Primer (SEQ ID NO:)	Target Gene
879	MECA_Y14051_4507_4530_F	58	MECA_Y14051_4555_4581_R	142	mecA
2056	MECTI-R_NC003923-41798-41609_33_60_F	62	MECTI-R_NC003923-41798-41609_86_113_R	147	MecI-R
2081	ERMA_NC002952-55890-56621_366_395_F	294	ERMA_NC002952-55890-56621_438_465_R	295	ermA
2086	ERM_C_NC005908-2004-2738_85_116_F	35	ERM_C_NC005908-2004-2738_173_206_R	121	esrMC
2095	PVLUK_NC003923-1529595-1531285_688_713_F	39	PVLUK_NC003923-1529595-1531285_775_804_R	125	Pv-luk
2249	TUFB_NC002758-615038-616222_696_725_F	47	TUFB_NC002758-615038-616222_793_820_R	132	tufB
2256	NUC_NC002758-894288-894974_316_345_F	55	NUC_NC002758-894288-894974_396_421_R	139	Nuc
3106	TSST1_NC002758.2-2137509-2138213_519_546_F	70	TSST1_NC002758.2-2137509-2138213_593-620_R	155	tsst1

[00131] Primer pair numbers 2256 and 2249 are confirmation primers configured with the aim of high-level identification of *Staphylococcus aureus*. The nuc gene is a *Staphylococcus aureus*-specific marker gene. The tufB gene is a universal housekeeping gene but the bioagent identifying amplicon defined by primer pair number 2249 provides a unique base composition (A43 G28 C19 T35) which distinguishes *Staphylococcus aureus* from other members of the genus *Staphylococcus*.

[00132] High level methicillin resistance in a given strain of *Staphylococcus aureus* is indicated by bioagent identifying amplicons defined by primer pair numbers 879 and 2056. Analyses have indicated that primer pair number 879 is not expected to prime *S. sciuri* homolog or *Enterococcus faecalis/faecium* ampicillin-resistant PBP5 homologs.

[00133] Macrolide and erythromycin resistance in a given strain of *Staphylococcus aureus* is indicated by bioagent identifying amplicons defined by primer pair numbers 2081 and 2086.

[00134] Resistance to mupirocin in a given strain of *Staphylococcus aureus* is indicated by bioagent identifying amplicons defined by primer pair numbers 2313 and 3016.

[00135] In the above panels, virulence in a given strain of *Staphylococcus aureus* can be indicated by bioagent identifying amplicons defined by primer pair numbers 2095 and 3106. Primer pair number 2095 can identify both the pvl (lukS-PV) gene and the lukD gene which encodes a homologous enterotoxin. A bioagent identifying amplicon of the lukD gene defined by primer pair number 2095 has a six nucleobase length difference relative to the lukS-PV gene. Further, primer pair number 3106 is configured to generate amplicons within the tsst-1 gene, which encodes for shock syndrome toxin, which causes toxic shock syndrome (TSS).

[00136] A total of 32 blinded samples of different strains of *Staphylococcus aureus* were provided by the Center for Disease Control (CDC). Each sample was analyzed by PCR amplification with the first of these eight primer pair panels (shown in Table 4), followed by purification and measurement of molecular masses of the amplification products by mass spectrometry. Base compositions for the amplification products were calculated. The base compositions provide the information summarized above for each primer pair. The results are shown in Tables 7A and 7B.

**Table 7A: Drug Resistance and Virulence Identified in Blinded Samples of Various Strains of *Staphylococcus aureus* with Primer Pair Nos. 2081, 2086, 2095 and 2256**

Sample Index No.	Primer Pair No. 2081 (ermA)	Primer Pair No. 2086 (ermC)	Primer Pair No. 2095 (pv-luk)	Primer Pair No. 2256 (nuc)
CDC0010	-	-	PVL-/lukD+	+
CDC0015	-	-	<b>PVL+/lukD+</b>	+
CDC0019	-	+	PVL-/lukD+	+
CDC0026	+	-	PVL-/lukD+	+
CDC0030	+	-	PVL-/lukD+	+
CDC004	-	-	<b>PVL+/lukD+</b>	+
CDC0014	-	+	<b>PVL+/lukD+</b>	+
CDC008	-	-	PVL-/lukD+	+
CDC001	+	-	PVL-/lukD+	+
CDC0022	+	-	PVL-/lukD+	+
CDC006	+	-	PVL-/lukD+	+
CDC007	-	-	PVL-/lukD+	+
CDCVRS A1	+	-	PVL-/lukD+	+
CDCVRS A2	+	+	PVL-/lukD+	+

CDC0011	+	-	PVL-/lukD+	+
CDC0012	-	-	PVL+/lukD-	+
CDC0021	+	-	PVL-/lukD+	+
CDC0023	+	-	PVL-/lukD+	+
CDC0025	+	-	PVL-/lukD+	+
CDC005	-	-	PVL-/lukD+	+
CDC0018	+	-	PVL+/lukD-	+
CDC002	-	-	PVL-/lukD+	+
CDC0028	+	-	PVL-/lukD+	+
CDC003	-	-	PVL-/lukD+	+
CDC0013	-	-	PVL+/lukD+	+
CDC0016	-	-	PVL-/lukD+	+
CDC0027	+	-	PVL-/lukD+	+
CDC0029	-	-	PVL+/lukD+	+
CDC0020	-	+	PVL-/lukD+	+
CDC0024	-	-	PVL-/lukD+	+
CDC0031	-	-	PVL-/lukD+	+

**Table 7B: Drug Resistance and Virulence Identified in Blinded Samples of Various Strains of *Staphylococcus aureus* with Primer Pair Nos. 2249, 879, 2056, and 2313**

Sample Index No.	Primer Pair No. 2249 (tufB)	Primer Pair No. 879 (mecA)	Primer Pair No. 2056 (mecI-R)	Primer Pair No. 2313 (mupR)
CDC0010	<i>Staphylococcus aureus</i>	+	+	-
CDC0015	<i>Staphylococcus aureus</i>	-	-	-
CDC0019	<i>Staphylococcus aureus</i>	+	+	-
CDC0026	<i>Staphylococcus aureus</i>	+	+	-
CDC0030	<i>Staphylococcus aureus</i>	+	+	-
CDC004	<i>Staphylococcus aureus</i>	+	+	-
CDC0014	<i>Staphylococcus aureus</i>	+	+	-
CDC008	<i>Staphylococcus aureus</i>	+	+	-
CDC001	<i>Staphylococcus aureus</i>	+	+	-
CDC0022	<i>Staphylococcus aureus</i>	+	+	-
CDC006	<i>Staphylococcus aureus</i>	+	+	+
CDC007	<i>Staphylococcus aureus</i>	+	+	-
CDCVISA1	<i>Staphylococcus aureus</i>	+	+	-
CDCVISA2	<i>Staphylococcus aureus</i>	+	+	-
CDC0011	<i>Staphylococcus aureus</i>	-	-	-
CDC0012	<i>Staphylococcus aureus</i>	+	+	-
CDC0021	<i>Staphylococcus aureus</i>	+	+	-
CDC0023	<i>Staphylococcus aureus</i>	+	+	-
CDC0025	<i>Staphylococcus aureus</i>	+	+	-
CDC005	<i>Staphylococcus aureus</i>	+	+	-

CDC0018	<i>Staphylococcus aureus</i>	+	+	-
CDC002	<i>Staphylococcus aureus</i>	+	+	-
CDC0028	<i>Staphylococcus aureus</i>	+	+	-
CDC003	<i>Staphylococcus aureus</i>	+	+	-
CDC0013	<i>Staphylococcus aureus</i>	+	+	-
CDC0016	<i>Staphylococcus aureus</i>	+	+	-
CDC0027	<i>Staphylococcus aureus</i>	+	+	-
CDC0029	<i>Staphylococcus aureus</i>	+	+	-
CDC0020	<i>Staphylococcus aureus</i>	-	-	-
CDC0024	<i>Staphylococcus aureus</i>	+	+	-
CDC0031	<i>Staphylococcus schleiferi</i>	-	-	-

[00137] Upon un-blinding of the samples illustrated in Tables 7A and 7B it was noted that each of the PVL+ identifications agreed with PVL+ identified in the same samples by standard PCR assays. These results indicate that the panel of eight primer pairs is useful for identification of drug resistance and virulence sub-species characteristics for *Staphylococcus aureus*. Thus, it is expected that a kit comprising one or more of the members of the panels provided in Tables 4-6, and/or one or more other drug-resistance or virulence-identifying primer pairs provided here will be a useful embodiment.

#### **Example 8: Selection and Use of Triangulation Genotyping Analysis Primer Pairs for *Staphylococcus aureus***

[00138] To combine the power of high-throughput mass spectrometric analysis of bioagent identifying amplicons with the sub-species characteristic resolving power provided by triangulation genotyping analysis, two panels of eight triangulation genotyping analysis primer pairs were selected. Each of the primer pairs in these panels is configured to produce bioagent identifying amplicons within one of six different housekeeping genes, which are listed in Tables 8 and 9. The primer sequences are found in Table 1 and are cross-referenced by the primer pair numbers, primer pair names and SEQ ID NOs listed in Tables 8 and 9.

**Table 8: Primer Pairs for Triangulation Genotyping Analysis of *Staphylococcus aureus***

Primer Pair No.	Forward Primer Name	Forward Primer (SEQ ID NO:)	Reverse Primer Name	Reverse Primer (SEQ ID NO:)	Target Gene
2146	ARCC_NC003923-2725050-2724595_131_161_F	72	ARCC_NC003923-2725050-2724595_214_245_R	156	arcC
2149	ARO_E_NC003923-1674726-1674277_30_62_F	79	ARO_E_NC003923-1674726-1674277_155_181_R	166	aroE
2150	ARO_E_NC003923-1674726-1674277_204_232_F	76	ARO_E_NC003923-1674726-1674277_308_335_R	162	aroE
2156	GMK_NC003923-1190906-1191334_301_329_F	83	GMK_NC003923-1190906-1191334_403_432_R	170	gmK
2157	PTA_NC003923-628885-629355_237_263_F	87	PTA_NC003923-628885-629355_314_345_R	172	pta
2161	TPI_NC003923-830671-831072_1_34_F	90	TPI_NC003923-830671-831072_97_129_R	177	tpi
2163	YQI_NC003923-378916-379431_142_167_F	93	YQI_NC003923-378916-379431_259_284_R	180	yqi
2166	YQI_NC003923-378916-379431_275_300_F	94	YQI_NC003923-378916-379431_364_396_R	181	yqi

**Table 9: Primer Pairs for Triangulation Genotyping Analysis of *Staphylococcus aureus***

Primer Pair No.	Forward Primer Name	Forward Primer (SEQ ID NO:)	Reverse Primer Name	Reverse Primer (SEQ ID NO:)	Target Gene
3025	ARCC_NC003923-2725050-2724595_131_161_F	72	ARCC_NC003923-2725050-2724595_232_260_R	158	arcC
2149	ARO_E_NC003923-1674726-1674277_30_62_F	79	ARO_E_NC003923-1674726-1674277_155_181_R	166	aroE
2150	ARO_E_NC003923-1674726-1674277_204_232_F	76	ARO_E_NC003923-1674726-1674277_308_335_R	162	aroE
2156	GMK_NC003923-1190906-1191334_301_329_F	83	GMK_NC003923-1190906-1191334_403_432_R	170	gmK
2157	PTA_NC003923-628885-629355_237_263_F	87	PTA_NC003923-628885-629355_314_345_R	172	pta
2161	TPI_NC003923-830671-831072_1_34_F	90	TPI_NC003923-830671-831072_97_129_R	177	tpi
2163	YQI_NC003923-378916-379431_142_167_F	93	YQI_NC003923-378916-379431_259_284_R	180	yqi
2166	YQI_NC003923-378916-379431_275_300_F	94	YQI_NC003923-378916-379431_364_396_R	181	yqi

[00139] The samples that were analyzed for drug resistance and virulence in Example 7 were subjected to triangulation genotyping analysis with the first panel of primers listed above. The primer pairs of Table 8 were used to produce amplification products by PCR, which were subsequently purified and measured by mass spectrometry. Base compositions were calculated from the molecular masses and are shown in Tables 10A and 10B.

**Table 10A: Triangulation Genotyping Analysis of Blinded Samples of Various Strains of *Staphylococcus aureus* with Primer Pair Nos. 2146, 2149, 2150 and 2156**

Sample Index No.	Strain	Primer Pair No. 2146 (arcC)	Primer Pair No. 2149 (aroE)	Primer Pair No. 2150 (aroE)	Primer Pair No. 2156 (gmk)
CDC0010	CCI	A44 G24 C18 T29	A59 G24 C18 T51	A40 G36 C13 T43	A50 G30 C20 T32
CDC0015	CCI	A44 G24 C18 T29	A59 G24 C18 T51	A40 G36 C13 T43	A50 G30 C20 T32
CDC0019	CCI	A44 G24 C18 T29	A59 G24 C18 T51	A40 G36 C13 T43	A50 G30 C20 T32
CDC0026	CCI	A44 G24 C18 T29	A59 G24 C18 T51	A40 G36 C13 T43	A50 G30 C20 T32
CDC0030	CCI	A44 G24 C18 T29	A59 G24 C18 T51	A40 G36 C13 T43	A50 G30 C20 T32
CDC004	CCI	A44 G24 C18 T29	A59 G24 C18 T51	A40 G36 C13 T43	A50 G30 C20 T32
CDC0014	CCI	A44 G24 C18 T29	A59 G24 C18 T51	A40 G36 C13 T43	A50 G30 C20 T32
CDC008	???	A44 G24 C18 T29	A59 G24 C18 T51	A40 G36 C13 T43	A50 G30 C20 T32
CDC001	Mu50	A45 G23 C20 T27	A58 G24 C18 T52	A40 G36 C13 T43	A51 G29 C21 T31
CDC0022	Mu50	A45 G23 C20 T27	A58 G24 C18 T52	A40 G36 C13 T43	A51 G29 C21 T31
CDC006	Mu50	A45 G23 C20 T27	A58 G24 C18 T52	A40 G36 C13 T43	A51 G29 C21 T31
CDC0011	MRSA252	A45 G24 C18 T28	A58 G24 C19 T51	A41 G36 C12 T43	A51 G29 C21 T31
CDC0012	MRSA252	A45 G24 C18 T28	A58 G24 C19 T51	A41 G36 C12 T43	A51 G29 C21 T31
CDC0021	MRSA252	A45 G24 C18 T28	A58 G24 C19 T51	A41 G36 C12 T43	A51 G29 C21 T31
CDC0023	ST:110	A45 G24 C18 T28	A59 G24 C18 T51	A40 G36 C13 T43	A50 G30 C20 T32
CDC0025	ST:110	A45 G24 C18 T28	A59 G24 C18 T51	A40 G36 C13 T43	A50 G30 C20 T32
CDC005	ST:338	A44 G24 C18 T29	A59 G23 C19 T51	A40 G36 C14 T42	A51 G29 C21 T31
CDC0016	ST:338	A44 G24 C18 T29	A59 G23 C19 T51	A40 G36 C14 T42	A51 G29 C21 T31
CDC002	ST:108	A46 G23 C20 T26	A58 G24 C19 T51	A42 G36 C12 T42	A51 G29 C20 T32
CDC0026	ST:108	A46 G23 C20 T26	A58 G24 C19 T51	A42 G36 C12 T42	A51 G29 C20 T32
CDC003	ST:107	A45 G23 C20 T27	A58 G24 C18 T52	A40 G36 C13 T43	A51 G29 C21 T31
CDC0013	ST:12	ND	A59 G24 C18 T51	A40 G36 C13 T43	A51 G29 C21 T31
CDC0016	ST:120	A45 G23 C18 T29	A58 G24 C19 T51	A40 G37 C13 T42	A51 G29 C21 T31
CDC0027	ST:105	A45 G23 C20 T27	A58 G24 C18 T52	A40 G36 C13 T43	A51 G29 C21 T31
CDC0029	MSSA476	A45 G23 C20 T27	A58 G24 C19 T51	A40 G36 C13 T43	A50 G30 C20 T32
CDC0020	ST:15	A44 G24 C21 T27	A59 G23 C18 T52	A40 G36 C13 T43	A50 G30 C20 T32
CDC0024	ST:137	A45 G23 C20 T27	A57 G25 C19 T51	A40 G36 C13 T43	A51 G29 C22 T30
CDC0031	***	No product	No product	No product	No product

**Table 10B: Triangulation Genotyping Analysis of Blinded Samples of Various Strains of *Staphylococcus aureus* with Primer Pair Nos. 2146, 2149, 2150 and 2156**

Sample Index No.	Strain	Primer Pair No. 2157 (pta)	Primer Pair No. 2161 (tpi)	Primer Pair No. 2163 (yqi)	Primer Pair No. 2166 (yqi)
CDC0010	CCI	A32 G25 C23 T29	A51 G28 C22 T28	A41 G37 C22 T43	A37 G30 C18 T37
CDC0015	CCI	A32 G25 C23 T29	A51 G28 C22 T28	A41 G37 C22 T43	A37 G30 C18 T37
CDC0019	CCI	A32 G25 C23 T29	A51 G28 C22 T28	A41 G37 C22 T43	A37 G30 C18 T37
CDC0026	CCI	A32 G25 C23 T29	A51 G28 C22 T28	A41 G37 C22 T43	A37 G30 C18 T37
CDC0030	CCI	A32 G25 C23 T29	A51 G28 C22 T28	A41 G37 C22 T43	A37 G30 C18 T37
CDC004	CCI	A32 G25 C23 T29	A51 G28 C22 T28	A41 G37 C22 T43	A37 G30 C18 T37
CDC0014	CCI	A32 G25 C23 T29	A51 G28 C22 T28	A41 G37 C22 T43	A37 G30 C18 T37
CDC008	unknown	A32 G25 C23 T29	A51 G28 C22 T28	A41 G37 C22 T43	A37 G30 C18 T37
CDC001	Mu50	A33 G25 C22 T29	A50 G28 C22 T29	A42 G36 C22 T43	A36 G31 C19 T36
CDC0022	Mu50	A33 G25 C22 T29	A50 G28 C22 T29	A42 G36 C22 T43	A36 G31 C19 T36
CDC006	Mu50	A33 G25 C22 T29	A50 G28 C22 T29	A42 G36 C22 T43	A36 G31 C19 T36
CDC0011	MRSA252	A32 G25 C23 T29	A50 G28 C22 T29	A42 G36 C22 T43	A37 G30 C18 T37
CDC0012	MRSA252	A32 G25 C23 T29	A50 G28 C22 T29	A42 G36 C22 T43	A37 G30 C18 T37
CDC0021	MRSA252	A32 G25 C23 T29	A50 G28 C22 T29	A42 G36 C22 T43	A37 G30 C18 T37
CDC0023	ST:110	A32 G25 C23 T29	A51 G28 C22 T28	A41 G37 C22 T43	A37 G30 C18 T37
CDC0025	ST:110	A32 G25 C23 T29	A51 G28 C22 T28	A41 G37 C22 T43	A37 G30 C18 T37
CDC005	ST:338	A32 G25 C24 T28	A51 G27 C21 T30	A42 G36 C22 T43	A37 G30 C18 T37
CDC0016	ST:338	A32 G25 C24 T28	A51 G27 C21 T30	A42 G36 C22 T43	A37 G30 C18 T37
CDC002	ST:108	A33 G25 C23 T28	A50 G28 C22 T29	A42 G36 C22 T43	A37 G30 C18 T37
CDC0026	ST:108	A33 G25 C23 T28	A50 G28 C22 T29	A42 G36 C22 T43	A37 G30 C18 T37
CDC003	ST:107	A32 G25 C23 T29	A51 G28 C22 T28	A41 G37 C22 T43	A37 G30 C18 T37
CDC0013	ST:12	A32 G25 C23 T29	A51 G28 C22 T28	A42 G36 C22 T43	A37 G30 C18 T37
CDC0016	ST:120	A32 G25 C24 T28	A50 G28 C21 T30	A42 G36 C22 T43	A37 G30 C18 T37

CDC0027	ST:105	A33 G25 C22 T29	A50 G28 C22 T29	A43 G36 C21 T43	A36 G31 C19 T36
CDC0029	MSSA476	A33 G25 C22 T29	A50 G28 C22 T29	A42 G36 C22 T43	A36 G31 C19 T36
CDC0020	ST:15	A33 G25 C22 T29	A50 G28 C21 T30	A42 G36 C22 T43	A36 G31 C18 T37
CDC0024	ST:137	A33 G25 C22 T29	A51 G28 C22 T28	A42 G36 C22 T43	A37 G30 C18 T37
CDC0031	***	A34 G25 C25 T25	A51 G27 C24 T27	No product	No product

[00140] Note: \*\*\* The sample CDC0031 was identified as *Staphylococcus schleiferi* as indicated in Example 7. Thus, the triangulation genotyping primers configured for *Staphylococcus aureus* would generally not be expected to prime and produce amplification products of this organism. Tables 10A and 10B indicate that amplification products are obtained for this organism only with primer pair numbers 2157 and 2161.

[00141] A total of thirteen different genotypes of *Staphylococcus aureus* were identified according to the unique combinations of base compositions across the eight different bioagent identifying amplicons obtained with the eight primer pairs. These results indicate that the eight primer pair panel is useful for analysis of unknown or newly emerging strains of *Staphylococcus aureus*, and thus it is expected that a kit comprising one or more of the members of the panels provided in Tables 8 and 9, and/or one or more other *Staphylococcus aureus* genotyping primer pairs provided herein, will be a useful embodiment.

#### **Example 9: Survey of 326 *Staphylococcus aureus* Clinical Isolates Using Primers to Drug Resistance / Virulence and Triangulation Genotyping Analysis Primer Pairs**

[00142] A total of 326 human clinical *Staphylococcus aureus* isolate samples were obtained from the Centers for Disease Control (CDC), Johns Hopkins University and University of Arizona. These samples were tested using a combination of 16 primer pairs comprising: the eight identification/resistance/virulence primer pairs listed in Table 4 and the eight genotyping primer pairs listed in Table 8. Virulence (PVL), antibiotic resistance (to Methicilin, Erythromycin and

Mupirocin), and strain type were determined for each of the 326 samples. Results are summarized in Table 11 and in Figure 2.

**Table 11: Identification and Determination of Virulence and Drug Resistance of 326 Clinical Isolates using *Staphylococcus aureus* Primer Pair Panel**

	Identification		Virulence	Antibiotic Resistance				
				Methicillin		Erythromycin		Mupirocin
# of Isolates	tufB	nuc	PVL	mecA	MecI-R	ermA	ermC	mupR
81	<i>S. aureus</i>	+	-	+	+	+	-	-
81	<i>S. aureus</i>	+	-	+	+	-	-	-
34	<i>S. aureus</i>	+	-	+	+	+	-	-
32	<i>S. aureus</i>	+	-	+	+	-	+	-
30	<i>S. aureus</i>	+	+	+	+	-	-	-
30	<i>S. aureus</i>	+	-	+	+	-	-	-
10	<i>S. aureus</i>	+	-	+	+	-	+	-
7	<i>S. aureus</i>	+	+	-	-	-	-	-
3	<i>S. aureus</i>	+	-	+	+	+	-	+

+: presence of indicated gene/virulence/resistance ; -: absence of indicated gene/virulence/resistance

[00143] As shown in Figure 2, *Staphylococcus aureus* strains USA 100, USA 300, USA 200/1100, and the extremely virulent USA 400 were identified among the 326 clinical isolate using the genotyping primer pairs used in this example. The genotyping data obtained using the methods provided here were consistent with data from by the agencies that provided the samples, obtained via pulse-field gel electrophoresis and sequencing. As illustrated in Table 11, tufB and nuc primer pairs confirmed that all 326 isolates belonged to the *Staphylococcus aureus* species. 37 samples exhibited virulence as identified by the presence of the PVL gene (as indicated by a “+”). Resistance to the indicated antibiotics (“+”) was identified in a number of the samples. These drug resistance and virulence data were greater than 99% concordant with data from the agencies that provided the samples, obtained via standard phenotypic and PCR methods. Further, the data show that accurate and precise identification, genotype, virulence, and drug resistance information can be determined for a large group of clinical samples using a panel combining the identification,

characterization and genotyping primer pairs in Examples 7 and 8. This observation suggests that a kit comprising a combination of any of the primer pairs in the panel of primer pairs used in this example, or a combination of any of the other *Staphylococcus aureus* primer pairs provided herein configured to hybridize within the genes in this example will be a useful embodiment.

#### Example 10: Primer Pairs for Determining Resistance and Sensitivity to Quinolones

[00144] Table 12 illustrates four primer pairs that were configured to determine quinolone resistance or sensitivity of *Staphylococcus aureus* bioagents. The primers of these pairs were configured to hybridize within regions of the *Staphylococcus aureus* gyrA gene. Sequences for these primers can be found in Table 1, and the primers are cross-referenced by primer name and SEQ ID NO. in Table 12.

**Table 12: Primer Pairs for Identification of Quinolone Resistance in *Staphylococcus aureus***

Primer Pair Number	Forward Primer Name	Forward Primer SEQ ID NO.	Reverse Primer Name	Reverse Primer SEQ ID NO.
2738	GYRA_NC002 953-7005- 9668_166_195_ F	2	GYRA_NC002 953-7005- 9668_265_287_ R	5
2739	GYRA_NC002 953-7005- 9668_221_249_ F	3	GYRA_NC002 953-7005- 9668_316_343_ R	6
2740	GYRA_NC002 953-7005- 9668_221_249_ F	3	GYRA_NC002 953-7005- 9668_253_283_ R	7
2741	GYRA_NC002 953-7005- 9668_234_261_ F	4	GYRA_NC002 953-7005- 9668_265_287_ R	5

[00145] Each of the primer pairs listed in Table 12 is configured to generate an amplicon within at least a portion of the QRDR region of the gyrA gene (SEQ ID NO.:10), which confers quinolone resistance or sensitivity. The QRDR comprises the position of a drug resistance-conferring SNP of

the *gyrA* gene sequence, comprising a change of a single “C” nucleobase to a “T” nucleobase that results in a leucine instead of a serine at amino acid of the gyrase A protein. In the case of the reference sequence used to configure the primer pairs of Table 12, the SNP is located at position 251 of the extraction sequence ((coordinates 7005-9668) SEQ ID NO.: 8), which is the *gyrA* gene, from GenBank gi number 49484912. Forward primers in Table 12 are configured to comprise sequence identity within SEQ ID NO.: 11, a region of GenBank gi number 49484912. The reverse primers in Table 12 are configured to comprise reverse complementarity within SEQ ID NO.: 12, another region of GenBank gi number 49484912. The *gyrA* primer pairs provided in Table 12, when used in the methods provided herein, can detect a single nucleotide change at this SNP position, and are thus able to determine the drug resistant/sensitive genotype for the *gyrA* gene for a given *Staphylococcus aureus* bioagent.

**Example 11: Characterizing *Staphylococcus aureus* in a Patient Sample Using Quinolone Resistant Primer Pairs and Other *Staphylococcus aureus* Primer Pairs**

[00146] Population genotypes for mixed populations of bioagents can be identified with high sensitivity by PCR-ESI/MS because amplified bioagent nucleic acids having different base compositions appear in different positions in the mass spectrum. The dynamic range for mixed PCR-ESI/MS detections has previously been determined to be approximately 100:1 (Hofstadler, S. A. *et al.*, Inter. J. Mass Spectrom. (2005) **242**, 23), which allows for detection of genotype variants with as low as 1% abundance in a mixed population. This detection using PCR-ESI/MS surveillance does not require secondary testing.

[00147] A wound sample from a patient infected with *Staphylococcus aureus* was analyzed directly by the methods provided herein using a panel of 17 primer pairs comprising: the eight identification/resistance/virulence primer pairs listed in Table 4, the eight genotyping primer pairs listed in Table 8, and the quinolone resistance determining primer pair (number 2740, SEQ ID NO: 3; SEQ ID NO: 7) listed in Table 12.

[00148] The sample was analyzed directly as described above in the previous examples using the primer pairs of Table 4, 8, and 12 (listed along the top of Table 13) in the methods provided herein. Further, a portion of the sample was cultured on an agar plate over a period of 2 days for further testing. Following the two-day culture, 9 colonies were picked and nucleic acids there from analyzed by the 17 primer pairs described above using the methods provided herein. The results are summarized in Table 13 and Figure 3.

**Table 13 Analysis of Patient Sample Comprising Mixed Population of *Staphylococcus aureus* Bioagents: Identification of Quinolone Resistant and Sensitive Genotypes**

	ID		Virulence		Antibiotic Resistance						Strain Type
					Methicillin		Erythromycin		Mupirocin	Quinolone	
	pp # 2249	pp # 2256	pp # 2095	pp # 2095	pp # 879	pp # 2056	pp # 2081	pp # 2086	pp # 2313	pp # 2740	panel of Table 8
	tuf B	nuc	luk D	PV L	mecA	MecI-R	ermA	ermC	mupR	gyrA	
Wound	SA	+	+	+	+	+	-	-	-	75% - 25%+	USA300
Colony 1	SA	+	+	+	+	+	-	-	-	-	USA300
Colony 2	SA	+	+	+	+	+	-	-	-	-	USA300
Colony 3	SA	+	+	+	+	+	-	-	-	+	USA300
Colony 4	SA	+	+	+	+	+	-	-	-	-	USA300
Colony 5	SA	+	+	+	+	+	-	-	-	-	USA300
Colony 6	SA	+	+	+	+	+	-	-	-	-	USA300
Colony 7	SA	+	+	+	+	+	-	-	-	-	USA300
Colony 8	SA	+	+	+	+	+	-	-	-	+	USA300
Colony 9	SA	+	+	+	+	+	-	-	-	-	USA300

ID : Identification; pp# : primer pair number; SA : *Staphylococcus aureus* ; + : presence of indicated gene/virulence/resistance ; - : absence of indicated gene/virulence/resistance

[00149] As shown in Table 13, the wound sample, and all colonies grown from that sample were determined to comprise one or more bioagents, identified by the methods provided here as Strain USA300 of MRSA *Staphylococcus aureus*. These one or more bioagents comprised in all samples

were also determined to be virulent (pvl, lukD), methicillin resistant (mecA, mecI-R), and sensitive to erythromycin and mupirocin (ermA, ermC, mupR).

**[00150]** However, use of primer pair # 2740, which is configured to generate amplicons within the *gyrA* gene, identified a mixed population of bioagents in the patient sample, with more than one distinguishable genotype for the *gyrA* gene. Figure 3 shows a mass spectrum for the sample generated using primer pair number 2740. The two peak groupings represent the forward and reverse strands of the amplicon. Two different base compositions for amplicons generated by the primer pair were identified in the sample, evidenced by the double peaks shown for each strand. These double peaks (and base compositions determined therefrom) indicate that two genotypes, differing only by a single nucleotide at a SNP position in *gyrA*, were present in the patient sample. One genotype, comprising a C at the SNP of the *gyrA* gene, conferring quinolone sensitivity, resulted in an amplicon with the base composition A.sub.19 G.sub.13 C.sub.11 T.sub.20. The other, comprising a T at the SNP position, conferring quinolone resistance, resulted in an amplicon with the base composition: A.sub.19 G.sub.13 C.sub.10 T.sub.21. As shown in the spectrum, the lower abundance genotype was present at approximately 25% of the population. This result is also indicated in Table 13, which lists the population genotype for the *gyrA* gene (Quinolone column), which comprises both quinolone resistant and quinolone sensitive genotypes at 25 and 75% respectively.

**[00151]** Further, Table 13 shows that two of the nine colonies (colony 3 and 8) screened in this example were found to comprise quinolone resistance, while the other six colonies comprised quinolone sensitivity, supporting the finding that the double peaks in the spectrum for the wound sample represent a mixed population with two distinguishable genotypes. A spectrum and a base composition for an example of each type of colony is also shown in Figure 3.

**[00152]** Thus, the primer pairs and methods used in this example identified a mixed population of *Staphylococcus aureus* bioagents in a patient sample, and identified the population genotype for this mixed population. The methods and primer pairs provided herein will likely be useful in identifying population genotypes, emerging genotypes, and emerging populations of bioagents. A kit

comprising a combination of any of the primer pairs used in this example or other *gyrA* primer pairs provided herein will likely be a useful embodiment.

#### **Example 12: Periodic Analysis of Population Genotypes in a Sample over time**

[00153] A sample, obtained from a patient or other sample source will be monitored over time using the primer pairs provided herein configured to identify quinolone resistant or sensitive genotypes. In this example, nucleic acids from the sample, obtained from a patient or other source suspected of comprising one or more bioagents, will be amplified using one or more of the primer pairs from Table 12, from each of any *Staphylococcus aureus* bioagents comprised in the sample. A base composition and/or molecular mass obtained using the methods provided herein will be compared to a database comprising molecular masses and/or base compositions, each indexed to the primer pair used and a bioagent genotype. Thus, a population genotype will be identified for the *gyrA* gene that will indicate the presence or absence of quinolone resistant and/or sensitive *Staphylococcus aureus* bioagents in the sample source. Optionally, one or more additional primer pairs will be used, such as any of the primer pairs from Tables 4-6 and 8-9 will be used to determine other characteristics of the bioagents in the sample.

[00154] An antibiotic regimen tailored to the identified genotype or genotypes will then be administered to the sample source. If the population comprises only the quinolone sensitive genotype, the antibiotic regimen may comprise a quinolone. If at least a percentage of the bioagents in the population of bioagents in the sample source comprises the quinolone resistant genotype, the antibiotic regimen will comprise an antibiotic for treating quinolone resistant bacteria. Periodically, samples will be subsequently obtained from the source, and the method repeated to monitor for emerging genotypes. Following each periodic repeat of the method, it will be determined whether there is an emerging genotype in the population of bioagents in the sample. If, after the initial identification, quinolones are being used in the antibiotic regimen tailored to treat the sample source and an emerging quinolone resistant genotype is identified during the periodic testing, the regimen will be modified to treat quinolone resistant bacteria. This modification will comprise addition of an antibiotic for treating quinolone resistant bacteria, and may further comprise discontinuation of

treatment with quinolones. In one embodiment, a combination of quinolones and an antibiotic to treat quinolone resistant bacteria may be used.

**[00155]** Various modifications to the description herein will be apparent to those skilled in the art from the foregoing description. Such modifications fall within the spirit and scope of the current invention and appended claims. Each reference (including, but not limited to, journal articles, U.S. and non-U.S. patents, patent application publications, international patent application publications, gene bank accession numbers, internet web sites, and the like) cited in the present application is incorporated herein by reference in its entirety.

**WHAT IS CLAIMED IS:**

We claim:

1. A method for identifying a population genotype comprising the steps of:
  - (a) obtaining a sample suspected of comprising a population of bioagents;
  - (b) amplifying a nucleic acid from each of two or more bioagents from said population of bioagents in said sample using a primer pair that is configured to generate an amplicon from within a region defined by SEQ ID NO: 10, thereby generating amplicons from said nucleic acids;
  - (c) determining a molecular mass measurement for each of said amplicons using a mass spectrometer;
  - (d) calculating a base composition from each molecular mass measurement; and
  - (e) identifying a population genotype for said population of bioagents by comparing each of said base compositions calculated in step (d) to a database of base compositions indexed to the primer pair of step (b) and a known bioagent genotype.
2. The method of claim 1 wherein said primer pair further comprises a forward member that is 20 to 35 nucleobases in length and comprises at least 80% identity to a first portion of SEQ ID NO: 10 and a reverse member that is 20 to 35 nucleobases in length and comprises at least 80% reverse complementarity to a second portion of SEQ ID NO: 10.
3. The method of claim 2 wherein said forward member comprises at least 90% identity to said first portion of SEQ ID NO: 10.
4. The method of claim 2 wherein said forward member comprises at least 95% identity to said first portion of SEQ ID NO: 10.
5. The method of claim 2 wherein said forward member comprises at least 97% identity to said first portion of SEQ ID NO: 10.

6. The method of claim 2 wherein said forward primer pair member comprises SEQ ID NO: 2 with 0-8 nucleobase deletions, additions and/or substitutions.
7. The method of claim 2 wherein said forward primer pair member comprises SEQ ID NO: 3 with 0-8 nucleobase deletions, additions and/or substitutions.
8. The method of claim 2 wherein said forward primer pair member comprises SEQ ID NO: 4 with 0-8 nucleobase deletions, additions and/or substitutions.
9. The method of claim 2 wherein said reverse member comprises at least 90% reverse complementarity to said second portion of SEQ ID NO: 10.
10. The method of claim 2 wherein said reverse member comprises at least 95% reverse complementarity to said second portion of SEQ ID NO: 10.
11. The method of claim 2 wherein said reverse member comprises at least 97% reverse complementarity to said second portion of SEQ ID NO: 10.
12. The method of claim 2 wherein said reverse primer pair member comprises SEQ ID NO: 5 with 0-6 nucleobase deletions, additions and/or substitutions.
13. The method of claim 2 wherein said reverse primer pair member comprises SEQ ID NO: 6 with 0-8 nucleobase deletions, additions and/or substitutions.
14. The method of claim 2 wherein said reverse primer pair member comprises SEQ ID NO: 7 with 0-9 nucleobase deletions, additions and/or substitutions.
15. The method of claim 1 wherein either or both of said primer members comprises at least one modified nucleobase.

16. The method of claim 15 wherein said modified nucleobase is a mass modified nucleobase.
17. The method of claim 16 wherein said modified nucleobase is 5-Iodo-C.
18. The method of claim 15 wherein said modified nucleobase is a universal nucleobase.
19. The method of claim 18 wherein said modified nucleobase is inosine.
20. The method of claim 1 wherein either or both of said primer members comprise a non-templated 5' T-residue.
21. The method of claim 1 wherein said population of bioagents comprises at least two bacteria belonging to the *Staphylococcus* genus.
22. The method of claim 21 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy.
23. The method of claim 21 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy and at least one of said bacteria is sensitive to quinolone antimicrobial therapy.
24. The method of claim 1 wherein said population of bioagents comprises at least two bacteria belonging to the *Staphylococcus aureus* species.
25. The method of claim 24 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy.
26. The method of claim 24 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy and at least one of said bacteria is sensitive to quinolone antimicrobial therapy.

27. The method of claim 1 wherein an antibiotic regimen tailored to treat the identified genotypes for the population of bioagents is delivered to the sample source.
28. The method of claim 1 wherein steps (a) to (e) are periodically repeated.
29. A method of reducing a population of bacteria in a person needing such a treatment comprising the steps of:
- (a) obtaining from a person a sample suspected of comprising a population of bacterial bioagents;
  - (b) amplifying a nucleic acid from each of two or more bacterial bioagents in said sample using a primer pair that is configured to generate an amplicon from within a region of defined by SEQ ID NO: 10, thereby generating amplicons from said nucleic acids;
  - (c) determining a molecular mass measurement for each of said amplicons using a mass spectrometer;
  - (d) calculating a base composition from each molecular mass measurement;
  - (e) identifying a population genotype for said population of bioagents by comparing each of said base compositions calculated in step (d) to a database of base compositions indexed to the primer pair of step (b) and a known bioagent genotype; and
  - (f) administering to a person in need thereof an antibiotic regimen tailored to treat the identified genotypes for the population of bacterial bioagents.
30. The method of claim 29 wherein said primer pair further comprises a forward member that is 20 to 35 nucleobases in length and comprises at least 80% identity to a first portion of SEQ ID NO: 10 and a reverse member that is 20 to 35 nucleobases in length and comprises at least 80% reverse complementarity to a second portion of SEQ ID NO: 10.
31. The method of claim 30 wherein said forward member comprises at least 90% identity to said first portion of SEQ ID NO: 10.

32. The method of claim 30 wherein said forward member comprises at least 95% identity to said first portion of SEQ ID NO: 10.
33. The method of claim 30 wherein said forward member comprises at least 97% identity to said first portion of SEQ ID NO: 10.
34. The method of claim 30 wherein said forward primer pair member comprises SEQ ID NO: 2 with 0-8 nucleobase deletions, additions and/or substitutions.
35. The method of claim 30 wherein said forward primer pair member comprises SEQ ID NO: 3 with 0-8 nucleobase deletions, additions and/or substitutions.
36. The method of claim 30 wherein said forward primer pair member comprises SEQ ID NO: 4 with 0-8 nucleobase deletions, additions and/or substitutions.
37. The method of claim 30 wherein said reverse member comprises at least 90% reverse complementarity to said second portion of SEQ ID NO: 10.
38. The method of claim 30 wherein said reverse member comprises at least 95% reverse complementarity to said second portion of SEQ ID NO: 10.
39. The method of claim 30 wherein said reverse member comprises at least 97% reverse complementarity to said second portion of SEQ ID NO: 10.
40. The method of claim 30 wherein said reverse primer pair member comprises SEQ ID NO: 5 with 0-6 nucleobase deletions, additions and/or substitutions.
41. The method of claim 30 wherein said reverse primer pair member comprises SEQ ID NO: 6 with 0-8 nucleobase deletions, additions and/or substitutions.

42. The method of claim 30 wherein said reverse primer pair member comprises SEQ ID NO: 7 with 0-9 nucleobase deletions, additions and/or substitutions.
43. The method of claim 30 wherein either or both of said primer members comprises at least one modified nucleobase.
44. The method of claim 43 wherein said modified nucleobase is a mass modified nucleobase.
45. The method of claim 44 wherein said modified nucleobase is 5-Iodo-C.
46. The method of claim 43 wherein said modified nucleobase is a universal nucleobase.
47. The method of claim 46 wherein said modified nucleobase is inosine.
48. The method of claim 29 wherein either or both of said primer members comprise a non-templated 5' T-residue.
49. The method of claim 29 wherein said population of bacterial bioagents comprises at least two bacteria belonging to the *Staphylococcus* genus.
50. The method of claim 49 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy.
51. The method of claim 49 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy and at least one of said bacteria is sensitive to quinolone antimicrobial therapy.
52. The method of claim 29 wherein said population of bacterial bioagents comprises at least two bacteria belonging to the *Staphylococcus aureus* species.

53. The method of claim 52 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy.
54. The method of claim 52 wherein at least one of said bacteria is resistant to quinolone antimicrobial therapy and at least one of said bacteria is sensitive to quinolone antimicrobial therapy.
55. The method of claim 29 wherein steps (a) to (e) are periodically repeated.
56. The method of claim 55 wherein an emerging genotype is identified in step (e) of one or more of said periodic repeats, further comprising modifying said antibiotic regimen to treat said emerging genotype.
57. The method of claim 29 wherein said antibiotic regimen comprises an antibiotic for treating quinolone resistant bacteria and an antibiotic for treating quinolone sensitive bacteria.
58. A composition of matter comprising a purified oligonucleotide primer pair wherein each primer member of said primer pair is 20 to 35 nucleobases in length and wherein the forward primer comprises at least 80% identity with a first portion of SEQ ID NO: 10 and the reverse primer comprises at least 80% reverse complementarity with a second portion of SEQ ID NO: 10.
59. The composition of claim 58 wherein the forward member comprises at least 90% identity to said first portion of SEQ ID NO: 10.
60. The composition of claim 58 wherein the forward member comprises at least 95% identity to said first portion of SEQ ID NO: 10.
61. The composition of claim 58 wherein the forward member comprises at least 97% identity to said first portion of SEQ ID NO: 10.

62. The composition of claim 58 wherein the forward primer pair member comprises SEQ ID NO: 2 with 0-8 nucleobase deletions, additions and/or substitutions.
63. The composition of claim 58 wherein the forward primer pair member comprises SEQ ID NO: 3 with 0-8 nucleobase deletions, additions and/or substitutions.
64. The composition of claim 58 wherein the forward primer pair member comprises SEQ ID NO: 4 with 0-8 nucleobase deletions, additions and/or substitutions.
65. The composition of claim 58 wherein the forward primer pair member comprises at least 80% identity with a portion of SEQ ID NO: 11.
66. The composition of claim 58 wherein the reverse member comprises at least 90% reverse complementarity to said second portion of SEQ ID NO: 10.
67. The composition of claim 58 wherein the reverse member comprises at least 95% reverse complementarity to said second portion of SEQ ID NO: 10.
68. The composition of claim 58 wherein the reverse member comprises at least 97% reverse complementarity to said second portion of SEQ ID NO: 10.
69. The composition of claim 58 wherein the reverse primer pair member comprises SEQ ID NO: 5 with 0-6 nucleobase deletions, additions and/or substitutions.
70. The composition of claim 58 wherein the reverse primer pair member comprises SEQ ID NO: 6 with 0-8 nucleobase deletions, additions and/or substitutions.
71. The composition of claim 58 wherein the reverse primer pair member comprises SEQ ID NO: 7 with 0-9 nucleobase deletions, additions and/or substitutions.

72. The composition of claim 58 wherein the reverse primer pair member comprises at least 80% reverse complementarity with a portion of SEQ ID NO: 12.
73. The composition of claim 58 wherein either or both of the primer members comprises at least one modified nucleobase.
74. The composition of claim 73 wherein the modified nucleobase is a mass modified nucleobase.
75. The composition of claim 74 wherein the modified nucleobase is 5-Iodo-C.
76. The composition of claim 73 wherein the modified nucleobase is a universal nucleobase.
77. The composition of claim 76 wherein the modified nucleobase is inosine.
78. The composition of claim 58 wherein either or both of the primer members comprise a non-templated 5' T-residue.
79. The composition of claim 58 wherein said primer pair is configured to generate an amplicon of between about 45 and about 192 nucleobases in length comprising a region of SEQ ID NO: 10.

1/4




Figure 1

2/4

Extremely  
virulent type  
USA400




Figure 2

3/4




Figure 3

4/4




Figure 4

# INTERNATIONAL SEARCH REPORT

International application No

PCT/US2008/057904

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, BIOSIS, Sequence Search, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2006/116127 A (ISIS PHARMACEUTICALS INC [US]; SAMPATH RANGARAJAN [US]; HALL THOMAS A) 2 November 2006 (2006-11-02)	58-79
Y	examples 14,15; sequences 163,171, 264, 912, 933,1112	1-57
Y	----- US 6 015 666 A (SPRINGER WOLFGANG [DE] ET AL) 18 January 2000 (2000-01-18) the whole document ----- -/--	1-57

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the International filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 August 2008

Date of mailing of the International search report

05/09/2008

Name and mailing address of the ISA/  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Dolce, Luca

## INTERNATIONAL SEARCH REPORT

International application No

PCT/US2008/057904

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	<p>OIZUMI N ET AL: "Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus."</p> <p>JOURNAL OF INFECTION AND CHEMOTHERAPY : OFFICIAL JOURNAL OF THE JAPAN SOCIETY OF CHEMOTHERAPY SEP 2001, vol. 7, no. 3, September 2001 (2001-09), pages 191-194, XP002492131 ISSN: 1341-321X the whole document</p> <p>-----</p>	1-57
Y	<p>YUN H J ET AL: "Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV"</p> <p>INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, AMSTERDAM, NL, vol. 25, no. 4, 1 April 2005 (2005-04-01), pages 334-337, XP004794011 ISSN: 0924-8579 the whole document</p> <p>-----</p>	1-57
Y	<p>TAKAHATA M ET AL: "Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus."</p> <p>THE JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY SEP 1996, vol. 38, no. 3, September 1996 (1996-09), pages 543-546, XP002492132 ISSN: 0305-7453 the whole document</p> <p>-----</p>	1-57
Y	<p>US 7 135 283 B1 (NERENBERG MICHAEL [US] ET AL) 14 November 2006 (2006-11-14) the whole document</p> <p>-----</p>	1-57
Y	<p>WO 02/070664 A (ISIS PHARMACEUTICALS INC [US]; ECKER DAVID J [US]; GRIFFEY RICHARD H []) 12 September 2002 (2002-09-12) the whole document</p> <p>-----</p>	1-57

-/--

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2008/057904

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>VAN BAAR B L M: "Characterisation of bacteria by matrix-assisted laser desorption/ionisation and electrospray mass spectrometry"</p> <p>FEMS MICROBIOLOGY REVIEWS, ELSEVIER, AMSTERDAM, NL,</p> <p>vol. 24, 1 January 2000 (2000-01-01), pages 195-219, XP002980425</p> <p>ISSN: 0168-6445</p> <p>the whole document -----</p>	1-57

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2008/057904

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006116127 A	02-11-2006	AU 2006239993 A1 CA 2607468 A1 EP 1882045 A2	02-11-2006 02-11-2006 30-01-2008
US 6015666 A	18-01-2000	CA 2152218 A1 DE 4421901 A1 EP 0688873 A2 HU 71861 A2 JP 8000298 A	24-12-1995 04-01-1996 27-12-1995 28-02-1996 09-01-1996
US 7135283 B1	14-11-2006	NONE	
WO 02070664 A	12-09-2002	AU 2002244250 B2 CA 2439655 A1 CN 1505685 A EP 1364064 A2 JP 2005504508 T MX PA03007927 A NZ 527857 A US 2003124556 A1 US 2008160512 A1 US 2003175695 A1 US 2003175696 A1 US 2003175697 A1 US 2003190605 A1 US 2004202997 A1 US 2003027135 A1 ZA 200306810 A	09-11-2006 12-09-2002 16-06-2004 26-11-2003 17-02-2005 15-10-2004 26-08-2005 03-07-2003 03-07-2008 18-09-2003 18-09-2003 18-09-2003 09-10-2003 14-10-2004 06-02-2003 06-09-2004